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ABSTRACT 
The purpose of this study wa~ to deteraine the 
pharaacokinetics of calcium leucoYorin in nor•al subjects 
and in patients undergoing High-Dose methotrexa~e therapy 
for the treat•ent of neoplastic disease- By characterizing 
the disposition of leucovorin it was hoped that the the 
efficacy of the aethotrexate therapy might be i•proved, 
while at the sa•e time, the incidence of toxicity could be 
di•inished. 
An assay for the separation and quantification of 
leucovorin in serua was developed. The reduced folate vas 
extracted from seru• using re•erse-phase chromatographic 
•inicoluans and a paired-ion reagent. Leucovorin was 
eluted from this systea in methanol and e•aporated to 
dryness under nitrogen. The extracted samples were stable 
for 3 days vhen stored at -4oc. Bigh pressure liquid 
chroaatoqraphy vas used to separate leuco•orin from the 
extracted Rerua coaponents using a reverse-phase, 
paired-ion mode. Aamonium phosphate, dibasic, vas found to 
be a suitable pairing agent. The recently developed 
radially coapressed reverse-phase coluans vere found to 
provide superior resolution of serua components than vas 
possible with conventional stainless steel columns. The 
effects of flov rate, pH, column teaperature, and buffer 
concentration on the separation of leucoYorin vere 
investigated. 
Electrochemical detection vas used to quantify the 
reduced folate in the extracted serum samples. An applied 
potential of 0.8 volts vas used to produce a sensitive and 
selective aeans of detecting leucovorin. The apparent 
lover limit of sensitivity under the conditions employed 
vas 12 ng leuco•orin. The effects of pH, buffer 
concentration, methanol concentration, and mobile phase 
flow rate on detector response vere investigated. 
The protein binding of leucovorin and its major 
aetabolite 5-aethyltetrahydrofolate to hu•an serum albumin 
was determined. Over the concentration range of 5.0x10-78 
to 1x10-•K neither folate saturated the available binding 
sites. Leucovorin binding was a constant 701, vhile 
aethyltetrahydrofolate decreased slightly over this range. 
When both folates vere present in the albumin solution, 
there was a significant decrease in the degree of binding 
of each. ftethotrexate did not affect the binding of 
leucovorin or its metabolite. 
The pharaacokinetics of leucovorin vas determined in 6 
noraal subjects and in 5 cancer patient s. There were no 
siqnif icant differences in the kinetic parameters 
calculated fro• either group. The disposition of 
leucovorin is best characterized by a two coapartment open 
aodel. ln initial half-life of 8.79 ± 4.44 minutes and a 
second, slower elimination phase of 231.46 ± 31.76 minutes 
vas determined. The volume of the central compartment vas 
calculated as 5.49 ± 3.53 Liters. Leucovorin serum 
concentrations in 3 cancer patients receiving High- Dose 
methotrexate vere deterained to be 3 to 11 times greater 
than vas predicted using methotrexate pharmacokinetic 
paraaeters. 
This study clearly deaonstrates that there are 
significant differences in the pharmacokinetics of 
leucovorin and methotrexate. The data presented in this 
study suggests that it aight be possible to reduce the 
aaount of leucovorin administered to patients being treated 
vith met.hotrexate. This may be expected to improve the 
efficacy of the antimetabolite therapy without additional 
risk of toxicity. 
( 
ABSTRACT 
ACKNOilLEDGEftENT 
TABLE OF CONTENTS 
LIST OP TABLES 
LIST OP FIGURES 
I. INTRODUCTION 
TABLE OF CONTENTS 
II. LITERATURE SURVEY 
A.. Folate Chemistry 
B. Leucovorin 
1. Physical-Cheaical Properties 
2. Isolation and Identification 
3~ Biocheaical Role 
4. Clinical Applications 
a. !eqaloblastic Anemia 
b. Reversal of Antifol Toxicity 
5. !ethotrexate 
ii 
v 
vi 
xi 
xiii 
1 
5 
5 
8 
8 
9 
10 
13 
13 
14 
15 
a. Physical-Chemical Properties 15 
b~ Biocheaistry and Pharsacoloqy 15 
c. Biqh Dose Methotrexate Therapy 16 
d. Pharmacokinetics 24 
i. Absorption 24 
vi 
( 
III. 
IV. 
,_ 
VI. 
ii.. Distribution 
iii. f!etabolis11 
iv. Excretion 
v. Pharaacokinetic ftodels 
6. teucovorin Disposition 
a. Plasma 
i. Intravenous 
ii. oral 
b. Urine 
c. 5-Methyl Tetrahydrofolate 
1. Physical-Chemical Properties 
2. Isolation and Identification 
3. Biochemical Role 
!'OLATE ASSAYS 
A. Kicrobioloqic 
B. Spectrophotometric 
1. Ultraviolet 
2. Fluorometric 
c. Others 
~ECTROCBE~ICAL DETECTION 
A. Theory 
B. Electrode rtaterials 
c. cell Geometry and Operations 
CHROMATOGRAPHY 
PROTEIN BINDING 
vii 
25 
28 
29 
30 
31 
32 
32 
36 
41 
42 
42 
43 
45 
47 
47 
48 
48 
49 
49 
53 
54 
60 
61 
63 
66 
VII. 
A.. Description of Protein-Drug 
Interactions 
B. Equations Describing Protein 
Binding 
c. Methods of Studying Protein 
Binding 
D. Folate Binding 
1. Folic Acid 
2. ftethylTetrahydrofolate 
3. Leucovorin 
EXPERJ:l!EITAL 
A. !aterials and l!ethods 
1. Drugs 
2.. Reagents 
3,. Chemicals 
4. Equipaent 
B. !!ethod 
1. Electrochemical 
a. Configuration 
b. Electronic Connections 
c. Electrode Preparation 
i.. carbon Paste 
ii.. Glassy Carbon Electrode 
2. Chromatographic 
a.. Apparatus 
b.. Solvent Systems 
viii 
66 
68 
72 
74 
74 
76 
76 
11 
77 
77 
77 
77 
79 
81 
81 
81 
83 
84 
84 
85 
87 
87 
87 
3. Protein Binding 89 
a. !eabrane Preparation 89 
b. saaple Preparation 89 
c. Oltrafiltration 90 
4 .. Human Studies 92 
a. Humans Subject Protection 92 
b,. Subject Selection 92 
c. cancer Patients 93 
d. !!ethod of Blood Sampling 94 
e. Extraction Procedure 96 
YIII,. RESULTS and DISCUSSION 98 
A. Electrocheaistry 98 
1. Electrode Evaluation 101 
a .. carbon paste, silicone-Oil 101 
b. Vax-iapreqnanted Graphite 103 
c. Glassy carbon 105 
i. Electroactivity of Polate 
Analogs 106 
ii- Durability 107 
iii. Effects of Flow Rate 109 
iv. Effects of Salt Concentration 114 
v. Effect of Kethanol on Detector 
Response 117 
B. Chromatography 
1. C-18 Stainless Steel Columns 118 
2.. Radial Compression Separation Systea 126 
ix 
( 
a. !valuation of Radial Compression 
System 126 
ia Effects of Flow Rate 
ii. Effects of Teaperature 
iii. Effects of Counter-Ion 
Strength 
iv. Effects of pH 
c.. Drug Assay 
1. Aqueous systems 
2. Serum 
a. Recovery 
b. Sample Stability 
3. separation of Leucovorin from serum 
components 
D. Protein Binding 
127 
128 
131 
134 
137 
137 
138 
139 
142 
143 
151 
1. Non-Specific Binding 151 
2. Analysis of Albuain Solutions 151 
3. Leucovorin Binding to Human serum 
Albuain 152 
4. Leucovorin Binding to Bovine serua 
Albumin 153 
5. !ethyltetrahydrofoalte Binding 156 
6. teucovorin-ftethyltetrahydrofolate 
Binding Interaction 160 
1. Leucovorin-Methyltetrahydrofolate 
Binding Interaction 
vith Methotrexate 164 
x 
l 
E. Leucovorin Pharmacokinetics 167 
1. Normal Subjects 167 
2. Cancer Patients 176 
3. Co•parison of Leucovorin 
Pharmacokinetics Derived fro• 
Microbiologic versus Electrocheaical 
Assay Methods 185 
IL CONCLUSIONS 
I. REFERENCES 
XI. APPENDICES 
A. Institutional Review Board Approval 
B. !ethotrexate Protocols and Informed 
Consent 
c. Leucovorin Protocol and Informed 
consent 
D. FORTRAN Subroutine DPUNC 
xi 
192 
198 
211 
211 
212 
215 
220 
LIST OP TABLES 
I. !ethot~exate Protocols 23 
II.. Patient Inforaa tion 95 
III. Mobile Phase Compositions 124 
IV. Effect of Temperature on Folate 
Retention time 132 
v. Effect of Buffer Concentration on 
Polate Retention Ti•e 135 
VI. Recoyery of Leucovorin from Serum 140 
VII. Stability of Frozen Leucovorin Extract 144 
VIII. Chromatographic Parameters Describing 146 
Leacovorin Separation fro• Serum Components 
IX. Leucovorin - Methyltetrahydrofolate Binding 
Interactions 162 
x. !ethyltetrahydrofolate - Leucovorin Binding 
Interactions 163 
XI. Effect of !ethotrexate on the Binding 
of Leucovorin 165 
XII. Effect of Methotrexate on the Binding of 
Methyltetrahydrofolate 166 
XIII. Leucovorin Pharmacokinetic Paraaeters 
Derived from 6 Koraal Subjects 173 
XIV. Co•parison of Leucovorin Pharaaco-
kinetic Paraaeters Between Males 
And Feaales 178 
xv. Co•parison of LeucoYorin Pharaacokinetic 
Parameters in cancer Patients 
and Boraal Volunteers 181 
xi 
IVI. Comparison of Predicted and calculated 
Leucovorin serum Concentrations in 
Cancer Patients 182 
XVII. Comparison of Pharmacokinetic Parameters 
For ~eucovorin and Kethotrexate 183 
XVIII. Comparison of Pharaacokinetic Parameters 
Derived from a Kicrobiologic Assay and 
from an Electrochemical Assay 190 
xii 
( 
LIST OP FIGURES 
1. Structures: Leucovorin. Methotrexate. 
Folic Acid. Methyltetrahydrofolate 6 
2. Metabolic Pathways Involving Leucovorin 1 
3. Leucovorin Biosynthetic Pathways 12 
4. Leucovorin Plasaa Decay Assayed by 
a !icrobiologic Disc Method 34 
5. Diagram of the Electrochemical Flov-
Through Cell 82 
6. LeucoYorin Hydrodynamic Voltamaogram 99 
1. !ethotrexate Hydrodynamic Voltammogram 100 
8. Peak Height as a Function of Applied 
Potential for Leucovorin and Methyl-
tetrahydrofolate 108 
9. Decline in Detector Response Measured as 
Peak Height as a function of Time 110 
10. Effect of !obile Phase Flov Rate on 
Leucovorin Peak Height 112 
11. Effect of !obile Phase Flow Rate on 
Methyltetrahydrofolate Peak Height 113 
12. Effect of Buffer concentration on 
Leucovorin Peak Height 115 
13~ Effect of Buffer Concentration on 
!ethyltetrahydrofolate Peat Height 116 
14. Peak Height as a Function of Methanol 
concentration in Injected sample 119 
15. Initial Leucovorin Chromatogram 122 
16. Resolution of Folate Analogs Using 
C-18 stainless Steel Coluan 125 
xiii 
( 
( 
17. Plot of Retention Time as a Function 
of !obile Phase Flow Rate for 
Leucovorin and Methyltetrahydrofolate 
18. Retention Time as a Function of 
Mobile Phase Flow Rate; Log-
Log Transformation 
19. Effect of Column Temperature on 
Leucovorin and !ethyltetrahydrofolate 
Retention Time 
20. Effect of pH on Leucovorin and 
!ethyltetrahydrofolate Retention Ti•e 
21. Leucovorin Recovery fro• serum 
22. Separation of Leucovorin and 
!ethyltetrahydrofolate Using 
the RCSS Module 
23. serus Blank; Subject K.B. 
24. Leucovorin in Serum; Subject K.B. 
25. Percent of L~ucovorin Bound to Human 
Seru• Albumin as a Function of 
Drug Concentration 
26. scatchard Plot for Leucovorin; 
r/a as a function of r 
27. Percent of Leucovorin Bound to Bovine 
Albuain as a Function of Drug 
Concentration 
28. Percent of !ethyltetrahydrofolate 
Bound to Huaan serum Albumin as a 
Function of Drug Concentration 
29. scatchard Plot for !ethyltetrahydro-
folate; r/a as a Function of r 
30. Leucovorin Seru• Concentration as a 
Function of Time; Noraal !ales 
31. Leucovorin Serum Concentration as a 
Function of Tiae; Noraal Females 
32. Two Coapartment Open !odel 
xiv 
129 
130 
133 
136 
141 
145 
149 
150 
154 
155 
157 
158 
159 
168 
169 
171 
33. LeucoYorin serum concentration as a 
Function of Time; Patient F.F. 179 ( 34. Leucovorin Serum Concentration as a 
Function of Time; Patient L.PI .. 180 
35. Leucovorin Serua Concentration as a 
Function of Tiae; Patient P.P. 186 
36. teucoYorin Serum Concentration as a Function 
of Time; Patient F. Y. 187 
37. LeucoYorin serum Concentration as a 
Function of Timer A coaparison Using 
Pharmacokinetic Parameters Derived f roa 
Two Different Assay Procedures 191 
( 
xv 
( 
The 
effective 
treataent 
of head 
I. INTRODUCTION 
folate antagonist aethotrexate (KTX) is an 
antineoplastic agent widely used for the 
of choriocarcinoaa. osteosarcoma. and a variety 
and neck tumors (Stoller ~al:.& 1977). It has 
also been used in non-neoplastic diseases such as psoriasis 
(Vanscott !i ~!~£ 1964) systemic lupus erytheaatosus 
(Swanson and Schwartz. 1976,. and psoriatic arthritis 
(Fosdick. 1968). Methotrexate acts Lt the cellular level 
by reversibly binding the enzyme dihydrofolate reductase. 
preventing the reduction of dihydrof olic acid to 
tetrahydrofolic acid. thereby depleting the reduced folate 
pool necessary for the transfer of 1-carbon units in a 
number of biocheaical pathways. As a result. ONA 
synthesis. purine synthesis. and several aaino acid 
interconversions are severely inhibited (Bleyer. 1977). 
!ethotrexate•s toxicity to normal and maliqnant cells is 
dependent on both the adainistered d~se and the duration of 
exposure (Ojerassi. 1975). 
Since Farber first reported the successful use of an 
antifolate for the treatment of leukemia (1948). MTI dosage 
( 
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schedules have changed dramatically. First used daily and 
qiven orally. progressively largec and more frequent doses 
(orally. intramuscularly. and intravenously) have provided 
consistently improved clinical response. Djerassi has 
reported success in treating previously resistant tumors 
with MTX dosages in the range of 100-200 mg per az where as 
little as 3 ag per mz had been employed. Bleyer (1977), 
Goldin (1978). and Djerassi (1975). have all discussed the 
historical background of high dose !TX therapy. 
The goal of !TX research has been to identify the 
maximum dose and frequency of adainistration tolerated by 
norsal tissues that vill still be effective against tumor 
cells. Toward this end the pharmacokinetics of !TX have 
been extensively studied (Bischoff ~ ~!~L 1971. Reich ~1 
~!~L 1977 and Huffman ~ ~!:.L 1973) and the absorption. 
distribution, aetabolism. and excretion of the drug in both 
animals and humans are well understood. 
Leucovorin (citrovorua factor. 5-formyl TBP. LEO) is a 
reduced folate, capable of supplying 1-carbon units in the 
biosynthetic pathways inhibi~ed by !TX. since its further 
reduction does not depend on dihydrofolate reductase. 
llthouqh the mechanism by which leucovorin "rescues" a host 
organism is unknown, the preYailing theory postulates a 
coapetition for a coamon transport mechanis• regulating 
entry into cells (Chabner ~1 ~ 1975,. As early as 1949 
Burchenal ~ ~1~ (1949.1950, had reported the prevention of 
therapeutic effect of !~I on mouse leukemia with the 
( 
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adainistration of LEU or pteroylglutamic acid~ Goldin ~ 
alLL (1953.1954.1955.1966) and Bernbaum ~ !l·L (1965) 
working with leukeaic mice produced results suggestinq that 
proper administration of LEU subsequent to "TX could 
prevent toxicity in normal celis without protectinq the 
malignant cells. Shoenbach ~ ~1:£ (1950) reported a case 
in which LEU vas successfully used to reverse KTX-induced 
toxicity in a patient. However. it was not until the work 
of Djerassi ~ ~l~ (1966.1967.1968.1970) and Lefkowitz ~ 
!.l~L (1967) that controlled studies clearly demonstrated 
the role of LEU in preventing !TX-induced toxicity. Since 
the publication of these works. the cancer literature has 
been flooded vith reports of improved clinical response in 
patients treated with high dose ~TX-LEU rescue regiaens. 
However. there is still considerable debate regarding the 
optiaal dose and schedule of LEU which should be employed. 
Penta (1975). in a review of IMD protocols discussed ten 
different treatment schedules while Nixon (1979) described 
a 100-fold range in the doses of LEU employed and labeled 
current regimens as arbitrary. 
Leucovorin has been assayed in huaan plasma 
biologically (!ehta ~ !!~ 1978). radiocheaically 
(Rothenberg ~ !!:.£ 1979). radioimaunologically (Raso. 
1977). spectrophotometrically (Chapaan. 1978). and by 
adainistration of radiolabelled drug (Nixon and Bertino. 
1972). The applicability to pharmacokinetic analysis of 
each of these methods. however. has severe limitations. 
/ 
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Spectrophotometric methods are not sufficiently sensitive 
to reduced folates; microbiologic assays are generally not 
precise enough for pharmacokinetic analysis; radiochemical 
and radioimmunologic techniqaes suffer from a lack of 
reproducibility; and the use of radiolabeled drug is 
inappropriate for the general patient population. 
The pharaacokinetic data deriYed from these methods is 
of limited value £or two reasons. First, these studies 
have been carried out at relatively lov doses and in the 
absence of methotrexate, and, therefore, th9y do not 
reflect the clinical conditions under which LEU is employed 
(1979). Second, although plasma concentrations of LEU have 
been deterained, these studies were not adequately designed 
with regard to sampling time and duration of sampling for 
complete pharaacokinetic analysis. 
The purpose of this work is twofold: (1) to develop a 
rapid, sensitiYe, and reproducible assay for LEU in plasma 
and; (2t to characterize the disposition of LEU in noraal 
subjects and in patients receiYing high dose !TX therapy~ 
Determination of the pharaacokinetic parameters governing 
LEU distribution and elimination should aake possible the 
optiaization of LEU rescue protocols without adversely 
af fectinq the anti-neoplastic activity of MTL 
( 
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II. LITERATURE SURVEY 
A. Polate Chemistry 
The folates are a series of compounds containing the 
pteroic acid nucleus, conjugated with one or more 
L-qlutaaic acid molecules (Figure 1) (Blakely, 1~69). 
Polic acid, N-(p-[[ (2-Amino-4-hydroxy-6-pteridinyl)-
aethyl]aaino] benzoyl]qlutamic acid or pteroylqlutamic acid 
(PGA), is a partially oxidized, stable form of folate found 
in pharmaceutical preparations but rarely in nature (Kixon, 
1979). Folic acid is rapidly reduced, first to 
dihydrofolate (DHF) , then to tetrahydrofolate (THP) by the 
enzymes dihydrofolate reductase and tetrahydrofolate 
reductase, respectively (1970). Tetrahydrofolate serves as 
an intermediate carrier of forayl, •ethyl, and 
hydroxy•ethyl one- carbon units, which are usually attached 
in the HS,Rto, or RS-to positions. These reduced folate 
forms are found in nearly all natural foods including 
aaamalian cells (Blakely, 1969). The so-called "folate 
coenzyaes" participate in a large number of enzymatic 
reactions in which one-carbon units are transferred froa 
one metabolite to another or alternatively may be 
interconverted to other coenzyae forms (1970). Figure 2 
represents 
f olloved 
the aetabolic pathways and interconversions 
by folic acid and various folate coenzyaes which 
result in the conversion of glycine to serine, hoaocysteine 
to aethionine and deoxyuridine monophosphate (dU!P) to 
thy•idylate aonophosphate (dT!P) and ultiaately th9 
page 6 
Ri = QJ i3 : 5-methyltet !!i ~ QI) . Le radrofolic acid 
' onnyl TIIF ·' • 1 ucovorin 5-F • MEIIlF 
f.1 . 
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12 
cxxm 
MIX 
Deoxyuridilic 
Acid 
~ 
Folic Acid Histidine 
Acid J Urocanic Acid 
~ 
Formiminoglutamic Acid 
Acid 
Serine 
THFA 
B6 Dependent 
S . . T A N Formimino HF 
NS Methyl THF Glycine 
5 10 N , Metheny! THFA 
S Formyl THFA NS,lO Methy-
lene THFA f.i Fo linic Ac id 
Figure 2: Metabolic Pathways Involving 
Reduced Folate Coenzymes 
Leucovorin 
'"d 
~ 
-..::i 
( 
( 
page 8 
synthesis of DNA. An excellent review of the biochemistry 
of f olic acid. folate coenzymes. and related pteridines has 
been published (Blakely. 1969). 
B. Leucovorin 
1. Physical-Chemical Properties 
Polinic acid. B-(p-(( (2-amino-5-formyl-5.6,7.8.-
tetrahydro -4- hydroxy -6-
pteridinyl) aethyl ]amino ]benzoyl ]-L glutaaic acid. molecular 
weight 511.513. is the formyl derivative of THF. It is one 
of the foras of reduced folate coenzymes found in the body. 
(Blakely, 1969). The term leucovorin generally refers to 
the chemically synthesized material containing both the -L 
and 1 diastereomers. while "folinic acid" or "citrovorum 
factor" applies to the biologically active l isomer only 
(Ponte!,!!!::.... 1979). 
lolinic acid (also called 5-formyl tetrahydrofolate ) 
is a yellovish-vhite or yellow, odorless. microcrystalline 
powder (Blacow, 1972). It is sparingly soluble in water 
and practically insoluble in alcohol. The pH of a 
saturated aqueous solution is 2.8 to 3.0, at which partial 
decomposition tates place. Three pKa values have been 
reported for the free acid; 3.1. 4.8. and 10.4. The first 
tvo are attributed to the qlutamyl carboxyl groups and the 
third to the C-4 hydroxyl group (Ponte ~ ~!~~ 1979). The 
greatest stability is at neutral or mildly alkaline pH 
(!erck Index. 1976). The commercially available salt form 
( page 9 
of folinic acid. calcium leucovorin pentahydrate. molecular 
weight 601.513. is freely soluble in water but remains 
practically insoluble in alcohol (Merck Index. 1976t. All 
the reduced folates are heat labile; folinic acid is. 
however. the most stable. and for this reason it is the 
only coaaercially available pharmaceutical preparation of a 
reduced folate coenzyae (Kastrup and Boyd. 1980t. An 
excellent review of the physical properties of LEU 
including inf rared spectrum. proton aagnetic resonance 
spectrua. C13 aagnetic resonance spectrua. aass spectrum. 
x-ray crystallography. optical rotation and circular 
dichroisa has recently been published (Ponte ~ al.L 1979). 
2. LEU Isolation and Identification 
During a survey of organisms suitable for a 
aicrobiological assay of alanine. Sauberlich and 
Bauaann(1948) discovered that ~~£2ll2§12£ ~ii~!Q~U! 8081 
failed to grov on a medium that had proved suitable for 
siailar assay organisas. They also reported that various 
"antianeaic" crude liver and yeast extracts promoted the 
growth of the organism and did so at a substantially faster 
rate than did folic acid4 
~eresztesy and Silveraan (1950) reported the partial 
purification and concentration from liver of a 
"citrovorum-factor" so named because of its ability to 
stimulate the growth of It:. £itrovo,ua:_ Brockaan ~ ~~ 
(1950t and Bardos ~ ~!~& (1949t reported the preparation 
( 
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of a coapound resulting from the formylation and reduction 
of pteroylglutamic acid (folic acid), whose activity was 
similar to the extracted aaterial. 
Keresztesy and Silverman (1951), and Silverman and 
Keresztesy (1951), compared the activity of the synthetic 
compound vith the liver extract and found that the latter 
was approximately twice as active, relative to ~ 
ci~rovor~ growth. It is now known that the synthetic 
aaterial contains both the inactive dL and active lL 
diasterioaers. The naturally occuring extracted aaterial 
contains only the active lL form, it is clear that, on a 
weight-weight basis, it would be more active than the 
synthetic material. 
Pohland ~ ~s..& 
folinic acid-sf ("sf" 
opposed to a liver 
(1951), proposed a structure for 
designates a synthetic folate, as 
extract as, S-formyl-5,6,7,8-
tetrahydropteroyl glutamic acid, (Figure 1). The synthesis 
from either pteroylglutamic acid or formylpteroyl glutamic 
acid, (Roth, 1952) as the cheaistry (Cosulich ~ ~!L, 1952) 
of LEU have since been reported in detail. 
3. Biochemical Role of LEU 
Leucovorin was the first naturally occurinq derivative 
of THF to be isolated, identified, and synthesized. 
(Blakely, 1969). Although the mechanism of its 
biosynthesis remains uncertain, three have been 
proposed (Figure 3): (1) the reverse of an ATP dependent 
( page 11 
conversion of LEU to NS,Nto, methenyl THF and ADP + Pi; (2) 
the reverse of a similar ATP dependent conversion of 
leucovorin to Nto formyl THF + ADP + Pi; and (3) the 
formation of LEU and L-glutamate from THF and 
foraylglutamate.(Donaldson and Keresztesy, 1959) Although 
the -first tvo mechanisms are possible, they are not favored 
thermodynamically, and the third is limited by the quantity 
of foraylglutamate available (Blakely, 1969t. 
Leucovorin is not believed to be involved in the 
direct transfer of one-carbon units in the biosynthesis of 
a•ino acids or the purine and pyrimidine units of DNA. 
(Blakely, 1969) Rather, it exists in equilibrium with the 
ss,vao methylene, aethenyl and 110 formyl folate coenzy•es 
which are directly involved in several syntheses 
(lehninger, 1970). 
The aajor role for LEU, although indirect, is in the 
synthesis of serine from glycine (Kislivk and Sakami,1955; 
Alexander and Greenb9rg, 1955; Blakely, 1954; and Blakely, 
1957). Leucovorin confers the one-carbon (formyl) group on 
1s,M&O-aethylene THF converting it to THP by donating the 
forayl group to glycine, resulting in the formation of 
serine (Figure 2). 
The formyl group originating from LEU also 
participates in tvo reactions important to purine 
biosynthesis. vs,Nto methenyl THP donates the forayl 
1-carbon nnit in the conversion of qlycinamide 
ribonucleotide (GAR) to formylglycinamide ribonuclieotide 
( 
1. 
2. 
3. 
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5-Formyl THF + H+ 
5,10· Methenyl THF +H2 0 
' 5-Formyl THF + ATP > 
10-Formyl THF + ADP + Pi 
5-Formyl THF + L-glutamate 
7 
THF + N-formyl-
glu tama te 
Figure 3: Leuc.ovorin Biosynthetic Pathways 
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(fGAR) (Calabresi and Parks, 1975). fftO formyl THF donates 
its formyl group in the conYersion of 5-aminoimidazole 
carboxamide ribonucleotide (AICAR) to 
5-foraamido-iaidazole-4-caboxamide ribonucleotide (FAICAIR) 
(Lehninger, 1970,. The synthesis of both fGAR and FAICAR 
are important steps in the biosynthesis of inosinic acid, 
and ultimately purine mononucleotides (Lehninger, 1970). 
4. Clinical Applications of LEU 
a. !egaloblastic Anemia 
Leucovorin may be used in the treatment of folate 
deficient megaloblastic anemias resulting from pregnancy, 
sprue, or nutritional deficiencies (A.S.H.P •• teucoTorin 
!onograph, 1980). However, LEU offers no advantage over 
f olic acid in treating these disorders and is considerably 
more expensive. LEU may be useful. in treating conditions 
of folate deficiency anemias in which the ability to reduce 
folic acid to the various coenzyme forms is impaired 
(A.s.H.P., Leucovorin !onograph. 1980). Anemia associated 
vith acute portal cirrhosis (alcoholic or Laennecc•s 
cirrhosis) often does not respond to folic acid therapy 
(Patek, 1969). This phenomena has been attributed to an 
inability to produce reduced coenzyme foras rather than an 
actual lack of folic acid itself. It has been suggested in 
such cases that because of its ready conYersion to other 
reduced coenzy•e forms LEU be used to treat the anemia 
(Patek, 1969). 
( 
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Tauro !!i !J:::.L (1976t reported two cases of 
meqaloblastic aneaia in infants resulting from a congenital 
~ 
deficiency of dihydrofolate reductase which prevented the 
reduction of dihydrofolate to THF. Both infants showed 
"satisfactory clinical response" following parenteral LEU 
therapy. 
b. ReYersal of Antifol Toxicity 
The aajor clinical application of leucovorin is as an 
antidote for the folate antagonists pyrimethaaine. 
triaethopria. and methotrexate (A.S.H.P. Leucovorin 
!onograph. 1980). Pyrimethamine is a folic acid antagonist 
used in the treataent of chloroquin-resistant malaria 
caused by susceptible strains of plasaodia (Waxaan and 
Herbertr 1969) and may be used to treat ocular 
toxoplasaosis (Giles ~ !l~L 1964). It can produce 
aegaloblastic anemia which. reportedly. has been reversed 
by LEU but not by folic acid (Giles !! sl:..&. 1964; and 
iaxaan and Herbert. 1969). 
Triaethopria acts as an inhibitor of dihydrofolate 
reductase. blocking the production of TBP (Kastrup and 
Boyd. 1980). Toxicity resulting from triaethoprim therapy 
could presuaably be treated by adainistering LEU and 
by-passing the point of enzyae blockade~ 
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5. Hethotrexate 
The use of LEU in conjunction with methotrexate (MTXl 
therapy represents the most important and widely studied 
application of a reduced folate in humans. 
a. Physical-Chemical Properties 
!ethotrexate, (amethopterin, MT~ • 
N-(p-(( (2.4-Diamino-6-pteridinyl)methyl]-methyl amino 
]benzoyl]glutamic Acid. molecular weight 454.45, is a 
yellow powder, structurally related to folic acid, Scheme 1 
(!erck Index, 1976). MTX is practically insoluble in 
water. alcohols. chloroform, and ether. It is freely 
soluble in dilute solutions of alkali hydroxides and 
carbonates (Blacov, 1972). The solubility of HTX has been 
reported to be 2.2 x 10-3 ! in urine at pH 5.1 and 2.2 x 10 
-2 ! at pH 6.9 (Bleyer, 1977). MTX has two pKa's; 4.8 and 
5.5, attributable to the two carboxyl groups of the 
glutamic acid portion of the aolecule (Bleyer, 1977). 
b. Biochemistry and Pharmacology 
Methotrexate, is one of seYeral derivates of 2-4 
diaainopteridine which inhibit dihydrofolate reductase 
(Plenderheith and Bertino, 1975), the enzyme responsible 
for the reduction of dihydrofolate to tetrahydrofolate. 
This enzyme block results in the depletion of THF and 
consequently the supply of folate coenzymes available fo~ 
( 
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thyaidylate and purine synthesis and the formation of 
serine and 
Thymidylate 
depletion of 
methionine (Calebresi and Parks. 1975). 
synthesis is reportedly the most sensitive to 
THF stores (Plenderheith and Bertino. 1975). 
As a result. DNA synthesis is affected to a greater degree 
than is RNA synthesis. Because DNA synthesis is most 
seYerly affected. MTX's mechanisa of action is considered 
to be cell cycle specific. acting in the "S-phase" of 
mitotic activity (Bleyer. 1977). In this aanner. those 
tissues undergoing rapid cellular turnover with a high 
percentage of cells in "S-phase" are most susceptible to 
the effects of !TX (Bleyer. 1977)a The binding ~f MTX to 
the enzyme is considered to be of a "tight" but reversible 
nature (e.g •• it is a coapetetive stoichiometric inhibitor 
(Plenderheith and Bertino. 1975; Blakely. 1969). Johns ~1 
aJ:~L (1964) • de•onstrated that ff3-MTX bound to 
intracellular enzyme in man could be displaced to 
extracellular spaces by unlabelled MTX or by dihydrofolate. 
In addition to MTX's affect on dihydrofolate 
reductase. Borsa and Whitmore (1969). have suggested that 
!TX may also act by direct inhibition of thymidylate 
synthetase. 
Because the mechanisms for methionine and serine 
synthesis . are disrupted by !TX. protein synthesis may also 
be affected (Bleyer. 1977). The author suggests that by 
this aechanisa !TX arrests cells in the G1 phase of 
development and in so doinq. protects those which surviv9 
( 
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!TI exposure by slowing their progression in the s-phase. 
If however. protein synthesis is disrupted for long 
periods. cells will. of course. be seriously injured. 
Goldman (1974) reported that for maxiaal suppresion of 
DIA synthesis. free intracellular metbotrexate 
concentrations must be greater than those required to 
stoichioaetrically bind with dihydrofolate r~ductase. The 
additional !TX is considered necessary to bind any nev 
redttctase which may be synthesized. and to saturate a 
(proposed) second class of enzyae binding sites with a much 
lover affinity for !TX (Goldin. 1974.1975). Chabner ~1 
al~, (1973) and Strauss and Goldstein (1943) • however. 
suggest that these findings are compatible vith 
interactions between !TX and a single. high affinity site. 
In either case the requireaent for free intracellular MTX 
has been established. It is now generally recognized that 
the antineoplastic activity of !TX is dependent upon 
aaintaining free intracellular levels above a threshold 
value which is specific for various tissues or tumor types) 
for prolonged periods and not siaply peak plasma !TX 
concentrations (Chabner and Younq. 1973). 
c. High-Dose Methotrexate-Leucovorin 
Rescue Regimens 
Farber (1948) reported the first successful treatment 
of cancer vith a folic acid derivative when a•inopterin was 
used to produce temporary remission of acute leukemia in 
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children. Similar results were reported by Sacks ~ al~L 
(1950)r with both aminopterin and !TXr in low daily doses 
of approximately 0.1 mg kg-•. Hoveverr Schoenbach ~al:.£ 
(1950) described a folic acid deficiencyr caused by the 
antimetabolites. which was manifested by "gastrointestinal 
crampsr diarrhear hemorrhager ulceration of the palate and 
oral mucous membranes and leukopenia which may progess to 
an aplastic anemia and alopecia". Because the appearance 
of these toxic aanifestations vas frequently delayedr the 
cumulative toxic dose might have been exceeded before 
syaptoms occured. As a resultr it has been suggested 
(Shoenbach ~ al=_L 1950) that sub-therapeutic doses of ~TX 
•iqht have been employed in an effort to prevent toxicity. 
Early treatment schedules involving ftTX usually 
required 
aqe of 
Working 
daily oral doses of 1 to 5 ag.r depending on the 
the patient (Acute Leukeaia Group B-r 1965). 
in mice with leukemia 1210, Goldin ~ sl~& (1956) 
experimented vith different dosage schedules and found that 
drug administration every fourth day produced better 
results than did either more frequent or less frequent 
administration. Based on these data. the Acute Leukemia 
Group Br (1965) compared intermittent parenteral 
administration to daily oral administration of MTX and 
found the nev treatment schedule improved survival time in 
childhood leukemic patients. However, the twice weekly 
parenteral !TX doses of 30 mg m-2 produced significantly 
more toxic syaptoas than did daily oral dose of 3 mg m-2. 
( 
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Papac !!. al.L (1967) used intravenously administered MTX, 
o.a mg kq-1 in a single bolus injection every four days to 
treat squamous cell carcinoma. Although good clinical 
response vas achieved there were frequent incidences of 
hematopoietic disorder, thereby limiting the duration of 
treatment. 
The toxic manifestations produced by MTX could not be 
reversed clinically with folic acid, crude liver extracts 
or vitamin B12. Folic acid. when given prior to !TX (under 
certain conditions), has been used to prevent antifol 
toxicity but the antineoplastic activity of MTX was also 
prevented (1950). When administered simultaneously or 
after !TX injection, folic acid afforded no protection from 
the toxic manifestations of antimetabolite therapy. 
The failure to reverse or eliminate MTX's toxicity vas 
a severe deterrent to optimal anti-metabolite therapy which 
had been proven beneficial in treating various forms of 
leukemia. Nichol and Welch (1950), reported that LEU had 
been used successfully to prevent the toxicity of 
aminopterin in both mice and rats. Schoenbach ~ al:.£ 
(1950) described the use of LEU to reverse aminopterin or 
amethop~erin-induced mucositis 
treatment with daily oral doses. 
it vas possible to continue 
in two patients under 
It was also reported that 
the antifol therapy while 
administering LEU to treat the induced toxicity. 
Preclinical studies by Goldin ~1 s!:.L (1953), 
demonstrated that simultaneous administration of LEU 
r 
( 
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reduced both the toxicity and antituaor eff~cts of MTX in 
both non-tumor and tumor-bearing mice. However, when it 
was administered in this manner, LEU actually reduced the 
survival time of mice that survived the initial drug 
toxicity. Further studies with murine L1210 leukemic mice 
confirmed that the prevention of toxicity is highly 
schedule-dependent and ~hat delayed administration of LEU 
might be therapeutically advantageous (Goldin, Vendetti, ~ 
al~L 1955). Goldin ~ !!~L (1953) deaonstrated that 
delaying the administration of LEU twenty-four hours from 
the tiae of !TX dosing increased the specificity of action 
of amethopterin, reducing toxicity and allowing the 
employment of higher MTX doses. Goldin ~ !~£ (1966» a!so 
reported that through proper scheduling of MTX with LEU 
rescue, it was possible to ad•inister as much as 1000 ag 
Kq-' to tumor-bearing aice without toxicity, a dose which, 
without LEU, was toxic to all animals. The work of Goldin 
~ als.a. (1953,1955,1956,1966) clearly demonstrated the 
increase in the margin of safety for !TX when used in 
conjunction with the delayed adainistration of LEU. 
On the basis of these findings, the LEU-rescue concept 
was extended to humans. Clinical studies in the treatment 
of metastatic osteoqenic sarcoma (Jaffee~ ~!:.L 1974), 
head and neck ~umors (Capizzi g~ ~!~L 1970), leukemia 
(Djerassi, 1967), and other solid tumors (Djerassi 21 al~L 
1972, Levitt !!i al:u, 1973) have since demonstrated the 
activity of hiqh dose MTI- LEU rescue regimens. To date, 
( 
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the dosages of LEU and ~TX usedr the length of the !TX 
inf usionr and the scheme for LEU rescue vary widely betv~en 
protocols and have been established largely on an empiric 
basis (Stollerr 1978). 
Recent vork in 
murine tumor models 
tissue cel1 culture and sarcoma 180 
has clearly shown a relationship 
between extracellular concentrations of !TX and LEU and the 
effectiveness of rescue. Penedo ~ ~ (1976) 
demonstrated a competetive reversal of MTX cytotoxicity 
such that the toxicity produced by 1Q-7M !TX vas completely 
reversed by equimolar concentrations of LEUr but with 
higher MTX concentrationsr relatively more LEU vas 
required. For exampler 10-sM ~TX p~oduced cytotoxic 
effects in cell culture which were not reversed until LEU 
concentrations reached 1Q-3M.; furthermor~r it was not 
possible to reverse the toxicity resulting from MTX 
concentrations greater than 10-•M. (Pinedo~ sl-L 1976). 
Sirotnak ~ al~L (1976)r demonstrated a dose and 
schedule-dependence for LEU rescue during in plasma high 
dose MTX therapy of ascitic forms of L1210 and sarcoma 180. 
The authors noted that "schedules with very delayed 
'lov-dose• LEU rescue following lethal doses of !TX vere 
highly effective in preventing toxicity and achieved a 
pronounced antitumor effect in both ascites tumor models". 
The best results were reportedly obtained vhen LEU vas 
withheld until 16 to 20 hours following ~TXr then 
adainistered every 2 hours for 5 doses. ~TX vas 
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administered at a dose of 400 mg Kg-1 and LEU at 12 mq 
Kg-t. Further increases in MTX doses did not substantially 
increase the anti-tumor activity; while progressively 
increasing the LEU dosage reduced both the toxicity and 
anti-tumor effect. These data clearly suggest that 
aanipulation of LEU dosage and schedule of administration 
can improve the therapeutic index of high dose !TX therapy. 
Based on these observations, several clinical trials 
involving high dose ~TX vith LEU rescue have been 
undertaken. Table I shows some of the protocols which have 
been developed. Stoller et al~L (1978) recently published 
a study (63) in vhich LEU was administered intravenously 
30, 36, and 42 hours following an 18 hour !TX infusion. 
Rather than use a standard LEU dose, the authors 
individualized the amount of LEU administered based on the 
plasma !TX clearance in the patient underqoing treatment. 
Plasaa samples were obtained from patients and, using 
appropriate pharaacokinetic principles, the !TX plasma 
level at 30 hours post infusion vas calculated. In this 
manner it vas possible to calculate an appropriate LEU 
dosage as well as identify as high risk patients, those 
individuals who were not clearing ftTX adequately. Although 
Pinedo ~ a~-& (1976) had shown that at lov !TX levels 
(i.e. less than 10- 7 ~) equimolar concentrations of LEU were 
sufficient to effect rescue, Stoller ~ ~1~£ (1978) elected 
to use a dose of LEU tenfold hiqher as a safety factor. 
The volume of distribution, distribution or elimination 
( 
( 
Methotrexate Dose 
(Lowest/Highest) 
{Fl - 100 mg/12g 
2 #2 - 240 mg/m /* 
#3 - 200/500 mg/kg 
#4 - 200 m;;/kg 
*Not Specified 
TABLE I 
METHOTREXATE PROTOCOLS 
Delay Time (Hrs.) 
for CF Rescue 
1. 5 
NONE 
4 
2 
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Dose & Schedule of 
CF Rescue 
6-25 mg q6h x 6-24 - IM 
2 40 mg/m over 6 hrs, 
then 25 mg q6h x 4 - IM 
9 mg q6h x 12 - Oral 
12 mg, wait 6 hrs, then 
12 mg q6h x 11 - IV, 
Oral 
( 
( 
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charac~eristics of LEU have not been reported, therefore, 
these authors assum~d that, since KTI and LEU are 
structurally related, LEU pharmacokinetic parameters were 
identical to those of MTX. Using this approximation, they 
vere able to minimize the LEU dosages employed and reduce 
the incidence of myelosuppresion in patients to less than 3 
percent, thus demonstrating that careful pharmacokinetic 
aonitoring could improve the therapeutic index of !TX. 
d. !TX Pharmacokinetics 
i. Absorption 
Henderson ~ s!~£ (1965) reported that H~-MTX, 
administered as a solution, was completely absorbed at a 
dose of 0.1 ag Kg-•. Freeman (1958) also found the drug to 
be completely absorbed fol1owing the oral administration of 
30 mg. of !TX. Peak plasma levels are reportedly achieved 
within one to four hours of oral doses. Wan ~ al:. (1974) 
described evidence which suggested biliary secretion and 
subsequent reabsorption of KTX. These authors found peak 
plasma concentrations following a 30 mg m-2 oral dose to be 
lover than those achieved when the identical dose was 
administered intravenously. Furthermore, the area under 
the plasaa concentration -time curve was approximately 47~ 
that of the intravenous dose. These authors also 
determined, via urinary excretion data, that approximately 
881 of the adainistered dose was absorbed. Burchenal ~! 
~al:..c. (1956) reportad a lover figure, approxiaately 401 of 
( 
( 
( 
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the drug vas recovered in urine within 24 hours of a 5 ag. 
oral dose. 
When ~TI was administered orally at a dose of 80 mg 
a-2, absorption was erratic and incomplete (Henderson ~~ 
~!~£ 1965 and Wan 2i ~!:..&. 1974t. At this dose only 311 of 
the drug was excreted in the urine, while fecal excretion 
increased from approximately 1~ following an intravenous 
dose to almost 30~. 
These data have led Bleyer (1977) to conclude that the 
absorption of !TX may involve a saturable intestinal 
absorption mechanism, possibly including an active 
transport mechanism. 
In addition to absorption from the gastrointestinal 
tract, MTX absorption into plasaa from the central nervous 
system has been reported. !TX is used for the treatment of 
aeningial leukemia and may be ad•inistered via ventricular 
or lumbar injection (Shapiro~ al~£ 1975). Jacobs~ al~ 
(1975) reported that the adainistration of 10 to 15 mg m-2 
intrathecally, resulted in plasaa concentrations above 10-e 
!, two to three times longer than the saae dose 
administered intravenously. 
ii. Distribution 
The disappearance from plas•a of intravenously 
administered ftTX has been described both as biphasic and 
triphasic. Huffman ~ al:.&. (1973) reported an initial 
half-life of o.75 ± 0.11 hr., most likely due to 
( 
( 
distribution. 
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Stoller !1! ~1&£ (1975) and Pratt ~i s!~L 
(1974) failed to detect such an early distributive phase 
because of inadequate plasma sampling immediately after 
druq adainistration. The second half-life reported by 
Huffaan ~i al. 4 (1973) corresponds vell with the first 
phase half-life of Stoller ~1 ~~L (1975t and Pratt ~ al~L 
(1974) and is between 2.0 and 4.0 hours. This half-life is 
attribQted to renal clearance (Bleyer, 1977t. The third 
and final phase half-life, attributable to biliary 
recycling, has been reported as 10., ! 1.8 hours by Stoller 
~ ~ (1975) and as 26.99 ! 4.44 hours by Huffman ~ al~L 
(1973). The discrepancy in the terminal phase half-life 
may be due either to differences in dosing schedules, or, 
the assay method used to measure MTX (Stoller ~1 ~l~L 
1975t. The third phase has been implicated in the toxicity 
associated with high dose-MTX regimens (Djerassi, 1975t. 
These observations suggest that the toxic effect of MTX on 
noraal tissue is primarily a function of the duration of 
exposure to suprathreshold concentration of of drug, rather 
than the peak plasma levels which may be achieved (Bleyer, 
1977). 
Huff•an ~ al:.&. (1973) calculated two volumes of 
distribution for !TX: an initial distribution volume was 
reported as 13.8 ! 1.09 L. vhich is considerably larger 
than the plasma voluae and indicates rapid tissue 
distribution of !TX. The second value reported was the 
apparent volume of distribution at steady state which vas 
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73.3 t 15.6 liters. 
Methotrexate has been shown to be protein bound. 
primarily to serum albumin. Wan ~ s!~ (1974) reported a 
mean of 45~ of plasma MTX bound to protein in twelve 
patients with drug concentrations between Oa3 and 3 mg. 
a1.-a. Liegler ~ a~ (1973t determined MTX plasma protein 
binding to be between 50 and 70~ in a group of fifteen 
patients. Taylor and Halprin (1977) also found 
approximately 60~ of serum KTX bound to albumin. In a more 
recent publication. Steele ~ s!~ (1979) reported MTX 
binding to albu•in to be approximately 87~ and to total 
plasma protein; 95~ over a concentration range of 1 to 30 
micromoles 1-t. These authors also performed Scatchard 
analysis on their data and determined that MTX binds to tvo 
distinct classgs of binding sites (Steele~~!~, 1979J. 
The displacement of MTX from its protein binding site(s) 
has been demonstrated with 
(Liegler ~~ ~ 1970) and 
Halprin. 1977). 
both para-aminohippuric acid 
salicylic acid (Taylor and 
Methotrexate. widely distributed in body tissues. is 
concentrated in the liver; liver to plasma ratios of 8:1 24 
hours after intravenous adainistration of 80 mg m-2 have 
been reported (Creaven ~ !!~£ 1973). Dedrick ~i ~ 
(1973) reported. for the rat. tissue:plasaa partition 
coefficients of 3 and 1 for the liver and skin 
respectively. Distribution into interstitial fluid spaces; 
cerebrospinal fluid. pleural. and peritoneal cavity occurs 
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slowlyr with characteristics described by Bleyer (1973) as 
reseablinq a passive transport system. Transport across 
cell membranes is achieved via an energy-coupled carrier 
mediated mechanism which has been described in detail 
(Flament-Durantr 1975 and Hall~ al.:.£ 1966). One of the 
reasons for employing high dose-MTX regiaens is to produce 
plasaa drug concentrations sufficiently heigh to permit 
facilitated diffusion into tumor cells deficient in 
transport sites (Bender~~!~£ 1977). 
iii. Metabolism 
Early studies of MTX administered at "conYentional" 
doses suggested thatr in aanr the drug is excreted 
unchanged into the urine (Henderson~~~ 1973). Wan~ 
~ (197q) detected a metabolite of KTX excreted in the 
urine which accounted for approximately 61 of a 30 mg. m-2 
intravenous dose. Following oral administration of the 
saae doser 35~ of the drug vas excreted in the form of 
aetabolites (Wan !1 al. 1 1977). It has also been shown 
that !TX is aetabolized during enterohepatic circulation by 
bacterial organisms within the gastrointestinal tract 
(Bleyerr 1977). These reports suggest that MTX metabolism 
in man occurs primarily in the gastrointestinal tract or 
"enterohepatic circuit" (Bleyer, 1977). Jacobs ~i ~1~ 
(1976) discovered that humans excrete "significant" amoonts 
of 7-hydroxymethotrexate vhen doses of KTX greater than 50 
mg Kg.-t are administered intravenously. The discovery of 
( 
( 
page 29 
this metabolite is significant because of its extremely low 
aqueous solubility which has been implicated as the cause 
of renal toxicity often associated with high dose MTX 
regimens (Jacobs~ al:u. 1976). 
iv. Excretion 
Excretion of ftTX is primarily renal. 
(1973) reported that ninety-six hours 
intravenously adainistered MTX. 66~ to 
Huffman ~! ~ 
following 
811 of the 
ad•inistered dose was excreted unchanged. The remaining 
191 to 34~ was accounted for by various metabolites. 
Huffman also reported a renal clearance rate of 78 ! 4.9 
ml. min.-• for "low" plasma concentrations of MTX. This 
report indicates that MTX is reabsorbed since the renal 
clearance vas less than the glomerular filtration rate in 
the patients studied. The clearance of MTX at "high" 
plasma concentrations was significantly higher than inulin 
clearance in 13 patients. suggesting active secretion of 
the compound (Liegler !isl~£ 1970). Approximately 1.51 of 
an intravenous dose appears in the feces, most likely 
caused by excretion of MTX from the liver into the bile 
(Huff•an ~ ~~£ 1973). These authors a l so reported that 
some patients shoved tvo or three increases in the rate of 
MTI excretion during a 96 hour urine collection period. 
Since 
food, 
biliary 
these 
it was 
increase were associated with ingestion of 
suggested that MTX undergoes substantial 
secretion and subsequent reabsorption (Huf faan ~ 
( 
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al:..&. 1973) • 
ea Pharaacokinetic ~odels 
The use of mathematic models in relation to drug 
disposition is important in formulating generally 
applicable predictions of plasma concentrations before drug 
is administered. In an effort to predict ~TX plasma levels 
in man, several aodels describing its disposition have been 
developed. 
Stoller §1 al~ (1975) used a two compartment open 
model, based on Equation 1 to describe MTX. 
Cp = Ae -°'-t + Be - ~t 
(Equation 1) 
Huffman ~ al:. (1973) found that plasma concentration-tiae 
data could best be described by a three coapartment open 
model and the corresponding tri-exponential equation~ 
(Equation 2) 
Reich (1977) has developed an expanded model consisting of 
seven distinct compartaents including shallow and deep 
intracellular spaces, aetabolite space, metabolite 
extracellular space and urine~ An interesting aspect of 
this model is the inclusion of Michealis-Menton kinetics to 
describe appearance of drug in the urine, however, the 
( 
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advantage of such a complex model over the previously 
described, simpler models has yet to be demonstrated. 
Bischoff ~ sl~ (1970,1971) have developed a 
"physiologic-perfusion" model to characterize the 
dispostion of MTX. Contrary to compartments with little or 
no physiologic meaning, the perfusion model is composed of 
specific body regions with si•ilar physiologic 
characteristics such as blood flow, and drug:tissue 
partition coefficients. The significance of perfusion 
models is in their ability to reflect physiologic 
conditions which affect drug dispostion whereas lumped 
coapartments are not suitably flexible for this purpose. 
6. Leucovorin Disposition 
Although the general disposition of orally or 
parenterally administered LEU has been determined, there 
have been no published reports which quantitatively 
characterize its pharmacokinetics, either alone or in 
coabination with high-dose !TX therapy (Nixon, 1979). The 
majority of published data which include LEU'S disposition, 
is primarily involved vith its rate of conversion to ~ETHF, 
the major component of naturally occuring, circulating 
serua folates (Herbert~ ~!~4 1962). Furthermore, much of 
these data are of a qualitative, rather than a quantitative 
nature, consequently, pharaacokinetic interpretation of 
these works is not possible. 
( 
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a. Plasma 
i. Intravenous 
Spray and Witts (1953) were the first to examine, in 
huaans, the rate of disappearance of intravenously 
administered LEU in normal subjects and patients suffering 
from "anemia". Following injection of 1.0 mg, peak plasma 
levels measured 10 minutes after dosing, varied from 44 to 
76 ng al-t in noraal subjects, and 33 and 54 ng a1-1 in 
aneaic patients. The authors made no statistical 
inferences regarding this data. The rate of disappearance 
of LEU 
than 10~ 
was described as "rapid", plasma levels were less 
of maximum within 1 1/2 to 2 hours after dosing. 
No differences in elimination rate be~veen normal and 
anemic subjects vas noted. These authors reported a 
"folinic acid-space" which vas calculated by dividing the 
total amount of LEU in the body by the corresponding plasma 
concentration. Two such spaces were reported; 10 minutes 
and 90 minutes post drug administration. At 10 minutes, 
the value of this space had a aean value of 17.2 liters in 
normals and 24.2 liters in anemia patients, which 
demonstrated a statistically significant more rapid uptake 
in the anemia patients. The space calculated at 90 minutes 
for controls and aneaia patients vas 342 liters and 547 
liters respectively. However. the meaning of this space is 
unclear, since it may reflect either the conversion of LEU 
to other folate forms or. that LEU is quickly taken up by 
( 
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tissues. 1 representative plot of drug concentration as a 
function of time from the normal subjects is shown in 
Figure 4. Baker ~ al~ (1965) r characterized the fate of 
parenterally administered "folinic acid" (LEU) by 
determining plasma folate activity from f~ ~~~i~ 
growth. Because a "great increase" in this organism's 
growth was observed. these authors concluded that 
"parenterally administered f olinic acid circulates 
unaltered". 
The disposition following intravenous ad•inistration 
of 5 ug Kg-1 of doable radiolabelled folinic acid 
(S-foray1-1•c-Feq-3H)r in a huaan patient was described by 
Nixon and Bertino (1972). Serum collected 90 minutes after 
dosing revealed that 401 of the radiolabel 
co-chromatographed with a folinic acid marker. Sixty 
percent of 3H label vas present as !ETHPr demonstrating 
conversion of LEU to the predominant circulating folate. 
The reaaining markers had been "labilized to non-absorbable 
•aterialsr perhaps amino acids" suggesting that little LEU 
remained in the circulation ninety minutes after dosing. 
In a more recent study. Rothenberg~ 51:..L (1979), 
characterized the plasma clearance of LEU following rapid 
intravenous injection in tvo normal subjects. The 
radiochemical assay measured both the active and inactive 
diastereoisomers of LEU. Peak plasma concentrations 
achieved in those two subjects following doses of 6.0 mg. 
and 3.0 ag. were approximately 1100 nq m1-1 and 1000 nq 
( 
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Figure 4: Leucovorin Plasma Decay as a Function 
of Time as Measured by a Microbiologic 
Assay Method 
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ml-• respectively. The plasma profiles shoved a "rapid 
clearance for the first 30 minutes" which "then plateaued 
and cleared very slowly over the next 90 •inutes". The 
description of a plateau following the rapid initial 
decline in plasma LEU is contrary to the reports of Spray 
and Witts (1953) and Nixon and Bertino (1972) vho described 
only a rapid plasaa clearance vith no aention of a second 
eliaination phase. Rothenberg ~ ~!~£ (1979) suggest thg 
slov second phase clearance is most probably due to the 
accumulation of the inactive diastereoisomer. since the 
kidney appears to preferentially excrete only the active 
form of LEU. 
Perry and Chanarin (1970). Chanarin and Perry (1970). 
and McLean (1967), have performed a series of experiaents 
designed to determine the origin of serum METBF after the 
intravenous adainistration of tritiua labelled folate 
analogues. These authors reported ~hat "when given 
parenterally ••• these compounds exchange with folates in 
body tissues, that is. vhen tritium-labelled dihydrofolate 
or tetrahydrofolate ••• is given by injection the labelled 
f olate disappears fro• plasma and is replaced by an 
unlabelled for•--·"· Furthermore. Johns !!, aL, (1961) 
reported that "when a parenteral dose of tritium-labelled 
f olic acid in man vas followed by a large dose of 
non-radioactive folic acid 24 hours later, a large amount 
of radioactivity vas displaced ••• ". 
These data suggest that the appearance of KETHP in 
( 
( 
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plasma following the intravenous administration of LEU is 
caused by a flushing of METHF from tissue rather than a 
direct metabolic conversion. 
ii. oral 
The fate of orally administered folates. including LEU 
has received considerable attention. Specifically. the 
rate at which folic acid crosses from the gut into the 
circulation and the rate and extent to which folates are 
converted to !ETBF. the predominant circulating reduced 
folate analog (Denko.1951; Spray and Witts, 1952; Chanarin. 
Anderson, and !ollin. 1958t. In addition Blakely (1969t 
has published an excellent review of folic acid 
biochemistry which includes the disposition of orally 
administered folate. Although the fate of orally 
administered 
interest in 
regimens has 
disposition. 
LEU has received considerably less attention, 
this route of adainistration in ~TX-rescue 
prompted relatively recent interest in its 
Baker ~ ~!=.£ (1965) administered 10mg. of racemic 
folinic acid to 48 normal subjects. Assay of serum folates 
was carried out by a combination of TLC and the standard 
microbiologic assay technique of Sauberlich and Baumann 
(1948). Serum folate activity ( 1:-_ case!l indicated a slow 
rate of absorption. the peak activity was not reached until 
4 hours after administration, followed by a rapid decline 
in activity at 8 hours, the last sampling time. Because 
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little or no activity was noted for either ~ t~~£ali2 or 
f~ ~~~!i2~a~& it was concluded that the circulating folate 
was not LEU but rather METHF which was rapidly converted 
f roa LEU in the intestine. 
Perry and Chanarin (1970) noted that, with the 
exception of Baker ~S a!&.£ (1965), al•ost all previous 
reports concerning the intestinal absorption of folates 
dealt with f olic acid alone. These authors reported the 
absorption of the reduced folate DHF and THF as well as 
their formyl and •ethyl derivatives. The evidence 
presented in 
to THF and 
this paper suggest that DHF is first reduced 
then aethylated in the saall gut during its 
intestinal 
which is 
that the 
absorption. Furthermore, " ••• tetrahydrofolate 
already reduced is methylated". It is suggested 
enzyme dihydrofolate reductase is involved with 
these reductions in the saall intestinea The selectivity 
of this reduction is demonstrated by the rapid conversion 
of DHP to THP coapared to the reduction of folic acid to 
DHF which is reported to occur at approximately one-tenth 
the rate of the former reaction (Zakrevski and Nicol, 
1960). Thus, it was reported that the reduced foras of 
folate, including LEU, were completely reduced to THP and 
•ethylated, whereas folic acid vas only partially reduced. 
Vhithead ~ a~ (1972) described the intestinal 
conversion of 2 ag. of racemic LEU to !ETHP in 3 subjects. 
Using the standard microbiologic technique, folate activity 
vas measured in both the peripheral venous plasma and the 
( 
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hepatic portal venous plasma. These authors defined newly 
absorbed fola~e as "the difference between the increment of 
folate activity in hepatic portal vein plasma and in 
systemic plasma". Although the data is not suitable for 
pharmacokinetic analysis certain trends are evident. Peak 
folate activity vas reached between 30 and 60 minutes of 
adainistration in all 3 subjects. However, the rate of 
druq clearance a•ong the subjects varied greatly. The 
half•life was estimated as 45 ainutes in one subject, 15 
ainutes in the second, and in the third a plateau in plasma 
concentration was observed making an estimate of half-life 
impossible. In agreement with Perry and Chanarin (1970), 
the predominant circulating folate found in plasma was not 
LEO but rather, !ETHF, indicated by an increased &~ ~~ 
activity and little activity for either f~ £~~!~§ia~ or ~ 
i!.ecalis. A small aaount of plasma folate active for these 
organisms was found early in the course of absorption. 
Whithead ~i s!:u. (1972) suggest that a s•all amount of 
folinic acid aay have reached the plasma Tia passive 
absorption vith water through the intracellular spaces. 
The appearance in plasma of ftETHP, measured by t.:_ ~i 
activity, following LEU administration vas also observed by 
Pratt and Cooper (1971). · However, ~ t!ecali~ and~ 
cerevisi~ activity was seen in plasma 30 minutes after 
dosing, suggesting that some LEO had been absorbed. Thin 
layer chromatography of serua samples confirmed that this 
folate was indeed LEU (Pratt and cooper, 1971). The 
( 
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absence of an increase in £:.. ~~12ia! activity in the 
bile vas taken by these authors to mean that little if any 
LEU appeared in the bile. Rather, it is concluded that 
f olates appearing in bile reflect the "intracellular 
folates of liver", and not orally absorbed analogs. 
LEU is known to for•, under the acid conditions 
existing in the stomach, NS-Nto methenyl THF which in turn 
forms, in the basic enTironment of the small intestine, the 
readily oxidized and unstable Nto formyl THF (!ay and 
Bardos !1 ~' 1951). Because the suitability of N'o 
f ormyl THP for rescue following high dose-MTX has not been 
established, LEU has been used parenterally in rescue 
protocols (Nixon and Bertino, 1972). Nixon and Bertino 
(1972) used radiotracer techniques to deter•ine whether 
orally administered LEU reached the blood pool in a for• 
that "contributes to expand the body pool of reduced folate 
coenzymes and so potentially to reverse the effects of 
antifolates". At doses of this co•pound as high as 50 ug 
Kg-1, oral absorption vas "close to 90 percent", since only 
8~ of the 3H and 5~ of the t•c was excreted in the stool 
within five days of drug administration. During transfer 
from the gastrointestinal tract to the systemic circulation 
substantial aetabclisa of LEU occured. Ninety percent of 
the serum folate3-H was identified as labelled !ETBP, vhile 
that label associated with the ••c-fORKYL group did not 
appear among the circulatinq serum folates, suggesting that 
this portion had been taken up by tissues. 
page qo 
These data taken with the previously described work of 
Whithead ~! s!~L (1972), Perry and Chanarin (1970, and 
Baker (1965), demonstrate that orally adainistered LEU 
raises levels of serum folate activity for ~ £S~ei but not 
[~ ~!!!§ or f~ £§~~i!~L and identifies KETHP as the 
predominant circulating folate. Because ~ETHF can 
circumvent the enzyae block imposed by ~TX, these works 
suggest that orally administered LEU may be useful in high 
dose-KTX regimens. 
Mehta ~ s!::..r. (1978) recently investigated the serua 
distribution of LEU following oral administration of 15 mg. 
of drug as a solution and as a tablet. Within 30 minutes, 
of oral administration, 90~ of the adainistered folate vas 
assayed as ftETHP. Peak plasma levels of LEU were observed 
30 minutes following dosing and fell off rapidly 
afterwards. The plasma half-life of LEU was reported as 
0.6q ± 0.07 hr. and 0.67 ± 0.07 hr after oral liquid and 
oral tablet administration respectiYely. From these data, 
it was further observed that peak KETHF levels were 
achieved approximately 2 hours following the adainistration 
of drug. KETHP was determined to have a half-life of 
approxiaately 2.2 hours. 
The reported LEU half-life of 0.67 hr is in general 
agreement vith the values of 30 lli.nutes reported for the 
elimination phase half-life determined by Spray and Witts 
(1953). The fact that Mehta ~ !!:..&. (1978) did not 
describe a distribution half-life is most likely caused by 
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difficulties in detecting rapid distribution following oral 
drug administration (Wagnerr 1975). 
b. Urinary Excretion Data 
The renal excretion of folic acid has received 
considerable attention ( !clean and Chanarinr 1966; Goresky 
~ ~1. 1 1963; Chanarin and !cleanr 1967)r and has been 
reviewed by Blakely (1969). ~ETHPr NtO-forayl THF and 
HSrN•o-aethenyl 
folates. There 
PH4 are the most co•monly detected urinary 
is howeverr a paucity of data dealing 
specifically with urinary excretion of LEU. 
Spray and Witts (1953) followed the urinary excretion 
of LEU following the intravenous adainistration of 1 mg. of 
drug to 5 nor•al subjects. The percent of drug excreted 
during the first two hours after dosing ranged fron 9.9 to 
19.2. and had an average value of 15.4. No folate activity 
·attributable to LEU vas observed after 2 hoursr indicating 
either conversion to another form or uptake of the drug by 
various tissues. 
Nixon and Bertino (1972) found a "fairly-constant" 
rate of urinary clearance of 110-formyl and NSrff'O methenyl 
FB4 following the administration of double radio-labelled 
LEU. In addition. these authors reported that the portion 
of urinary !ETHP vas approximately proportional to the 
serum concentration of identifiable radio-labelled ~ETHF. 
Furthermore. "large amounts of radio-labelled 5-formyl" FH4 
were found in the urine 0-2 hours post dosing. even when no 
f 
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corresponding label vas identifiable in the serum. In a 
si•ilar study of administered radio-labelled !ETHF, no 
formyl folate was excreted in the urine (Nixon and Bertino 
1970). These data led the authors to conclude that the 
"---kidney may have both regulatory and metabolic roles in 
the excretion of folates: serum 5-methyl PH4 may be 
conserved by the kidney in preference to 5-formyl FH4 ••• ". 
Recently. Rothenberg ~ ~l~, (1979) examined the 
urinary clearance of LEU in a subject vho received 3 •g. of 
intravenously administered racemic LEU. The total urinary 
excretion in tvo hours was ·calculated to be 578 ug or 19.31 
of the administered dose. a value that is in general 
agreement with the earlier work of Spray and Witts (1953t. 
The urinary excretion of LEU in tvo subjects receiving only 
the active isoaer of LEU was also determined. The ~vo hour 
cu•ulative urinary excretion in the 2 subjects vere 16.61 
and 20~ of the administered dosea It was concluded f~o• 
these data that since the percent of dose excreted 
following the administration of either the racemic mixture. 
or active diastereoisomer. of LEU were similar that only 
the ~iv~ rather than the inactive for• is rapidly 
excreted. 
c. 5• Methyl Tetrahydrof olate 
1. Physical-Chemical Properties 
Prefolic A (S-methyl THF. ~ETHF). N-amino-5- methyl 
s.6.1.a.-tetrahydro- 4-hydroxy-6-pteridinyl)methyl 
( 
• 
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aminobenzoyl L-glutamic acid. is a yellowish white or white 
crystalline powder. The anhydrous barium salt has a 
aolecular weight of 594.Sr commercial preparations usually 
contain four molecules of water per mole of compound (Sigma 
Product Catalog. 1980)0 The aqueous solubility of KETHP 
has been reported as 1G1 grams per 100 ml. It is 
practically insoluble in organic solvents (Conti ~ al~L 
1974). The aelting point of METHF is reported as greater 
than 3oooc. (Conti ~S !!:..&. 1974). At alkaline pH. !ETHP is 
easily oxidized by air or hydrogen peroxide-perioxidase to 
a dihydrofolate (Gupta and Huennekens. 1967) r vhich in 
turn. can be reduced back to METHF by hydrogen in the 
presence of platinum. ascorbic acid or borohydride 
(Blakely. 1969). 
Spectral characteristics for METHFr in phosphate 
buffer pH 7.0. have been reported (Blair and Saunders. 
1977; Conti ~ al:..&. 1974; and Chanarin and Perry. 1967). 
The molar absorptivity vas determined to be 3.18 x 10-• m-1 
ca-1 (24a). The ultraviolet spectrum shoved a maximum at 
290 nm. and a ainimu• at 245 na. (Conti ~ al:..&. 1974r and 
Chanarin and Perry. 1967). The infrared spectrua for the 
magnesiua salt has ben characterized by Conti !11 al.L 
(1974). and the proton magnetic resonance spectrua vas 
reported by Blair and Saunders (1970). 
2. !ETHFr Isolation and Identification 
Donaldson and Keresztesy (1959) reported the 
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extraction from horse liver of a "citrovorum factor 
precursor" which did not support the growth of either ~~ 
fa~~li§ or ~~ cit~.!2~~~ The precursorr named Prefolic 
Ar vas reportedly converted to citrovorum factor by tvo 
separate enzyme systemsr an FAD-Linked system and a 
transformylase aechanism (Donaldson and Keres~tesfr 1959). 
These authors also shoved that Prefolic A could be readily 
convertedr Yia enzymatic oxidationr to THPA and 
formaldehyde. 
Larrabee and Buchanan (1961) discovered an 
intermediate of methionine biosynthesis which vas 
identified as a f olate compound containing a one carbon 
substituent. The folate derivative did not support the 
growth of either ~~ ;aecalis or 1~!:. citrovorumr but it 
was later deterained that it would support the growth of ~~ 
£a§~ (Larrabbe ~ ~!~£ 1961). This compound vas found to 
contain approximately one mole of aethyl group per mole of 
compound. Larabee ~ sJ:~ (1961, used Prefolic A as the 
substrate in the conversion of methionine to homocysteine 
(in the presence of DPNB. PAD, ftg+z, ATP and "B12 enzyae")a 
These authors proposed NS •ethyl THP as the tentative 
structure of the folate deriYative (Larrabbe ~ s!:.~ 1961)~ 
Prefolic &, as the barium saltr was isolated in 
"essentially" pure fora from horse liver by Donaldson and 
Keresztesy (1961) vho reported that its spectral 
characteristics were similar to those of dihydro and 
tetrahydro folic acids. Keresztesy and Donaldson (1961, 
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reported the chemical synthesis of Pref olic A from dl THP. 
The synthetic material was approximately as active as the 
natural Prefolic A relative to L~ £s2ei activity, and it 
vas found to have the same ultraviolet absorption 
characteristics (Donaldson and Keresztesy, 1961). Blair 
and Saunders (1974t have since reported the preparation of 
• (+,-)-!ETHF fro• folic acid, using sodium borohydride as a 
reducing agent. 
3. Biochemical Role of METHF 
The enzyme Ns-10 methylene THF reductase, found in the 
liver of various vertebrates and in c~rtain bacteria 
(Blakely, 1969), catalyses the reduction of ss-10 methylene 
THF to METHF. This reaction represents the major 
biosynthetic pathway for ~ETHF. This reaction can use 
either NlDB. NADPH, or FADB2 as the electron donor 
(Donaldson and Keresztesy 1962). 
Wagner (1966, isolated an enzyme, tentatively named 
triaethylsulfonium: tetrahydrofolate methyltransferase 
which catalyzes the methylation of TBP as shown in Figure 
4. This, however, is not a aajor mechanism for the 
synthesis of ~ETHF. 
In addition to the identified enzyme mediated 
aechanisas of METBF biosynthesis, indirect evidence 
suggests a third pathway. Serua concentrations of METHF 
are •uch higher f ollovinq oral administration of folic acid 
or folinic acid (LEU) than after identical doses 
( 
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administered parenterally (Nixon and Bertino. 1972. Mehta 
~ al:..L i978). This observation has led to speculation 
that significant synthesis of HETHF occurs in the 
intestinal mucosa (Baker et s1~£ 1965. and Chanarin and 
Perry. 1970) although the precise mechanisms responsible 
for the synthesis have not yet been elucidatedo 
Larabee ~ sl~ (1961) first identified HETBF as the 
folate intermediate in the interconversion of homocysteine 
to methionine. In the presence of appropriate enzymes and 
cofactors ~ETHP transaethylates with hoaocysteine resulting 
in the synthesis of methionine and THF. 
This transmethylation requires several cofactors: ATP. 
!g+2. and either PADH2, NADH or PAD (Larrabbe !1 al~£ 1961) 
as the electron donor. This appears to be the only 
synthetic pathway involving !ETHP. 
page 47 
III. FOLATE ASSAYS 
A. Microbiologic 
Interest in the quantification of serum folate 
concentrations vas initially focused on determining the 
etiology of various anemias (Kamen and Caston. 1974). by 
aicrobiologic methods- Sauberlich and Baumann (1948) 
described such an assay using ~~£2nostoc citro!2IY! ATCC 
8081. later identified as f~diocoCCY,2 ~revisia~& for which 
LEU is an essential growth factor- The determination of 
LEU concentration (or activity) was carried out by 
measuring the zone of growth around standard paper discs 
saturated with leucovorin solutions. 1s~2~~cill~~ £s§~i 
ATCC 7469 and str~etococcu§ t~ali§ 9 have been used in a 
similar manner (Grossowicz ~ llL~ 1962). 
The microbiologic assays are not specific. For 
exaaple. ~ ~!i ATCC 7469 responds not only to pteroyl 
glutaaic acid but LEU and also certain polyglutaaates 
(Grossovicz ~ !!:..c. 1962). §:. !s~£ali§ utilizes folic acid 
and several 
~~evisae-
tetrahydrofolic 
In addition to 
acid 
their 
derivatives as does f~ 
lack of specificity. 
microbiologic assays are generally tiae consuainq. often 
requiring eighteen to tventy-four hours of incubation time 
and. aore importantly, may be affected by antimicrobial and 
antineoplastic agents in the blood (Kamen and Caston, 
1974). However. Hutchinson and Burchenal (1952) isolated a 
methotrexate resistant strain of Its. citrovorum ATCC 8051 
( 
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and !ehta and Hutchinson (1975) reported the use of this 
strain for the determination of LEU in the presence of 
methotrexate. The eventual isolation of a 
methotrexate-resistant strains of k=. ~~~i and s. ~cali§ 
made possible the determination of METHF as well (Mehta and 
Hutchinson. 1977). ~ ~2!.~ responds to all forms of 
folate. from which total folate activity can be measured. 
while ~ fae£~li2 var. Durans responds to all forms of 
folate except ftETHF (Kehta and Hutchinson. 1977t •• 
Thereby. the difference in activities between the tvo 
microbiologic assays is attributable to serum levels of 
METHF. These methods. although useful. remain subject to 
interference by antimicrobial agents and other 
antineoplastic agents which may be used in combination 
che•otherapy. 
B. Spectrophotometric Methods 
1. Ultraviolet 
The extinction coefficient (282 nm.) for LEU has been 
reported as 2.39 to 2.41x10M-l cm-a in 0.1N NaOH 
(Zakrzewski and Sanson. 1971t. Ultraviolet spectroscopy. 
however. has not been employed for LEU analysis for tvo 
reasons: (1) the aolar absorptivity reported is not 
considered to be reliable because of frequent impurities in 
samples; and (2) LEU readily dehydrates under acidic 
conditions to Ns.s10 methenyl THP. vhich absorbs at 352 
na •• thus affecting the accuracy of leucovorin analysis 
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(Ponte 2i al., 1979). 
Pont 2i sl~L (1979) state that LEU aay be analyzed by 
acidification with 0.1 N BCl followed after 1.5 ~o 2.0 
hours by UV aeasurementr provided that no interfering 
species are present. Interfering species are considered to 
be folate derivatives which might convert to 
anhydroleucovorin upon acidification. Because such folates 
are thought to exist in blood (Blakely. 1969) UV 
spectroscopy is not considered applicable to the analysis 
of LEU in biologic fluids. 
2. Fluorometric 
LEU exhibits maximum natural fluorescenc~ at pH 7.0 
with excitation and emission at 370 na and 460 nm {Dugan ~ 
~LL 1957) and 314 nm and 365 nm (Uyeda and Rabinowitz, 
1963) respectively. The differences in wavelengths 
reported were . attributed to sa•ple impurities. pH 
variations. and quenching (Ponte ~ ~B..L 1979). Although 
LEU will fluoresce and quantitative results are similar to 
those obtained by microbiologic methods (Ponte ~ a_~ 
1979)r fluoroaetric methods have not been applied to the 
determination of LEU. 
3. Other 
several radiochemical techniques for serum folate 
analysis have been reported recently {Kaaen and Caston, 
1974; Rothenberg ~1 al-~ 1979; and Raso, 1977). All of 
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these aethods rely on the competition between METHF and 
tritiated pteroylglutamic acid (3H PGA) • for the binding 
sites on naturally occuring protein. (~ETBF is used as the 
reference folate because it is the major circulating serua 
folate.) The protein source may vary but •ilk protein is 
the most common binder in use (Rothenberg !!1 ~l.L 1979). 
In these methods. tritiated 3B PGA is displaced from the 
binding site by !ETHFr and standard curves are prepared by 
plotting percent 3B PGA bound as a function of METHF 
concentration. The higher the !ETBF concentration. the 
less 3H PGA bound. 
These techniques. however. cannot be applied to LEU 
because the affinity of the binding protein for the formyl 
tetrahydrofolate (LEU) is not strong enough to displace 3H 
PGA (Rothenberg. ~1 s!~L 1979)0 Further. since some 
circulating folate is present in the bound fora these 
methods do not reflect total folate activity but rather are 
an indication of actiYity relative to METHP standard (Kamen 
and Caston. 1974). Finally. the effect of other agents 
notably antiaicrobials and antineoplastic agents (e.g •• 
methotrexate) on these methods has not been reported. 
Rothenberg !!1 al=..c. (1979) deTeloped an indirect 
approach in order to measure LEU using the radiochemical 
technique. METHF is first measured in a portion of serum 
or urine sample using standard radiochemical techniques. 
Another portion of the saae serum or urine sample is then 
acidified and exposed to sodium borohydride vhich converts 
( 
LEU (formylFH4) to methy1FH4. 
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The difference in METHF 
concentrations between the treated and untreated samples is 
assumed to be due to the original concentration of LEU. 
Langone and Levine (1979) have published a preliminary 
report of a radioimmunologic assay for leucovorin using an 
anti-leucovorin antibody produced in rabbits. The method 
is reported to be sensitive to 0.10 nanograms of LEU added 
to serum. Other forms of f olates and methotrexate 
reportedly do not interfere with the determination of LEU; 
howeverr due to the antibody's specificitYr the method is 
not applicable to the predominant circulating folater 
!BTBF. 
Anion exchange chromatography was the first HPLC 
application for the separation of mono-pteroylglutamates 
(Stout ~ al.L 1976 including LEU and !ETHF (Reed and 
Archer 1976). Howeverr these methods are relatively 
inefficient; in addition they require long chromatographic 
columns (4 1/2 ft.) and unacceptably long chroaatographic 
run times. Other HPLC methods have recently been reported 
(Reif ~ sl•£ 1977r and Chapaan ~ al:..a, 1978) and a 
complete review of chromatographic naethods applicable to 
various pteridine and/or pteroylglutanates has been 
published (!ontgoaery ~ ~4 1975). 
The use of HPLC coupled with electrochemical detection 
has been recently reported for the determination of ftETHF 
in plasaa and spinal fluid (Lankelma and Van der Kleijnr 
1980). A detection limit of 2x10-•M !ETHF and 100~ 
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recovery fro• body fluids is claimed. The low limit of 
detection is attributable to on-column concentration of the 
folate. Sample 
trichloroacetic 
treatment requires the use of ten percent 
acid in 0.1 N HCl to precipitate plasma 
protein prior to centrifugation and sample injection. 
Because of "early plasma peaks in the chromatogram" and 
"foreign eluent"• it vas necessary to "vent" the column to 
prevent "poisoning" of the electrode surface (Lankelma and 
Van der Kleijn, 1980). The method is not applicable to LEU 
which is not detected under the chromatoqraphic and 
electrocheaical conditions employed. The use of 
trichloroacetic acid in 0.1 N HCl raises considerable doubt 
regarding th~ integrity of the various forms of reduc~d 
folate in the saaples so treated. For exaaple. when LEU is 
acidified it loses vater to become NS.fflO methenylFH4 
(1969). Other reduced folates are subject to rapid 
hydrolysis as well (Blakely 1969). The possibility exists 
that all folate present in plasma samples treated by this 
method are converted to some interaediate form of reduced 
folate or to !ETHF. If this were indeed the case the 
reported sensitivity would be erroneous since the total 
peak height or peak area vould not be due solely to METBP. 
In addition to the methods applicable to the assay ~f 
LEU and/or for !ETHP in biologic fluids. several t~chniques 
have been reported for the separation and identification of 
folate derivatives. These methods are not sufficiently 
sensitive to the analysis of folates in biologic fluids. 
( 
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Brovn. Davidson. and Scott (1973) reported the separation 
of pteroylglutaaates and related compounds by thin layer 
chromatography. This and other methods have been 
thoroughly reviewed by Blakely (1960). 
IV. ELECTROCHEMICAL DETECTION 
A severe limitation to the application of high 
pressure liquid chromatography (HPLC) to the analysis of 
drugs in biological fluids has been the lack of a suitable 
detector (Riggin ~1 al~L 1975). Five basic require•ents of 
an HPLC detector have be~n recently enumerated by Hashimoto 
and Maruyama (1978): (1) high sensitivity and 
reproducibility; a> versatility; (3) continous monitoring 
of column effluent; (4) independence from operating 
parameters such as flov rate and mobile phase composition; 
and (5) a vide linear response. Also important is the ease 
of operation as vell as the durability and stability of the 
systea. The spectrophotometric methods. i.e •• ultraviolet. 
visible and fluorometric. although suitable in many 
respects. are not applicable for compounds without 
chromophores. those vith lov molar absorptivity. or those 
that do not fluoresce. Refractive index. although 
versatile. is not particularly sensitive and is therefore 
not generally applicable for the analysis of drugs in 
biological fluids. 
The possibility of using electrochemical techniques to 
( 
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monitor HPLC effluents vas first discussed by Kemula 
(1952). although the technology available at that time 
severely restricted the application of this method. 
Kissinger ~s!~L (1973). Takata and Muto (1973) and Pleet 
and Little (1975). have recently described electrochemical 
detectors compatible vith modern HPLC technology. Since 
these reports appeared electrocheaical techniques have been 
applied widely to the quantification of drug substances in 
biological fluids (Greenberg and ~ayer. 1979; White. 1979; 
and !unson ~ al.L 1978). Although the electrochemical 
detector 
HPLC, it 
is not the widely sought "universal" detector for 
provides a selective and sensitive method of 
detection for suitable compounds. 
A. Theory 
The coupling of electrochemical detection to high 
pressure liquid chromatography relies on introducing the 
column effluent to a region. or cell. in vhich electrolysis 
can occur (Takata and ~oto. 1973). Electrochemical 
detectors in current use are based on "DC hydrodynamic 
chronoamperometry" 
function of time 
fixed electrode 
in which "current is measured as a 
with a constant potential applied at a 
exposed to a moving fluid" (Shoup. 1979). 
This nay best be conceived as electrolysis at a fixed point 
along a flowing stream. Electrolysis can result in either 
oxidation or reduction reactions. Since reduction of 
dissolved oxygen, metal ions. and hydrogen can hinder 
l 
page 55 
electrochemical detection. most practical applications have 
been carried out in the oxidation mode (Shoup. 1979). 
Scheme I represgnts the simplified reaction vhich 
occurs vhen an organic compound R is oxidized to an 
intermediate compound o. yielding n electrons (et. The 
unstable intermediate may be expected to form. 
irreversibly. the stable product P. 
R---- 0 ----) P ~-
e --~) E (Schere 1) 
This is a siaplified Yiev and qenerally the 
electrochemistry of organic aolecules of clinical 
significance is not well understood (Kissinger ~ al.L 
1979). 
The quantity of electricity required for this reaction 
can be calculated according to Faraday's Lav Equation 3. 
Q - n*F*N (Equation 3) 
Where; 
Q = the number of coulombs used in the conversion 
N = the number of •oles of material converted 
n = the number of electrons generated per mole of 
material conYerted 
F = Paraday•s constant 
Current is a measure of the rate at which the 
oxidation proceeds and is described by Equation 4. 
( 
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i = dQ/dt and nF * (dN/dt) 
(Equation 4) 
Where i represents current and all other terms are as 
described earlier. 
The efficiency with which aaterial is oxidized (or 
reduced) and current is produced, can be calculated from 
the number of moles of material that react (N) and the 
total number of •oles entering the electrode region 
(Ntotal), according to Equation 5. 
Efficiency (Eff) = (N *Ntotal) x 100 
(Equation 5) 
Amperoaetric detectors typically operate vith efficiencies 
ranging from four to ten percent (Kissinger, 1977). The 
current produced via electrochemical reactions and hence 
the efficiency of the systea is affected by several 
parameters, soae of which are goYerned by the 
electrochemical process and others of which may be 
controlled experimentally. Equation 6 relates these 
paraaeters to the liaiting current (i lim) (Willard ~ al~£ 
197 4) -
i lim = (nFAD ~ulk) I e. 
(Equation 6) 
page 57 
Where; 
n= number of moles of material converted 
electrochemicaly 
F = Paraday•s constant 
A = surface area of the electrode 
D = diffusion coefficient of the electroactive species 
in the solvent or mobile phase. 
Cbulk = the concentration of the electroactive species 
in the bulk or mobile phase. 
(s) = the diffusion layer thickness. 
Paraday•s constant and D are properties of the 
electroactive species and cannot be controlled 
experimentally .. The diffusion layer thickness and 
electrode surf ace area are variables which can be used to 
influence the current generated from the electrolysis of a 
sample. Diffusion layer thickness. (s)r refers to the 
distance through which the electroactive species must 
travel from the solution (or mobile phase) to reach the 
electrode surface. Por an electrochemical reaction to 
occur. the electroactive species must: (1) diffuse from the 
balk solution to the electrode surface; and then (2) 
transfer electrons at the surface (Kissinger. 1977. and 
The rate-determining step is 
considered to be diffusion through the bulk solution. which 
is governed by Fick•s First Lav (Willard~!!~£ i91q)r 
Equation 7. 
J = D * ( Cbulk - £ ) 
(Equation 7) · 
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Where 
J = flux 
D = diffusion coefficient 
Cbulk = concentration of solute in the bulk phase 
Co = concentration in the electrode surface 
(s) = diffusion layer thickness 
It is apparent from Equations 6 and 7 that flux is 
inversely proportional to the distance electroactive 
species must travel and by decreasing (s) , the current 
generated can be increased. Experimentally, (s) can be 
regulated in two ways: first, by confining the sample 
within a thin fil• of electrolyte passing over the 
electrode surface, an application of the principle of lov 
volume flov thru cells (Figure 5) ; secondly, by varying the 
flov rate of solution through the thin layer cell to effect 
an increase or decrease in the value of (s). Increasing 
flov coapresses (s), resulting in a saaller diffusion 
distance, thereby increasing dN dt-1 and the current 
generated (Kissinger, 1977; and Buchta and Papa, 1976). In 
practice, however, high effluent flow rates decrease the 
residence time of electrons within the electrochemical cell 
and may actually decrease the current generated by an 
electroactive species. 
The rate at which material reaches the electrode 
surface is not only a function of flux, J, but of the 
electrode surface area A, (Willard~ al::..&. 1974), according 
to Equation 8. 
cIN/dt = A * J 
(Equation 8) 
( 
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Increasing the surface area of an electrode will result in 
a faster rate of electron production and. according to 
Equation a. will generate a larger current. However. the 
conversion of material in the mobile phase. i.e •• 
electrolytes, trace metals, etc, will also increase. This 
increase in background current may negate the advantages of 
using electrodes with large surface areas. 
current say be influenced by another aeans. not 
apparent from Equation 6. Equation 9 describes the 
relationship between the potential applied to the electrode 
surface and the resulting current: 
Where; 
e = e! + ...!!__ 
nF 
e = applied potential 
* ln ( 
e1/2 = standard electrode potential 
r = molar gas constant 
t = absolute temperature 
n = nuaber of electrons transferred 
P = Paraday•s constant 
i = current 
ilia = liaitinq current 
(Equation 9) 
A current-voltage curve. (hydrodynamic Yoltammogram) 
can be produced by plotting current as a function of 
applied potential. The selectivity of electrochemical 
detection is based on the difference in behaviour between 
electroactive species and the currents produced at various 
potentials:. "For example, methoxyhydroxy compounds are 
( 
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more difficult to oxidize than are catechols and therefore 
can be •tuned out• of a chromatogram by lowering the 
applied potential" (Kissinger. 1977). 
B. Electrode Material 
A vide range of electrode •aterials have been applied 
to electrocheaical detectors. Liquid chromatography 
electrochemical detectors have been prepared fro• carbon 
paste (Atuma and Lindquist. 1973). mercury (Pleete and 
Little. 1974), platinum (MacDonald and Duke. 1973). 
pyrolytic carbon (Wightman ~ !l~L 1978), glassy carbon 
(Birmingham ~ sl=.&. 1979) •silver (Takata and euto. 1973). 
and graphite i•pregnated silicone rubber (Zaradi ~ ~L 
1974). Mercury is •ost of ten used for reduction reactions 
while carbon paste and glassy carbon electrodes have been 
the most widely used for oxidation procedures (Shoup. 
1979). Because the reported detection limits for 
oxidizable substances are considerably lover than for 
reducible coapounds, the various forms of carbon and carbon 
paste have received the most attention (Wightman ~ al.L 
1978). 
The choice of electrode material may be governed by 
several considerations. Mobile phase coaposition is an 
important factor; for example, carbon electrodes with oil 
1 
bases are adversely (in terms of surface distortion) 
affected to a greater degree by high concentrations of 
organic in a mobile phase than are either carbon 
( impregnanted wax or glassy carbon. 
react at significantly different 
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~any organic compounds 
rates depending on the 
electrode used. 
by finding the 
The greatest sensitivity can be achieved 
electrode producing the fastest rate of 
electron transfer for a given compound (Kissinger. 1977). 
Further. the electrode material is prone to 
auto-oxidation (or reductiont which will contribute to 
residual (background) current. The extent to which 
residual currents can be tolerated will also play a role in 
the selection of the proper electrode. 
All carbon paste electrodes suffer from three basic 
problems: (1) non-reproducibility of electrode surface; (2) 
adsorption of material from mobile phase; and (3) surface 
oxide for•ation (Fleet and Little. 1975). The degree to 
which electrode surfaces are "poisoned" by the latter two 
factors. and the ease with which surfaces can be 
r~generated are paramount in deter•ining the usefulness of 
an electrode material (Pleet and Little. 1975t. A 
significant disadvantage in the use of electroanalytical 
techniques is the fact that electrochemical details at any 
electrode surface are poorly understood. as are the 
differences between types of carbon electrodes (Kissinger. 
1974). 
c. Cell Geoaetry and Operation 
Several designs for thin layer. low voluae. 
electrochemical cells have been described (Buchta and 
Pappa. 1976; Hashimot and Maruyama. 1975; and Riggin ~ 
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al~L 1975). Virtaally all designs use a three electrode 
configuration (figure 2). The critical parameter in 
electroanalytical techniques, as discussed by Kissinger 
(Kissinger. 1977), is accurate control of the potential 
difference between the electrode and mobile phase (bulk 
solution>- In the noraal operating mode the working 
electrode (w) is set to the desired oxidation potential. 
The reference electrode aonitors the voltage impressed 
between the working and reference electrode. No current 
passes through this electrode, it simply measures 
potential. As the potential at the working electrode 
drifts, an electronic feedback mechanism adjusts the 
potential of the auxillary electrode to compensate and 
return the potential difference between the working 
electrode and bulk solution to its operator deterained 
value (Kissinger, 1979). 
In operation, the carrier electrolyte in the mobile 
phase will produce a current. This current will increase 
as the concentration of solute (sample) rises within the 
electrochemical region. The resistance within the 
electrochemical cell vill drop, and, is compensated for by 
a decrease in the potential of the auxiliary electrode. 
This action will result in a constant applied potential at 
the surface of the working electrode. The change in 
current produced by the solute (sa•ple) passing through the 
cell is proportional to concentration as previously 
described. 
( 
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V. CHROMATOGRAPHY 
"The object of any chromatographic experiment is to 
s9parate the components of a mixture by placing a saall 
sample 
divided 
eluting 
of mixture 
partitioning 
the mixture 
onto the head of a column of a finely 
aaterial and subsequently washing or 
through the column by passage of a 
suitable eluent ••• One hopes that the different components 
of the mixture vill then migrate along the column at 
different rates and so form discrete bands which disengage 
as they migrate" (Knox 1977). 
Since 1976 an estimated 60~ to 70~ of the analytical 
wort preforaed by High Pressure Liquid Chromatography 
(BPLC) has been carried out by "reverse-phase 
chromatography" (Horvath and Melander, 1977). The term 
"reversed-phase" was coined by Hovard and Kartin (1950) to 
iistinguish chromatographic systems employing a non-polar 
stationary phase and a polar mobile phase, from the 
conventional system of using a polar stationary phase and a 
less polar aobile or eluent phase (Horvath and Melander, 
1977). 
In reverse-phase chromatographic systems 5 and 10 um 
diameter "hydrocarbonaceous bonded" stationary phase 
particles having octadecyl or octyl functions bound via 
siloxane bridges to the silica surfaces are the aost common 
(Horvath and Melander, 1978t. A wide variety of elution 
phases such as aqueous buffers, hydro-organic mixtures or 
( 
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non-aqueous organic solvents may be used. giYing the method 
considerable flexibility. In addition. the use of 
complexing agents and pH changes can be used to advantage 
in manipulating retention values. 
Reverse-phase chromatography is a for• of 
liquid-liquid chromatography in which the mobile phase is 
in contact vith the stationary phase over a large surface 
area. Under those conditions. equilibrium distributions of 
the solute between the two phases occurs rapidly. 
Non-polar compounds are retained by the stationary phase to 
a greater degree than are ionic material. Thus. c·ompounds 
elute from reverse-phase columns in order of decreasing 
polarity. 
The development 
attributed to Schill 
of ion-pair chromatography has been 
and co-workers (Gloor and Johnson. 
1977). In this technique ionic or ionizable coapounds can 
be paired with a counter-ion of the opposite charge to form 
a reversible ion-pair complex. The complex then behaves as 
an electrically neutral and non-polar compound. which 
results in the complex having an increased retention in 
reversed-phase systems. By varying the size or charge of 
the counter-ion the degree of retention and hence 
resolution. of a compound can be controlled. 
Two mechanisms for the retention of the ion-pair 
complex have been proposed. the first postulates that the 
ion-pair complex partitions directly in the stationary 
phase. The second postulates that the counter-ion 
( 
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partitions into the stationary phase with the ionic group 
oriented at the surface. and in this configuration may act 
as an ion exchange column (Gloor and Johnson 1977). These 
authors. 
ion-pair 
in a review of practical aspects of reverse-phase 
chromatography. suggest that the actual mechanism 
is aore complex and involves both postulated mechanisms as 
well as adsorption. aicelle formation. and complexation of 
both the solute and ion-pair reagent. Johnson and Gloor 
(1977) have published an excellent reviev of the practical 
aspects of ion-pair chromatography. 
Because aost drug substances are weak organic acids or 
bases. they may be expected to possess some charge. 
dependent upon pH. Paired-ion chromatography has provided 
a •echanism wherein the advantages of reverse-phase 
chroaatography: flexibility; selectivity; resolution; and 
economy can be applied to the analysis of drug substances. 
The ability to systematically control the separation of 
ionic coapounds of videly different types is perhaps. 
reversed-phase paired-ion chromatography's most important 
asset. The application of this technique in drug research. 
both in quality control and in therapeutic drug monitoring. 
has been the subject of recent reviews (Johansson ~! sl~ 
1978. Schill !1 ~!.. 1977. and Sadee and Beelen. 1980t. 
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VI PROTEIN BINDING 
A. Description of Protein Binding Interactions 
Protein-drug binding results from an intramolecular 
interaction between a biological macromolecule and a 
relatively small drug molecule (Klotz, 1973). The binding 
of drugs to plasma proteins assuaes considerable interest 
since it is generally accepted that only the free or 
unbound drug can diffuse across cell membranes, reach 
receptor sites and exert a pharmacological effect 
(Ritchell, 1975). Moreover, the extent of protein binding 
can profoundly affect the distribution and eliaination 
characteristics of a drug (Gillete, 1973 and Dayton, 
Israili, and Perel, 1973). Competitive displacement fros a 
binding site, by drugs or plasma components, may be an 
important factor for a drug vith a high degree of binding 
(Wagner, 1975). By increasing the concentration of free 
drug in plasma, displacement may result in an increase in 
therapeutic response and lead to drug toxicity. such is 
the case, for example, vith phenytoin, (ftorselli, 1970), 
dicumarol (Sellers and Koch-Weser, 1970) and !TX (Dixon, 
1965). In addition, such alteration in protein binding may 
affect the rate of elimination, (Gillete, 1973 and Levy and 
Yacobi, 1974) and alter a drug's Yolume of distribution. 
The major plasma and tissue protein responsible for the 
non-specific binding of most drug substances in albumin 
(Dayton, ~ ~~ 1973 and Chignel, 1971). Other plasma 
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constituents, ~g~ the lipoproteins and globulins, may also 
bind drugs; however, since these components are present in 
much lover concentrations in plasma than in albumin, their 
contribution to the protein binding of drugs is considered 
to be of secondary importance (Spector ~ ~L 1973 and 
Perkins~ al.~ 1969). 
Albumin is composed exclusively of amino acid 
residues; eighteen amino acids have been identified 
(Hughes, 1954). The molecular weight of albumin has been 
reported at between 65,000 and 69,000 daltons (Borga ~ 
alLL 1969). The concentration of albumin in humans is 
generally accepted to be 5.9x10-•M, although various 
disease states can greatly alter the albumin concentration 
(Dayton !_i ai~L 1973). The structure of the protein has 
been described as an "elongated ellipsoid" with a length 
and diameter of approximately 150 and 38 Angstro•s, 
respectively (Hughes, 1954). Albumin is a highly charged 
aolecule having about 100 ionizable carboxyl groups and a 
nearly equal nu•ber of groups which are positively charged 
at the isoelectric point (pH 5.0) (Tanford ~ ~ 1955 and 
Borga ~i s~ 1969). At physiological pR of 7.4 albumin 
possesses a~ (-19) negative charge. Positively charged 
drugs vill be strongly attracted to ·the negative sites on 
the aolecule with the formation of strong ionic bonds. 
Since the aacroaolecule has a net negative charge, 
negatively charged drugs are repelled to some extent; 
however, binding of negatively charged drugs to positively 
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charged sites can occur (Settle~ al., 1971). In addition 
to ionic bonds, arug-protein coaplexes can be formed 
through van der Waal's forces, hydrophobic bonds and 
hydrogen bonding (Chignell, 1971 and Ritchell, 1975). 
Basic drugs, positively charged at physiological pH, are 
loosely bound, occupy a large number of binding sites and 
are easily displaced. Acidic drugs, negatively charged, 
are strongly bound to albuain and generally occupy only one 
or tvo sites. Displacement of acidic drugs is of a more 
specific nature than that for basic compounds (Piafsky and 
Borga, 1977 and Borga ~ al~L 1969). Since acidic 
compounds bind only to a limited number of sites, 
displaceaent occurs only if a second drug has an affinity 
for the same binding site (Schwartz, 1979). The basic 
groups from the amino acid residues of arginine, histidine, 
and lysine and the acidic groups of aspartic acid, glutaaic 
a·cid and tyrosine are responsible for the binding of acidic 
and basic drugs respectively (Ritchell, 1975). 
B. Equations Describing Protein Binding 
Protein binding can be described in terms of the 
fraction of drug present vhich is bound to plasma protein. 
Since, in aost cases, the concentration of free drug i.e., 
the non-protein bound portion (as opposed to bound drug) is 
determined analytically, the expression regarding the 
percent of drug bound is frequently written as follows: 
( 
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(F.quation 10 ) 
Where Dt and Of represent the total and free drag 
concentrations respectively. 
The degree to which drugs bind to proteins is 
frequently a function of the total drug concentration 
present. As the total concentration increases. saturating 
the available binding sites. the percent of drug bound 
decreases (Curry. 1970. and Kunin. 1967t. Protein 
concentration also affects binding. low plasma protein 
levels. such as those in hypoalbuminemia. can reduce the 
number of available binding sites and result in increased 
fre~ drug concentration (Dayton ~ ~l., 1973 and Lund ~l 
ll~L 1971) .. Conversely. if the concentration of either 
albumin or other protein is elevated. an increase in the 
number of binding sites may result in lover concentrations 
of free drug (Benhold. 1966). When reporting the extent of 
drug binding. it is important that the total drug 
concentration and the albu•in (or other binding protein) 
concentration be described~ 
Protein binding can also be characterized by using 
affinity constants and numbers of binding sites to which a 
drug is bound (Scatchard. 1949). The basic assuaption of 
this aethod is that all sites of a given class are 
independent of each other and binding of one •olecule does 
not effect the binding of any other drug molecule. 
Drug-protein binding equilibrium is generally 
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considered to be an instantaneous. reversible process 
(Keyer and Gutman. 1968). The reaction between drug and 
protein can be expressed as follows: 
(DJ [P) 
(Equation 11) 
Where O and P represent the molar concentrations of free 
drug and protein respectively. DP is the molar 
concentration of the drug-protein complex. and ka. kd are 
the association and dissociation rate constants 
respectively (Scatchard. 1949). 
The association constant. Ka. can be written as: 
Ka = (PD) I [PJ [DJ 
(Equation 12) 
The degree of binding. r. can be expressed as the 
aoles of drug bound per mole of protein: 
r = (PD) / [PD) + [_P) 
(Equation 13) 
Which can also be defined as: 
r = Ka [D 1 I C 1 + Ka [n 1 ) 
(Equation 14) 
If the protein is determined to have n independent and 
equivalent binding sites. the quantity r can be written as 
follows: 
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r = nKa [DJ I c1 + Ka [D) ) 
(Equation 15) 
If more than 1 group of equivalent binding sites are 
present. Equation 13 can be expressed in a more general 
form: 
r = n . * Ka. rn] / (1 + Ka. 'nJ ) l l i.; l i.: 
(Equation 16) 
Where ni represents the number of binding sites of class i 
and Kai is the associa.tion constant for class i. 
Numerical values for n•s (number of binding sites) and 
Ka•s (affinity constants) can be calculated either by 
graphical techniques or by computer analysis. The 
Scatchard method (Scatchard. 1949) in vhich (D) as a 
function of r is plotted is the most common method by which 
protein binding data is presented. The Scatchard equation 
in this form is written as follows: 
r/a = Ka * N - r*Ka 
(Equation 17) 
When only one type of binding site is present. this plot 
will yield a straight line vith a slope of -~a and with X 
and Y intercepts equal to n and nK~ respectively. If 
multiple binding sites are present a plot of this type vill 
become non-linear and is best analyzed by non-linear 
( 
( 
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iterative techniques. In addition to the Scatchard method. 
Klotz (1946t and Scott (1956) have presented 
transformations of Equation 8 that are linear for single 
site binding systems but become non-linear in the case of 
multiple binding sites. Although either of these methods 
vill provide protein binding parameters they are not as 
popular as the Scatchard aethod. 
Several methods describing the computer analysis of 
protein binding in the case of multiple binding sites haYe 
been reported (~etzler ~ ~!:.L 1974; Schwartz. 1979; and 
Pletcher and Ashbrook. 1973). Each of these methods uses 
iterative techniques for obtaining estimates of affinity 
constants and numbers of binding sites. 
c. !ethods of Studying Protein Binding 
ftany methods are available for the study of drug 
binding to proteins. These methods depend on determining 
the concentration of free drug or detecting a change in a 
physicochemical property of the bound drug or binding 
protein due to the drug-protein interaction (Klotz. 1973). 
Techniques for studying binding can be broadly classified 
as either spectrophotometric or non-spectrophotometric 
(Chignell. 1971). The spectrophotometric methods include 
optical spectroscopy. optical rotatory dispersion. circular 
• 
dichroism. and fluoresence. (Klotz. 1973). Electron spin 
resonance. nuclear magnetic resonance and x-ray 
crystallography. although not strictly sp~ctrophotometric 
( 
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methods. may be included in this broad classification. 
Advantages of these methods include the sensitivity 
attainable and their non-destructive nature .. 
The non-spectrophotoaetric methods rely on determining 
the concentration of unbound drug following the 
distribution of free and bound forms between tvo phases 
(Klotz. 1973) .. Equilibrium dialysis is the most commonly 
used non-spectrophotometric technique. Ultrafiltration. 
ultracentrifugation. diafiltration. and qel filtration are 
also included in this category. 
Ultrafiltration. like equilibrium dialysis and gel 
filtration. relies on the physical separation of unbound 
and protein bound drug_ (Bush and Alvin. 1973) .. This 
separation is accomplished by the use of a aembrane which 
allows unbound drug to pass but retains macromolecules 
including the drug-protein coaplex~ The membrane used for 
ultrafiltration usually consists of a microporous cellulose 
base coated vith a continuous polymer film (Chignell. 
1977). 
In ultrafiltration. a saaple containing both drug and 
protein is placed in a reservoir on one side of a aembrane. 
Unlike dialysis in which the driving force governing the 
separation is siaple diffusion. ultrafiltration relies on 
nitrogen gas pressure as the driving force for free drug to 
cross the membrane. The concentration of drug in the 
filtered aliquot (Of) and in the sa•ple solution (Dt) • are 
measured and the percent drug bound is calculated according 
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to Equation 1. This process may be repeated to determine 
binding over a wide range of total drug concentration. 
The advantages of ultrafiltration include the speed in 
which analysis can be achieved and the small sample volume 
(usually 2-3 al.) which is required. 
D. Folate Binding 
1. Folic -Acid 
The binding of folates to huaan serum is complex. The 
extent of binding reported for folates ranges from almost 
nothing to approximately 65 percent depending on the method 
used for study. 
!etz (1968) reported the binding of folic acid to 
human serua to be "weakn. Condit and Grob (1958) and Neal 
and Williams (1965t reported that almost no folic acid was 
bound to plasma proteins when determined via 
elctrophoresis. Elsborg (1972), however, has suggested 
that the electrophoretic process might disrupt the 
drug-protein coaplex. 
Measuring folic acid activity by 1=:_ casei activity, 
following Sephadex chromatography, Markkanen ~ 5l:. (1972), 
Markannen and Peltola (1971), and Markannen (1968) 
determined that approximately 30' to 40~ of folic acid 
activity is bound to plasma protein. ~oreover, binding was 
found to occur with alpha2-aacroglobulin, albumin, and 
transferrin. 
Johns and Sperti (1961) , using equilibriu• dialysis at 
( page 75 37oc, calculated the binding of f olic acid to human serum 
(determined using tritium labelled pteroylglutamic acid) to 
be a constant 64~ over a concentration range of 5 to 3000 
micrograas/liter. Similar results (70.31) vere reported by 
Alter et al~ (1971) using the saae technique. 
Ultrafiltration of plasma samples containing tritiated 
folic acid deaonstrated SS• to 65~ (Neal !1 !!:.4 1965) and 
SOI to SS• (Elsborg, 1972) of total folic acid to be bound-
In addition, increased binding capacity for folates 
has been shown in patients vith uremia, leukeaia and folate 
deficiency states. Rheumatoid arthritis vas found to 
result in a decreased folate binding capacity (Alter, 
1971)~ 
The extent to which folates bind vith plasma proteins 
has been reported, the nature of the binding i.e, veak and 
nonspecific or "tight" and of a specific nature has been 
only recently addressed. Zettner and Duley (1974) studying 
folate binding by incubating serum with tritiated PGA, 
deterained the reaction to be a "reversible equilibrium" 
process. They suggested that the large differences 
reported in the binding of folate to human sera result from 
the folate binders being at varying degrees of saturation. 
The specificity of the f olate binding site is 
suggested by Zettner and Duly (1974) through experiments in 
which 
(in 
the 
tritiated PGl, !ETHP, leucovorin, and aethotrexate 
descending order) were found to be capable of lovering 
binding of folic acid. Non-folate compounds, however, 
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e.q., barbiturates, phenytoin, and salicylic acid did not 
effect PGA binding. 
2. METBF 
The binding of c-14 labelled METHF to normal human 
sera has been reported by Spector !! s!:..c. (1975) Serum 
binding was deterained by ultrafiltration at 23oc with a 
head pressure of 5 psi Nitrogen. Sixty to seventy percent 
of the druq was reported to be bound, and was constant over 
the concentration ranqe tested. In addition. phenytoin. 
probenecid, and aspirin were found not to alter the binding 
of !ETHF. 
3. LEU 
The protein binding of leucovorin has not been 
reported. 
( 
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VI. EXPERiftENTAL 
I. !aterials and Equipment 
A. Drugs 
Calciu• Leucovorin, Lederle Laboratories, Pearl 
River, NY. 
Methotrexate. Lederle Laboratories, Pearl River, 
NY. 
dl-N-5-methyltetrahydrofolic acid, Barium salt, 
Sigma Che•ical co., St. Louis, ~o. 
!-Ascorbic acid, Sigma Chemical Co., St. Louis, 
MO. 
Folic Acid, Sigma Cheaical Co., St. Louis, ~o. 
Gamma-amino-butyric acid, Sigma Chemical Co., St. 
Louis, MO. 
Dihydrofolic ~cid, Sigaa Chemical co., St. Louis, 
MO. 
Tetrahydrofolic Acid, Sigma Chemical co., St. 
Louis, MO. 
!ethylene Tetrahydrof olic acid was obtained from 
the National Institutes of Health, Bethesda Md. 
B. Reagents 
Sorenson's Phosphate Buffer, pH 7.4, was prepared 
by aixing together 1/15 M monopotassium phosphate (576 ml.) 
and 1/15 M disodium phosphate (424 ml.) 
Paired-ion reagents, 1-pentane, 1-heptane, and 
1-octane sulfonic acid, Pie as. B7, and PS respectively 
were obtained fro• Waters Associates, Milford, MA. 
c. Chemicals 
Aaaonium Phosphate, dibasic, A.C.S, Fisher 
Scientific Co., Fairlawn, NJ. 
( 
page 78 
!ethanol, UV Grade, Waters Assoc., Inc., "ilford, 
PIA. 
Acetonitrile, UV Grade, Waters Assoc., Inc., 
"ilfordir !!A. 
Disodium ethylenediamine tetraacetate, A.c.s." 
Allied Chemical, Specialty Chemicals Division, 
Morristown, NJ. 
Phosphoric Acid, 85, A.c.s" Fisher Scientific Co., 
Fairlawn, NJ .. 
Potassium Hydroxide, A.c.s., Fisher scientific 
co., Fairlawn, NJ. 
Sodium Phosphate, Dibasic, A.C.S., Fisher 
Scientific Co., Pairlavn, NJ. 
Potassiua Phosphate" !onobasic, A.Cos, Fisher 
Scientific Co., Fairlawn, NJ. 
Tetrabutylamaonium Chloride, Eastman Kodak co., 
Rochester, NY. 
Oxalic Acid, A.c.s, Fisher scientific co." 
Fairlawn, NJ. 
Glacial Acetic Acid, A .. c .. s, Fisher Scientific co., 
Fairlawn, MJ .. 
Nitric Acid, A.C.Sir Fisher Scientific co., 
Fairlawn, NJ. 
Crystalline Human Serua Albumin, Calbiochem, Inc., 
San Diego, CA. 
Crystalline Bovine Serua Albumin, Calbiochem, 
Inc., 
San Diego, CA. 
Spectroscopic Powder, grade SP 2, Union Carbide 
Corporation" Nev York, NY. 
Ceresin Flakes" !atheson Chemical Coapany, 
Lyndhurst, NJ. 
( 
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D. Equipment 
Ultrafiltration Apparatus. ftodel 8Mc. Aaicon 
corp •• Lexington. MA. 
Ultrafiltration Membranes. io.ooo mv cutoff. 
P!-10. Amicon. Corp •• Lexington. MA. 
Dialyzer Tubing. 2.5 cm. wide. 1.6 cm. diameter. 
Fisher Scientific co •• ?airlavn. NJ. 
High Pressure Liquid Chromatographic Pump. Model 
!-6000A. Waters Assoc •• Inc •• Milford. MA. 
uBondapak C18 reverse phase stainless steel 
colu•n. waters Assoc •• Inc •• !ilford. MA. 
Radial Pat A Liquid Chromatographic Column. 5 mm. 
I.o •• Waters Assoc •• Inc •• Milford. MA. 
Radial Compression Module. Waters Assoc.. Inc •• 
!ilford. MA. 
Sep-Pak. c-ia cartridges. Waters Assoc •• Inc •• 
Milford. MA. 
HPLC Loop Injector. !odel 7120. Rheodyne. Inc •• 
Berkley. CA. 
Constant Temperature Drying oven. Thelco Model is. 
Precision Scientific Co •• Chicago. IL. 
Digital Multimeter. B and K Precision !odel 2800. 
Dynascan. Corp •• Chicago. IL. 
Active Noise Filter. Model Sc102. Foxboro 
Analytical Division. North Haven. CT. 
Series-Parallel RC Combination Box. Eico. model 
1140. Electronic Instruments co •• Long Island 
City. NY. 
Electronic Controller !odel LC-2a. Bioanalytical 
Systems Inc •• W. Lafayette. IN. 
Plexiglass Paste Cell. Model Tl-3. Bioanalytical 
Systems Inc •• w. Lafayette. IN. 
Kel-P. Glassy carbon Cell. Model Tl-SA. 
Bioanalytical Systems Inc •• w. Lafayette. IN-
Silver-Silver chloride Reference Electrode. Model 
( paqe 80 
RC-1, Bioanalytical Systems Inc., w. Lafayette, 
IN. 
Sa•ple Concentrator ftodel 190, Fisher Scientific 
CoQ, Fairlawn, NJ. 
• 
( 
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To Colurrm Outlet 
Working 
Figure 5: Diagram of the Electrochemical 
Flow-Through Cell 
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and auxiliary electrodes were downstreaa from the working 
electrode in this arrangement. The completed unit was 
mounted inside an aluminum box (20 cm. x 15 cm. x 11.5 cm.t 
which servgd as a support mechanism for the cell. 
b. Electronic connection 
The electrochemical cell was connected to the LC-21 
controller in the following •anner. The four leads 
extending from the controller unit were fitted with banana 
plugs, one each for the working, reference, and auxiliary 
electrodes, and the fourth for ground. Four corresponding 
banana jacks were installed on one side of the support box. 
One jack served as a ground, to each of the remaining three 
a short piece of insulated wire was soldered and connected 
to the individual electrodes using miniature alligator 
clips. Each lead was tested to insure continuity of 
current flow before use. 
The LC-2A output jacks were connected to an ANlLABS, 
ftodel SC 102 active noise filter, which served ~o reduce 
the residual currant (background noise) inherent in the 
detector. The output from the noise filter was coupled to 
the appropriate input terminal of the electronic 
integrator. 
A 0.8 volt potential was applied to the working 
electrode for routine quantification of LEU and !ETHF. For 
most applications the suaming amplifier was set at 50 
nanoaaps/volt although in some cases the 20 nanoamp/volt 
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scale was used. The active noise filter re•ained set at a 
constant gain of ten which boosted the input signal to the 
integrator approximately tenfold. 
Oxidation of the mobile phase components, i.e, 
supporting electrolyte, trace metals, and dissolved oxygen 
produced a background current ranging from 30 to 70 
nanoamps/volt. 
c. Electrode Preparation 
i. carbon Paste Electrodes 
The method of preparing carbon paste electrodes was 
identical whether graphite/aineral oil, silicone oil, or 
vax-i•pregnated graphite/oil pastes vere used• The working 
electrode block was carefully cleaned with water and 
methanol, taking care to remove any old paste from the 
electrode vell. The cell vas then dried carefully vith 
Kimvipes and further allowed to air dry. A fev milligram 
sample of paste aaterial vas placed on a folded computer 
card or piece of glassine paper. The paste was then poured 
into the three ••· diameter electrode well in several 
portions. A wooden applicator stick, tvo to three mm. in 
diameter, was used to tamp dovn the paste between 
additions. This process was continued until the paste vas 
approximately level vith the cell surface • . A small pile of 
paste vas then placed on a clean computer card and the 
inverted electrode block pressed onto the pile. Using 
randoa aotion the block vas aoved around the card until a 
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flat. s•ooth surface was obtained. The entire 
electrochemical cell was then reassembled as described. 
Special care was giYen to keep electrode paste away from 
other cell surfaces and to avoid scratching the cell 
surface. 
After connecting all electrodes and the ground. the 
appropriate voltage was iapressed between the working and 
reference electrodes. The rate at which the cell surface 
was "conditioned"• i.e •• the time required for background 
current to decay to the 20 to 70 nanoamp/volt range varied. 
In •any cases one and one-half to three hours was required. 
in some instances the residual current did not decrease to 
acceptable levels after overnight operation. in which case 
the electrode vas repacked. 
ii. Glassy Carbon Electrode 
Regeneration of the highly polished surface of a 
glassy carbon electrode was accomplished in any one of 
several ways. After long periods of continuous operation. 
i.e •• six to eight weeks. a decline in detector sensitivity 
vas often noted. Examination of the electrode surface 
shoved a dulling of the mirror finish which has been 
attributed to the formation of oxide films and adsorption 
of products and reactants 
.. · 
(Pleet and Little. 1975). In 
most cases simply rinsing the cell surface with distilled 
water. followed by methanol vas sufficient to restore the 
cell surface. 
( page 86 In some cases the treatment detailed above did not 
restore the cell surface and polishing was required. The 
glassy carbon vas first washed with distilled water and 
left vet. A small quantity, one to two ml. of jeweler's 
alumina paste was placed on a felt pad and vetted slightly. 
The glassy carbon surface was then impressed upon the paste 
and the entire electrode block moved in a random motion 
about the pad for approximately one minute. The carbon 
surface was. then rinsed vith distilled water and a drop of 
6N Nitric Acid was placed on the carbon and allowed to 
stand for 30 minutes. The cell vas then rinsed with water 
and methanol, allowed to air dry, and reassembled. 
A potential was then applied to the working electrode 
for a miniaum of four hours before quantitative 
determinations vere attempted; in most cases the detector 
required ov~rnight operation to become "conditioned". 
If polishing the carbon electrode with alumina did not 
regenerate the cell surface, an additional step was added 
to the polishing procedure~ A saall amount of a diamond 
dust ilurry vas placed on a disc of "660 vet dry" abrasive. 
The cell surface was "rough" polished by this method before 
progressing to the aluaina paste and subsequent steps as 
described above. 
Once a potential was impressed between working and 
reference electrodes, the system remained charged until the 
electrode surf ace required regeneration. 
( 
2. Chromatography 
a. Apparatus 
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The liquid chromatograph consisted of: a Waters 
Associates Model 6000! solvent delivery system; a Rheodyne 
Model 7120 syringe loading saaple injector equipped with a 
100 ul loop; either a Waters Assoc. uBONDAPAK c-18 reverse 
phase colu•n (4mm x 30cm). or an Sam IoD. RADIAL-PAK c-18 
cartridge (13mm x 10cm) and RCK-100 Radial Compression 
Module; Thelco Model 15, constant temperature oven; and a 
BAS ~odel LC-2!, electrochemical detector. The 1 volt 
output of this detector was "stepped-down" and connected to 
a Waters Assoc •• "Data Module". electronic integrator. 
b. Solvent Systems 
Paired-ion chromatography was used for the separation 
and quantification of LEU and !ETHF in aqueous systems and 
fro• serum. Two classes of pairing agents; pentane, 
heptane, or octane sulfonic acid, and dibasic aamonium 
phosphate (HH4)2HP04 were evaluated for their suitability 
in the determination of reduced folates. 
Sulfonic acid buffers were prepared by pouring the 
contents 
BS, B7, 
which was 
water, to 
The pH of 
of one vial of pre-mixed paired-ion reagent, PIC 
B8 (Waters Assoc.) into a liter volumetric flask 
then brought to voluae with distilled-deionized 
yield a final paired-ion concentration of Sm!. 
this buffer system vas maintained at 3.5 and was 
c 
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used without further modification. The organic component 
of mobile phases which contained sulfonic acids ranged from 
10S to 40~ methanol and O~ to 10~ acetonitrileo The final 
mobile phase was prepared by adding an approp~iate volume 
of organic solvent (CB30H or CB3CN) to a 1 liter volumetric 
flask which was then brought to volume with the previously 
prepared sulfonic acid reagent solution. 
Dibasic aamoniua phosphate, (NH4)2HP04, was also used 
as a "paired-ion" reagent. Several concentrations of 
ammonium phosphate between O.OOSM and 0.5~ were eyaluated. 
An appropriate amount of reagent vas placed in a volumetric 
flask and brought to volume using distilled-deionized 
water. prepared as described above. The pH of ammonium 
phosphate aobile phases was varied between pH 3.5 and pH 
7.0, and was adjusted after the mobile phase; buffer 
solution plus organic components, had been prepared. No 
corrections vere made for the different aaounts of H3P04 
which were added to bring the mobile phase to the desired 
pH. 
Sodiu• EDTA has been reported to be Yaluable in 
quieting "electrochemical detector noise", (R. Shoop, 1978) 
presumably by chelating trace metals which may be found in 
the aobile phase components or in the chromatograph itself. 
Ten mM Sodium EDTA was therefore added to each mobile phase 
as a "precautionary measure". 
All mobile phases were freshly prepared on the day 
they were to be evaluated. Following preparation each 
( 
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mobile phase was filtered through a Millipore Type-Fa. 43mm 
filter. which had been wetted with methanol. The mobile 
phase vas stored in glass Erlenmeyer flasks and covered 
with Parafilm during use. 
3. Protein Binding 
a. Preparation of the Membrane 
The ultrafiltration membrane was soaked in distilled. 
deionized water for one hour to remove the glycerin coating 
the membrane. The membrane vas then placed in the 
ultrafiltration apparatus. sev·en ml. of water (one cell 
volume) vas forced through the membrane. followed by an 
equal volu~e of Sorenson's buffer. pH 7.4. The interior of 
the cell~ membrane surface. and teflon tubing through which 
the filtrate emerges were dried with a Ki•vipe before 
beginning a binding determination. 
b. Sample Preparation 
Human serum albuain vas prepared as an eight percent 
(v/v) solution with Sorenson's buffer. pH 7.4. twenty four 
hours prior to a protein bindinq determination. The 
protein vas vetted with buffer and gently agitated to aid 
dissolution. Poaming of the solution was avoided since 
this can result in surface denaturation of the protein. 
Fifty ml. of the albumin solution was then poured into a 25 
cm. section of dialysis meabrane which had been previously 
soaked in buffer solution and knotted at one end. The 
dialysis tube was tied off and placed in a one liter flask 
( 
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filled with Sorenson's buffer, pH 7.4, tightly covered and 
stored at40c until used. 
Bovine serum albumin was prepared in Sorenson's 
buffer, pH 7.4, as a four percent (v/v) concentration, the 
normal concentration of albumin in seruma The binding of 
leucovorin to bovine albumin was carried out using the 
ultrafiltration technique described previously. The range 
of total drug concentrations studied was from 2.sx10-• ! to 
1.ox10-• "· Samples were assayed in duplicate immediately 
after ultrafiltration. 
Leucovorin, 5-aethyl THF and methotrexate solutions 
vere prepared daily using Sorenson's buffer, pH 7.4. Drug 
stock solutions were stored in tightly capped, opaque 
vials, to prevent light catalyzed oxidation and were stored 
on ice during the binding experiaent. 
c. Ultrafiltration 
Equal volumes (three and one-half ml. ) of drug and 
albumin solutions were pipetted into the previously treated 
ultrafiltration cell. The final albumin concentration 
produced in 
drug-protein 
45 seconds 
this manner was four percent (v/v). The 
solution vas stirred for approximately 30 to 
before beginning the ultrafiltration and then 
throughout the entire filtration process. Stirring insures 
coaplete mixing of the drug and albumin solutions before 
beginning filtration and prevents "concentration 
polarization", i.e., accuaulation of the retained protein 
( 
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at the membrane surface creating a "boundary layer". The 
accumulated protein restricts the f lov of solution through 
the membrane, alters the filtration characteristics of the 
system and slows the rate of filtration (Anonyaous, Amicon 
Product Literature, 1980). 
Nitrogen gas (20 psi) was applied to the cell, forcing 
the solution across the membrane~ The first four drops of 
filtrate, approximately 200 microliters, was discarded, the 
following 400 to 500 microliters vas collected in a 12 x 75 
mm. glass test tube, covered, protected from light and 
stored on ice until analyzed. All samples were analyzed on 
the day the ultrafiltration was carried out. The 
ultrafiltration cell vas washed with Sorenson's buffer, pH 
7.4, between each binding determination and a small 
quantity of buffer was forced through the membrane. The 
cell vas then dried as previously described in preparation 
for the next analysis. Experiments were always carried out 
in order of increasing total drug concentration to minimize 
potential error due to drug carry-over from the previous 
sample. Each binding experiment was carried out in 
triplicate. Samples vere assayed twice and the average 
value used to deteraine the free drug c oncentration. In 
order to examine non-specific binding, i.e., the .binding of 
drug to material other than albuain, notably the 
ultrafiltration cell or membrane, seven ml. aliquots of 
leucovorin and 5-aethyl THF, in Sorenson's buffer, pH 7.4, 
were pipetted into the cell and filtered as previously 
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described. Quantitative analysis vas performed on the pre 
and post filtered samples to detect any changes in drug 
concentration following filtration. 
Three and one-half al. each of albumin solution and 
Sorenson's buffer, pH 7.4, (drug free) were pipetted into 
the ultrafiltration cell and filtered. The collected 
filtrate vas analy~ed to detect any components eluting from 
the albumin which aiqht interfere with the quantification 
of leucovorin or 5-•ethyl THF. 
4. Huaan Studies 
· a. Human Subject Protection 
A detailed report of the proposed project, its 
objectives, methods and potential hazards was submitted to 
Human Studies Coamittees and Institutional Review Boards at 
both the University of Rhode Island and Roger Williams 
General Hospital (Appendix I). Each subject who 
volunteered for the study was provided with a copy of the 
experimental protocol and was required to read and sign an 
inf oraed consent form which explained the study in detail 
(Appendix II). 
b. Subject Selection 
Six subjects meeting the criteria described in the 
experimental protocol vere selected for inclusion in the 
study. All subjects, three males and three females, vere 
healthy volunteers between the ages of 28 and 33. They 
( 
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weighed between 45 Kg and 100 Kg. and body surface areas 
were between 1.37 m2 and 2.28 m2. The volunteers were free 
from known hypersensitivity to folic acid or its 
derivatives and had no medical abnormalities which would, 
in the opinion of the attending physician, add further risk 
to the subjects or complicate the study. 
Participants were required to abstain from all drugs, 
including alcohol, for 48 hoars prior to the test period. 
In addition, the participants vere asked to fast for 12 
hours before drug administration and two hours after 
dosing .. 
Leucovorin was prepared for intravenous injection by 
reconstituting 50 mg. of Calcium Leucovorin (Lederle 
Laboratories, lot no. 616-302) with 5 ml. of sterile water 
for injection to yield a final concentration of 10 mg. 
a1.-1 Each subject received 10 mgo of drug imaediately 
after a "zero-time" or "blank" blood sample was obtained .. 
The collection of subsequent blood samples was scheduled as 
follows; 5, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240, 300, 
and 360 ainutes.. The actual tiae of each sample collection 
was docuaented so that actual saapling times were available 
for subsequent analyses. 
c. cancer Patients 
Patients undergoing high dose aethotrexate-leucovorin 
rescue therapy under the experimental protocols established 
by the Oncology Section at Roger Williams General Hospital, 
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(Appendix !II) were evaluated for possible inclusion in the 
project. Nine patients were admitted to the MTX program 
between November 1979 and November 1980; five of them were 
asked to participate in the LEU pharmacokinetics project-
Table II details the diagnosis. age. sex. weight. and LEU 
dose received by each patient. Since these patients were 
already involved in an experimental protocol (e.g. high 
dose !TXt. participation the the current project required 
only the patient's consent to obtain appropriate blood 
saaples following the administration of LEU. This was 
considered by the physicians involved to constitute no 
additional risk to the patients. All patients were treated 
in the clinical oncology unit of the hospital where their 
blood samples were obtained by the regular nursing and 
support staff personnel in the same manner as for the 
"normal" volunteers. All patients were free to terainate 
the blood sampling at any time. for any reason. 
d. Method of Blood Sample Collection 
An intermittent infusion set. 19G x 2.22 cm •• was 
inserted by a physician into a vein on the subject's 
forearm and carefully taped in place. After drawing a zero 
time. or blank . sample. the catheter vas filled with 0.5 ml. 
of a dilute, 100 anits al-'• heparin solution in order to 
prevent blood clot formation within the tube. At the time 
of sample collection a latex tourniquet was tightened on 
the subject's ara above the position of the catheter. and 
Patient Age 
F.F. 48 
L.M. 56 
P.F. 26 
F.Y. 62 
( 
TABL£ II 
METHOTREXATE PATIENT INFORMATION 
Sex Diagnosis 
M Osteogenic Sarcoma 
M Osteogenic Sarcoma 
F Choriocarcinoma 
M Osteogenic Sarcoma 
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Methotrexate Dose 
3. 71 mg IV 
4.30 mg IV 
1. 78 mg IV 
12 mg I.M. 
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the heparin solution was withdrawn from the catheter vith a 
1 ml. disposable syringe. Using a fresh 5 ml. disposable 
syringe vith a 21G needle. a 3 to 5 ml. blood sample was 
carefully withdrawn and placed in a 10 mla "yellow-top" 
Yacutainer tube containing 5 mg of ascorbic acid. The 
catheter was immediately flushed with the dilute heparin 
solution which remained in the catheter until the time of 
the next sample collection. 
Blood samples were allowed to clot for at least 1 hour 
at room temperature. and were then centrifuged for 10 
minutes at 2000 rpm. The serum was carefully removed and 
placed in 12mm. x 72mm. disposable glass test tubes to 
which had been added 20 ul. of a 100 mg. m1-1 solution of 
ascorbic acid. The test tubes were then covered with 
Parafilm and stored fro~en until assayed. 
e. Extraction Procedure 
Leucovorin was extracted fro• plasma or serum samples 
in the following aanner. A Waters C-18 Sep-Pak cartridge 
vas connected to a 10 ml. disposable syringe fro• which the 
plunger had been removed. Ten al. of methanol vas added to 
the syringe and. using the plunger. slowly pushed through 
the Sep-Pak. When all the aethanol had eluted fros the 
Sep-Pak. the cartridge was gently removed from the syringe 
and the plunger withdrawn once again. After reconnecting 
the Sep-Pak cartridge. the process was repeated using 10 
al. of a O.OOSM (NB4)2BP04 buffer. pH S.S. Again. care vas 
( 
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taken not to force the fluid completely out of the 
cartridge before remoYing it from the syringe. 
Following the above two step conditioning process. the 
plasaa or serum sample was loaded through the barrel onto 
the Sep-Pak. to be followed by 1 ml. of the ammonium 
phosphate buffer. This mixture was then slowly forced 
through the cartridge and the effluent was discarded. An 
additional 3 ml. of buffer was then eluted through the 
Sep-Pak. However. in this case the plunger was pushed 
through the barrel with sufficient force 
essehtially all s~lution from the Sep-Pak. 
to elute 
The effluent 
from this step was also discarded. The outlet end of the 
cartridge was then connected to a vacuum tube and the 
Sep-Pak was air-dried for 5 minutes. 
The dried Sep-Pak vas then eluted vith 2 ml. of 
methanol and the elnent collected in sample dishes designed 
for use in a Fisher Model 190 sample evaporator. The 
sample dishes vere placed in the evaporator which had been 
previously heated to sooc and then placed under a vacuum. 
Nitrogen gas was then allowed to flov slowly into the 
evaporator until all samples had been evaporated to 
dryness. An additional 200 ul. of methanol was added to 
each dish; any residue fros the sides of the dish was 
vashed toward the bottom. This volume of methanol was also 
evaporated to dryness. Each sample was then covered with 
Parafila. placed in a dessicator. and stored frozen. and 
protected from light until assayed. 
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VII. RESULTS and DISCUSSION 
The electroactivity of a wide variety of organic 
functional groups i.e., hydrocarbons, amines or amides, 
phenols, catecholamines- for oxidation, and esters, ketones, 
aldehydes, diazo, and nitro compounds for reduction have 
been reported (Fleet and Little, 1977). However, the 
electrochemistry of complex organic molecules is not well 
understood (Kissinger, 1977). The suitability of 
electrochemical detection for a compound is best determined 
by a voltaamogram in which current (generated by the 
oxidation or reduction of an electroactive species) is 
plotted as a function of applied voltage. 
Samples of calciua leucovorin and methotrexate vere 
shipped to Bioanalytical Systeas Inc., w. Lafayette, IN., 
to determine the electroactivity of the folate analogs. 
Figures 6 and 7 are the resultant voltammograms. Calcium 
leucovorin vas dissolved in 0.1 M acetate buffer and 
subjected to an oxidizing potential. No current was 
detected until the applied potential reached 0.5 voltsa 
The current maximum, approximately 20 nanoamps, was 
achieved at 0.6 volts. Both figures shov an apparent 
decline in current at higher potential. This is the result 
of the depletion of oxidizable species in the sample; any 
applied potential greater than 0.6 volts would be expected 
to generate the same current. 
8ethotrexate, dissolved in 1 M acetate buffer (with 
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( 
twenty percent ammonium 
dissolution) produced a 
microamps at a potential 
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carbonate (0.1M) to aid 
peak current of approximately 10 
of 0.8 volts. As was the case 
with LEU, the current declined rapidly due to depletion of 
electroactive species. 
Although both compounds were examined under the sa•e 
conditions, e.g., voltage scan rate, working electrode, and 
reference electrode, different media were used to dissolve 
the drugs. Since the balk solution could vary in 
characteristics such as resistance and diffusion 
coefficients, it was difficult to reach conclusions 
concerning the relative electroactivities of leucovorin and 
aethotrexate. However, the voltammoqraas confirm the 
electroactivity of the folate analogs and the feasability 
of using amperometry as a method of detection. 
1. Electrode Evaluation 
a. carbon Paste, Silicone-Oil 
carbon paste, silicon oil base electrode material, 
Cp-o, was evaluated using mobile phases of 201 to 301 
aethanol in Sa! 1-pentane, 1-heptane, or 1-octane sulfonic 
acid, pH 3.5. The flov rates used ranged between 0.7 and 
1.0 al. per minute~ At an applied potential of 1.0 volt, 
it vas possible to measure routinely LEU concentrations of 
5x10-7 ! (50 nanograms). The apparent lover limit of 
sensitivity was sx10-a e. 
The aYerage useful life of a Cp-o working electrode 
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vas only two to three days. contrary to the veeks or aonths 
of stability reported for this electrode (Kissinger, 1977). 
The working electrode was considered unusable when the 
background, or residual current was greater than 90 to 100 
nanoaaps per volt applied across the working electrode. 
Because four to eight hours of continuous operation were 
frequently requirea for a newly packed or resurfaced 
electrode to stabilize to lov residual currents. the Cp-o 
paste was considered to be unacceptable for routine 
applications. 
The instability of the electrode surface has been 
attributed to an uneven surface in which paste can project 
into the mobile phase flow and flake apart. creating a high 
background noise. (Keller. !a.i a!:.... 1976). Furthermore, 
during the packing process. it is possible for some paste 
to become imbedded in surface imperfections on the 
electrode blockr creating additional residual current 
(~eller ~ al&L 1976). Air bubbles may become trapped 
within the paste material during the cell packing process. 
these bubbles may also contribute to high background 
current and decreased useful life (~issingerr 1977). 
Electrode to electrode reproducibility was inadequate. a 
result of the aanner in which the electrode well was packed 
and the surf ace prepared~ Osing the method of cell 
preparation described previously, electrodes vere produced 
vith lover limits of sensitivity ranging fro• s.ox10-• ~ to 
1.ox10-s !. The Cp-o paste vas considered unsuited for 
( 
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routine use under the chromatoqraphic conditions employed 
because of the short useful life and the inability to 
produce electrodes with consistent levels of sensitivity. 
b. Wax-Impregnated Graphite with Silicone 
Oil 
One investigator claims that vax-impregnanted 
graphite/silicone oil (Cp-W) electrodes are more durable 
and more easily resurfaced than previously used carbon 
pastes (ftosher, 1978). l supply of wax-impregnated paste, 
prepared by the method of Atuma and Lindquist (1973) was 
obtained fro• Pfizer Laboratories, the generous gift of 
Prank ~osher. 
The vax was evaluated, using aobile phases containing 
201 to 30~ methanol in 5 mft sulfonic acid reagents, pH 3.5. 
"obile phase flow rates ranged from 0.7 to 1o0 ml. per 
minute. At an applied potential of 1 volt, the lover limit 
of detection which was achieved vith the vax, vas 
comparable to the Cp-0 pastes. The baseline noise, or 
residual current, produced vith this electrode vas lover 
than that vith the previous system; fever noise spikes or 
random peaks were generally observed. 
The relatively low residual current may be 
attributable to the ceresin content of the electrode 
material which results in a stiffer paste than do aineral 
or silicone oil-based electrodes. The harder paste can be 
rigorously "polished" and clearly provides a more uniform 
and smooth surface than other pastes. Furthermore, because 
( 
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it is a stiffer material. the wax electrode material is 
apparently not as susceptible to distortion caused by the 
motion of aobile phase flowing over its surface. Such 
distortion is one of the major causes of excessive residual 
current (Kissinger. 1977). 
The average useful life of wax-impregnanted pastes was 
significantly longer than for oil-based electrodes. Two to 
three weeks of continous operation were frequently possible 
vith Cp-W electrodes. As vith Cp-0 electrodes. vhen 
background currents exceeded 90 to 100 nanoamperes per 
volt. it became necessary to resurface or completely repack 
the electrode well. Several hours were required to 
establish a stable baseline current in the range of 20 to 
30 nanoamperes per volt following the packing of a new 
electrode. Increasing the appplied potential to the 
maximum 1.2 volts did not significantly affect the time 
required for an electrode to be adequately conditioned. It 
vas not possible to pack the electrode cell and achieve 
consistent. reproducible detector responses. Tvo or three 
cell packings vere often necessary to produce an electrode 
with a suitable sensitivity and residual current. Despite 
this disadvantage. Cp-W vas routinely used under the 
chro•atographic conditions described aboYe. since an 
adequately conditioned cell had a useful life five to ten 
times that of Cp-0 electrodes. 
In order to improve the resolution between LEO and 
!ETHF it became necessary to add acetonitrile to the •obile 
( 
( 
page 105 
phas~. Cp-W electrode paste is not stable in mobile phases 
containing large amounts of organic solvents notably 
methanol or acetonitrile. Exposure to the ternary mobile 
phase resulted in the rapid destruction of the electrode 
surface rendering Cp-W inadequate for farther use in 
detecting the reduced folatesa 
The continued use of wax-impregnanted paste was 
further hampered by the inabiliy to produce a suitable 
material using the reported aethod (Atuma and Lindquist, 
1973). Although several batches of the wax-impregnated 
paste were manufactured, each resulted in a residual 
current greater than 100 nanoamperes per volt which could 
not be offset electronically. thus rendering the electrode 
useless. 
c. Glassy Carbon 
The lack of reproducibility among electrode surfaces 
and short useful life inherent in paste electrodes prompted 
a search for alternate electrode ma~erial. Pleet and 
Little (1977) suggested that solid electrode voltammetry 
may be a useful alternative to pastes and reported a cell 
design using a piece of highly polished (glassy) carbon as 
a working electrode. Lankelma and Poppe (1976) and 
Hashimoto and Maruyama 1978 have reported on the utility 
and stability of glassy-carbon electrodes. 
( 
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i. Electroactivity of Polate Analogs 
A five mm. glassy-carbon working electrode was 
obtained from Bio-Analytical systems Inc. and evaluated 
with mobile phases containing four to forty percent 
methanol, three to fifteen percent acetonitrile and having 
pH values ranging fro• 3.5 to 7.0. The applied potential 
varied from 0.1 to 1.0 volts. 
mobile phase flow rates as 
The electrode vas exposed to 
high as 8.0 ml. per minute 
without apparent damage to the cell surface. 
The electroactivity of LEU and METHF was determined 
over an applied potential range of 0.1 to 0.9 volts. The 
suaming amplifier vas set an 50 nanoamperes per volt. 
Chromatographic conditions were; mobile phase II, column 
temperature 37oc, and a flow rate of 3.0 al. per minute. 
Figure 8 is a plot of detector response, measured as 
log peak height per mole of drug, as a function of applied 
potential. No current vas generated from LEU until the 
applied potential reached 0.4 volts. The current produced 
by LEU increased from 0.4 volts to an apparent plateau 
between 0.7 and 0.8 volts. The residual current resulting 
from an applied potential of 0.9 volts vas greater than 100 
nanoamperes per volt and therefore could not be compensated 
for electronically. As a result current produced by the 
oxidation of leucovorin could not be quantified above 0.8 
volts. 
!ETHF, unlike LEU, did not produce a measureable 
( 
current 
Between 
oxidation 
figure 8 
until the applied 
0.3 and 0.8 volts 
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potential reached 0.3 volts. 
the current produced by the 
of ~ETHF remained constant. It is apparent fro• 
that. under the electrochemical and 
chromatographic conditions described above. METBF is a more 
readily oxidized compound than is tEU. Further. if 
chromatographic methods were not able to resolve the tvo 
folatesr KETHF could be quantified by operating at an 
applied potential of 0.3 volts. 
Under the chromatographic and electrochemical 
conditions described previously. and at an applied 
potential of 0.8 volts. it vas possible to generate 
reproducible standard curves of peak height as a function 
of concentration for both tEO and KETHF. A linear response 
vas obtained for both drugs over the concentration range of 
2.5x10-7K to 3x10-•!. Correlation coefficients in both 
cases were routinely greater than 0.99. Analysis of 
variance of linear regression shoved a significan~ 
correlation for both drugs (p<0.05). 
ii. Durability 
The glassy-carbon electrode has an indefinite useful 
life. Routine operation with a five ••· diameter electrode 
has been carried out for sixteen months; no treatment other 
than renewal of the electrode surface has been necessary. 
Auto-oxidation of the electrode surface and absorption 
of effluent material are the two factors most responsible 
-
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Figure 8: Peak Height as a Function of Applied 
Potential for Leucovorin and Methyl-
tetrahydrofolate • 
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for the decrease in sensitivity common to glassy-carbon 
electrodes (Fleet and Littler 1977). After several weeks 
of continuous operation a decline in residual current and 
sensitivity were observed. Figure 9 represents a series of 
--
standard curYes, peak height as a function of 
concentrationr generated from the regression coefficients 
for leucovorin. The constantly decreasing slope evident in 
A-Dr figure 9 clearly demonstrates the loss in sensitivity 
over a six-day period of continous operation. Removal of 
the adsorbed material at the electrode surface is all that 
is usually necessary to reestablish the sensitivity of the 
electrochemical detector. This vas accomplished by rinsing 
the cell surface vith distilled water, followed by 
methanolr and allowing the cell to air dry before being 
reassembled. cycling the applied potential between -2 and 
+2 volts has been suggested as a means of regenerating a 
glassy-carbon surface; howeverr this method was not 
successful. ~echanical removal of adsorbed material was 
the only adequate means of restoring the sensitivity of the 
system. 
iii. Effect of Plov Rate 
The effect of mobile phase velocity on the diffusion 
layer thickness (s) within the electrochemical cell and the 
resulting effect on current yield has been previously 
discussed. The optimal flow rater in terms of detector 
response, for LEU and METHF was determined by plotting 
,.-
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response. aeasured as peak height, as a function of flow 
rate. It is apparent fro• Figures 10 and 11 (LEO and METHF 
respectively). that peak height decreases with increasing 
flow rate between 1.0 and 7.0 per minute. one vay !MOVA 
shoved that flov rate had a significant (p<0.05) effect on 
peak height for both coapounds. ANOVA vith linear 
regression shows a significant linear effect (p.0.05t for 
LEO (rZ = 0.89, n=33) and for METHP (rZ = 0.11. n=33). 
However, the analysis also shoved a significant departure 
from regression (p<0.05) for both drugs. This would 
suggest that the best model describing peak height as a 
function of flow rate should allow for curvilinear 
regression. 
Although a flow rate of 1.0 ml per minute produced the 
optiaal detector response for both LEU and !ETHFr 3.0 ml. 
per minute vas chosen as the usual operating mobile phase 
velocity for two reasons. First. flow rates less than 3.0 
ml. per minute resulted in unacceptably long 
chroaatographic run times. secondly, although 
statistically significant, the difference in peak height at 
1.0 versus 3.0 ml. per ainute vas not considered to be of 
practical significance and, further, would not appreciably 
affect either the lover li•it or reproducibility of the 
assay. The use of higher flov rates vas precluded since 
rates greater than 3.0 mlo per minute resulted in loss of 
resolution between some early eluting peaks as well as loss 
in detector response evident in Figures 10 and 11. 
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Figure 10: Effect of Mobile Phase Velocity 
on Detector Response to Leucovorin 
7 
I 
page 113 
1 2 3 4 5 6 
Mobile Phase Velocity (ml. /min. ) 
Figure 11: Effect of Mobile Phase Velocity on 
Detector Response to Methyltetra-
hydrofolate 
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iv. Effect of Salt Concentration 
High electrolyte concentrations are necessary in 
mobile phases to reduce resistance and produce the greatest 
current at the electrode. Varying concentrations of 
electrolyte •ay also be expected to affect the diffusion 
coefficient of the electroactive species, which according 
to equation 6, will affect the li•iting current produced at 
the electrode. 
Amaonium phosphate, dibasic, vas the optimum 
paired-ion reagent in the separation of the reduced 
folates. The effect of varying salt concentrations on 
detector response ~as determined for LEU and 8ETHF (Figures 
12 and 13 respectively). The concentration of buffer 
ranged fro• 0.005 ! to 0.5 ! and was increased at one-half 
log intervals.. The pH of the mobile phase was 5.5 and the 
flow rate vas 3.0 ml. per minute. 
One vay !NOVA with linear regression shoved a 
significant effect (p<0.05) of mobile phase salt strength 
on response, measured as peak height for both LEU and 
!ETHP. 
described 
There is 
The 
by 
a 
concentration 
plot for leucovorin (Figure 12) is best 
curvilinear regression (rZ= 0.98, n=15). 
constant increase in . response with salt 
until an apparent plateau is reached between 
0.1 ! and 0.5 ! salt concentration. 
Figure 13 represents KETHF peak height as a function 
of ammonium phosphate concentration. Rather than increase 
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to a plateau value as vas expected, the response of ~ETHF 
described no discernible pattern. As the salt 
concentration rose. the response first decreased, then 
increased and finally decreased to a level lover than the 
initial salt concentration. This result was unexpected and 
cannot be explained readily. 
v. Effect of Methanol on Detector 
Response 
The elution of the reduced folates from the Sep-Pak 
minicolumnns required a higher methanol concentration than 
was present in the mobile phase, e.g., 50~ versus 4~. 
Reece and Cozaaanis (1979) have reported that samples 
dissolved in aethanol show decreased detector response and 
poor resolution. They attributed the effect to the high 
local concentration of organic solvent altering the peak 
shape and causing band broadening. The effect is 
particularly pronounced with sample loops larger than fifty 
to 100 microliters and are used for sample loading. The 
effect of methanol on detector response to LEU and METHF 
was studied by preparing drug standards in solutions 
containing varying concentrations of methanol in 0.5 e 
aaaoniua phosphate pH 5.5. The electrocheaical detector 
vas set at +0.8 V applied potential; the summing aaplifier 
was set at 50 nanoamps per volt; and the filter gain was 
set at 10. The chromatographic conditions for this 
( 
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experiment were: MPII: with a flow rate of 3.0 ml. per 
minute; and the colamn temperature vas 400C. 
Figure 14 represents peak height as a function of 
methanol concentration for LEU and KETBF. One way ANOVA 
shoved a significant methanol effect (p<0.05) on peak 
heiqht for both coapounds. The effect of methanol was more 
pronounced on LEU than vas the case for METHF. The effect 
of methanol on LEU can best be described by a straight line 
(rZ = 0.94, n=18). ftETHF response is best described by soae 
curvilinear function (rz, = 0.92, n=18). This may be 
explained by the fact that !ETHF is apparently a more 
easily oxidized compound that LEU and, as such, is less 
subject to variation. in response. contrary to the findings 
of Reece and Cozaainis (1979), no significant difference in 
peak width (or resolution) vas noted with increasing 
methanol concentration. Although a high methanol content 
in injected samples is clearly not desireable, the final 
orqanic strength was dictated by the eluent which removed 
the folates fro• the minicolumn aost efficiently. 
B. Chromatography 
Reverse-phase chromatographic methods are estimated to 
account for 601 to 70% of all analytical vork performed 
using BPLC (Horvath and McLean, 1977). A review of the 
recent pharmaceutical and chemical literature shows that 
reversed-phase systems. particularly those which use 
aicroparticalate octadecyl-, octyl-, or phenyl silica 
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stationary phases, are becoming increasingly popular for 
the analysis of drugs. 
1. C-18 Stain1ess Steel Column 
A microparticulate octadecyl-silica stationary phase 
was chosen for evaluation for three reasons; (1) MTX, 
structurally related to LEO, has been successfully 
chromatographed using this system, (2l stationary phases 
having high carbon content, i.e., octadecyl vs octyl-silica 
are reported to have a large intrinsic retentive capacity 
(Horvath and !cLander,1977) and (3) there is a large body 
of information available regarding drug analyses employing 
this stationary phase. 
Because the reduced folates to be chromatographed are 
amphoteric compounds, the use of paired-ion reagents was 
considered necessary. Gloor and Johnson (1977), reported 
that for strong and weak acids, typical counter-ions such 
as quaternary amines (tetrabutylaamoniua chloride for 
example) are generally used and, that for strong and weak 
bases alkyl and aryl sulfonates, such as pentane, heptane, 
and octane sulfonic acids are aaong the best choices. The 
paired-ion reagents best suited for use with amphoteric 
coapounds is however, less well defined. It has been 
suggested (Bausch, 1977) that sulfonic acids aay provide 
the best separation of amphoteric coapounds similar in 
structure to the reduced folates. 
The aost commonly eaployed solvent systems in 
( 
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reversed-phase paired-ion chroaatography are vater/methanol 
or water/acetonitrile combinations. Therefore. the first 
mobile phases evaluated were combinations of methanol and 
water with SmK PIC as. (pentane sulfonic acid, Waters 
Assoc.). Figure 15 is the chromatogram resulting from the 
separation and detection of 1x10-•M LEU in a mobile phase 
consisting of 25~ MeOH: 75i Pie BS. p3.5. The retention of 
LEU was found to be 7.25 minutes. The peak however, was 
broad, and eluted over a prolonged, 4 minute period. In 
addition the system was not suitably sensitive, as is 
etident froa the ~mall peak obtained for LEU. 
Various combinations of paired-ion reagents, organic 
solvents, and pH's were prepared and evaluated. Three 
factors were considered in the evaluation of a mobile 
phase; capacity, selectivity and sensitivity for the 
reduced folates. 
Capacity aay be calculated according to Equation xx 
and aay be defined as the ability of a chromatographic 
system to retain a compound. 
k' 
v 
0 
(Equation 18) 
Where Vt is the retention voluae (or tiae) of the 
compound of interest, and Vo is the void volume or volume 
in which a non-retained compound would elute. 
Selectivity is the ratio of 2 capacity factors and 
( 
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15 min. ) 
Figure 15: Leucovorin Chromatogram 
using Paired-Ion Reagent B7 
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describes the ability of the system to separate tvo 
compounds. 
Table III shows representative mobile phase 
coapositions used with the microparticulate C-18 column, 
and the resulting capacities and selectivities vhich vere 
obtained. Figure 16 is the chromatogram of vhat vas 
considered the optimua separation obtained from the reduced 
folate analogs vhich could be detected. In general the 
capacities calculated for LEU vere relatively low, while 
those obtained for ~ETHF considerably larger. 
The addition of aqueous buffer to some of the mobile 
phase systems described in Table III was the result of the 
poor sensitivity obtain~d from systems containing only 
paired-ion reagents. Such systems have relatively high 
resistance, and as a result the current produced from the 
oxidation of a sample is lov. The increased ionic strength 
of mobile phases containing the various buffers increased 
sensitivity but, in general, had a negative effect on 
capacities, resolution. and efficiencies. 
A reported advantage of reversed-phase paired-ion 
chro•atography is the ability to aake direct injection of 
biological fluids without prior extraction or sample 
"clean-up" (Johansson!! al~ 1979). This, however, was not 
possible under the chroaatographic conditions employed. 
Plasma or serum injected directly onto columns produced 
chromatograms of (presumably) polar compounds eluting for 
longer than 20 minutes. and less polar compounds still 
( Page 124 
TABLE III 
REPRESENTATIVE MOBILE PHASE COMPOSITIONS 
USED WITH REVERSE-PHASE C-18 
STAINLESS STEEL COLUMNS 
Mobile Phase Retention Time (Min.) 
LEU METHF 
(1) Octane Sulfonic Acid: CH30H: 7.5 26.5 
CH3CN; 70: 25: 5· , pH 3.5 
(2) Octane Sulfonic Acid: CH30H: 7.5 20.5 
CH3CN; 70: 22: 8· , pH 3.5 
( (3) Acetic Acid: Sodium Acetate O. lM: 10.0 10.0 
CH3CN; 75: 25; pH 4.5 
(4) Heptane Sulfonic Acid: CH30H: 12.9 20.0 
CH3CN; 82: 15: 3· , pH 3.0 
(5) Heptane Sulfonic Acid: . OlM in KH2 17 .07 8.23 
P04: CH30H: CH3CN; 80: 17: 3 
pH 3.0 
(6) (NH4 ) 2HPo4 50mM: CH30H: CH3CN; 4.52 3.75 
80: 17: 3· , pH 6.5 
( 
( 
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20 Min. 
Resolution of Folate Analogs Using 
C-18 Stainless Steel Column 
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evident 60 minutes after injection. Similar reports of 
interfering compounds adversely effecting electrochemical 
detectors have been published by Kissinger (1974) and 
Lankelaa and Van der Kleijn (1978). 
It vas not possible to devise a separation system 
using the c-18 column which could suitably separate the 
reduced folates from plasma constituents. 
2. Radial Compression Separation System 
l recent advance in analytical liquid chromatographic 
technology is the developaent of radial compression column 
sys~ems. Radial compression has been reported to have 
several advantages over conventional stainless steel column 
technology including: high efficiency at higher flow rates, 
increased resolution, greater column to column 
reproducibility. low system operating back-pressures, and 
longer column life. The operation of this system and its 
advantages have been reviewed recently by Fallick and 
Rausch (1979t and Little !!1 !!~ (1976). 
a. Evaluation of the Radial Coapression 
1 Radial Compression Separation System (RCSS) vas 
evaluated for its applicability to the separation of 
reduced folates in aqueous systems and serum. The column 
used for this purpose vas an octadecyl-silane reverse-phase 
materal vith an 8ma I.D. and a 3.0 ml internal volume. 
Dibasic amaoniua phosphate, (NHqt2HP04, vas considered 
( 
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the most promising buffer, with respect to resolution and 
sensitivity achieved on C-18 packing •aterial, and was the 
paired-ion agent first used in evaluating RCSS technology. 
Chromatographic conditions suitable for conventional 
reversed-phase separations may not be directly applicable 
to the RCSS technology. Decreasing the organic solvent 
strength by approximately one-half of that in a 
conYentional systea has been recommended as a aeans of 
obtaining a suitable mobile phase from which to experiaent. 
Because of the reported differences in performance between 
the two chromatographic methods and the paucity of 
published data regarding its operation, a characterization 
of several. RCSS operating parameters, vith respect to 
reduced folates, vas undertaken. The four characteristics 
used to eYalaate the RCSS were: mobile phase flow rate; 
coluan teaperature; buffer strength; and pH. 
i. Effects of Flow Rate 
The large internal Yolume and shorter length of the 
radial pat cartridge, in comparison to conventional 
stainless steel coluans, results in lover operating 
pressures for any giYen flov rate. As a result, it vas 
possible to operate the RCSS at flow rates as high as 6.0 
al min-' without exceeding back-pressures of 2000 psi. 
Figure 17 is a plot of the retention times as a function of 
flow rate for both LEU and !ETHF. The mobile phase used in 
these determinations vas 0.5~ (HB4)2HP04 93i, CBJCM 3~, 
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CH30H q~. pH S.S. conventional chromatographic systems are 
limited to flow rates of 1.5 to 2.0 ml min-•. higher rates 
exceed column back-pressures of 2000 psi and may damaqe the 
packing aaterial. Over these limited solvent flow rates. 
plots of retention times as a function of flow rate are 
linear. However. when higher flow rates vere used. 
deviations froa linearity were evident. It is apparent 
from this figure that both the capacity and selectivity of 
the RCSS decreased with an increase in flov rate above 3.0 
to q.o ml min-1. Figure 18 is a log-log transformation of 
the retention times as a function of flow rate. The linear 
regression coefficients obtained from this plot vere 
subsequently used to predict the retention of LEU and ~ETHP 
during 
It was 
phase 
systems 
the development of optimal mobile phase conditions. 
possible to extrapolate this data from the mobile 
tested and predict retentions in other aobile phase 
as aight be expected. These observations are in 
general agreement vith studies of flow control in HPLC 
reported by schrenker (1978). 
ii. Effects of Teaperature 
"In HPLC there has been a tendency to overlook the 
influence of temperature on chromatographic measurements" 
(Gilpin and Sisco 1978). These authors report that both 
normal and bonded phases may be affected by temperature. 
and that variations in capacity greater than 25~ have been 
observed with temperature changes of 1oc. or less. Because 
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of the high efficiency and reactivity associated vith RCSS 
colu•ns the effect of temperature on retention times of LEU 
and ~ETHP vas investigated. 
Table IV is a comparison of LEU and ftETHF retention 
and the corresponding column selectivity calculated at 
2ooc. 3ooc. 4ooc. and sooc. Figure 19 shows the 
chromatograms obtained from the injection of a LEO-!ETHF 
coabination at 20°c and so0 c. The decrease in retention 
tiaes (capacity) at the tvo temperatures is evident. 
however. the selectivity of the system actually improved at 
~he higher teaperature. This can best be explained by a 
decrease in botL LEU and !ETHF peak width. 
Teaperature fluctuations were found to affect daily 
chromatographic results. Ambient temperatures fluctuated 
as auch as 1ooc. during the course of a day. causing as 
much as 201 changes in observed retention times for folate 
compounds using the same mobile phase. The installation of 
a Thelco. Model 15. constant temperature oven. circumvented 
the effects of temperature. Column temperatures vere held 
constant at 40°c ± 3oc and retention times for LEU and 
!ETHP vere found to be reproducible within the 51 limits of 
the RCSS system. 
iii. Effects of counter-Ion Strength 
The effect of counter-ion (buffer) concentration on 
the retention of LEU and !ETHP vas characterized during the 
evaluation of mobile phase characteristics. 
( 
Temperature 
(OC) 
20° 
30° 
40° 
50° 
TABLE IV 
EFFECT OF TEMPERATURE 
ON FOLATE RETENTION 
Retention Time 
(Minutes) 
LEU 5-METHYL 
4.60 8.10 
4.13 7.52 
3.50 6.59 
2.68 4.90 
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Selectivity 
( ct ) 
1. 95 
1.89 
2.27 
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Figure 19: Effect of Colunn Tenperature on 
Leucovorin and Methyltetrahydro-
folate Retention. 
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The aobile phase contained Buffer:MeOH:CH3CN in the ratio 
93:4:3. The pH vas maintained at S.S. Table v describes 
the retention times for LEU and METHF as a function of 
ammonium phosphate concentration. Although the mechanism 
of the ion-pair reaction is unclear (Gloor and Johnson. 
1977) and is further clouded by the presence of positive 
and negative counter-ions from the ammoniua phosphate. the 
general trend is in agreement vith published data 
suqqesting that increasing counter-ion concentration 
increases retention up to a limiting value. 
iv. Effect of pH 
The effect of pH is dependent upon the nature of the 
solute. However. retention increases as changes in pH tend 
to maximize the concentration of the ionic form of the 
solute. This presumably increases the equilibrium in favor 
of the ion-pair coaplex. Figure 20 is a plot of the 
retention of LEU and METHP as a function of pH. The aobile 
phase used was O.SM Phosphate Buffer:CH30H:ch3cn in the 
ratio 93:4:3. It is evident that pH affects LEU retention 
to a greater degree than it does METHF. This result 
however. is not easily explained. Although pKa values have 
not been reported for METBF it would seem likely that it 
would have values siailar to those of LEU. Both compounds 
have the saae ionizable groups. e.g. C4 hydroxyl group. and 
2 glutaayl carboxyl groups. It vould seem likely that the 
disassociation of these groqps would be similar 
( 
( 
TABLE V 
THE EFFECT OF BUFFER CONCENTRATION 
ON FOLATE RETENTION 
Retention Time (Min.) 
Buffer Molarity LEU 
0.5 3.85 
0.3 3. 79 
0.1 2.91 
0.05 2.62 
0.01 1. 63 
0.005 1. 57 
Mobile Phase Composition: 
Buffer: CH30H: CH3CN; 92:4.5:3.5 pH 5.5 
Flow Rate = 3.0 ml/min. 
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for both compounds. Since the only structural difference 
between LEU and !ETHF is in the NS substituent, formyl and 
methyl respectively, these data suggest that the functional 
qroup in this position contributes to the retention 
characteristics of these reduced folate analogs. 
c. Drug Assay 
1. Aqueous Syste•s 
The electrochemical detector response to LEU or !ETHP, 
measured as peak height, declined rapidly from a •axiaum 
value observed imaediately after the cell was resurfaced. 
As a result, it was necessary to generate standard curves 
of peak height as a function of concentration, whenever 
quantitative measures were to be performed. 
Calcium LEU or Barium !ETBF were used as received 
without further purification. LEU and METBF solutions of 
1x10-3! and 1x10-•ft respectively were freshly prepared in 
1N KOH. 111 further dilutions were made with the solvent 
in which the drug was to be chroaatographed; Sorenson's 
Buffer for protein binding (LEO or ftETHP) or, mobile phase 
for LEU serum concentrations. All drug solutions prepared 
in this manner vere protected fro• light with aluminum foil 
and stored on ice. Fresh stock solutions were prepared 
daily. No degradation in either drug solution was noted; 
no detectable changes in peak heights of the chromatograms 
or by changes in the shape of peaks or by the appearance of 
other peaks or shoulders in the chromatograms during the 
( 
( 
( 
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course of an experiment. 
Standard curves for both LEU and METHP were generated 
by plotting peak height as a function of drug 
concentration. Drug concentrations for this purpose were 
between 2.Sx10-7! and 5.0x10-•M. At least 5 concentrations 
were used to generate these standard curves. Each point 
represents the average of 2 deter•inations; each 
concentration was determined in triplicate. Thus, each 
standard cur•e consisted of at least 15 data points. A 
linear plot vas obtained o•er the concentration range 
specified for both drugs (rZ>0.99 in all casest. All 
unknown solutions were analyzed in duplicate and 
concentrations were determined from the regressions 
coefficients of the appropriate standard curve. 
2. Seru• 
A LEU stock solution, 1x10-~M, in 1M KOH, vas 
prepared, and fro• this stock solution, additions were made 
to pooled husan serum to yield final LEU concentrations 
between 2.Sx10-7ft and 2.5x10-•!- The serum samples vere 
then extracted in the manner described previously. All 
saaples were analyzed the saae day as extracted. 
The evaporated serum samples were . reconstituted in 0.5 
ml of mobile phase. Since the extraction was carried out 
vith 1.0 al of seru•, this represents a tvo-fold 
concentration of sample. 
of the sample dish to 
care was taken to rinse the walls 
insure collection of the entire 
( 
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sample. Identity of the LEU peak in the sample matrix was 
confirmed by analyzing serum-blanks which exhibited no 
peaks vith retention times corresponding to LEU, and by the 
addition of LEU to reconstituted samples and noting an 
increase in the height of the peak identif~.ed as LEU .. 
a.. Recovery 
The recovery of LEU added to pooled human serum was 
virtually complete. The recovery over the concentration 
range 
93. 60% 
studied vas 
to 117 .. 20~ .. 
101.11~, with a range in recoveries of 
Table YI shows the amount of LEU added 
to serum saaples, the calculated amount of LEU measured and 
the percent recovery at each concentration.. Figure 21 is a 
plot of the observed LEU concentration as a function of the 
known LEU concentration in each sample. A plot of LEU peak 
height as a function of concentration was linear over the 
concentration range 2.5x10-7M to 2.Sx10-6M,. A statistical 
analysis of the regression coefficients obtained from 
standard curves of LEU in serum and mobile phase was 
perforaed. No difference (p<0 .. 05) vas noted in the slope 
of the regression.. The intercepts, however, shoved a 
siqnficant difference (p<0.05t, those obtained froa LEU in 
serum vere larger than fro• aqueous systems. Although the 
differences in y-axis intercepts were statistically 
different (p<0 .. 05), the error caused by using the 
regression coefficients obtained from LEU in mobile phase 
( 
( 
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TABLE VI 
RECOVERY OF LEUCOVORIN FROM HUMAN SERUM 
Initial Serum 
Concentration a 
(Moles/Liter) 
2.5 
5.0 
7.5 
10.0 
15.0 
20.0 
25.0 
+ n=3 
a = x 
Calculated Serum 
Concentration a 
(Moles/Liter) 
(Mean + S.D.) 
2.34 + 0. 30 
5.86 + 0.60 
7.50 + 0.20 
9.62 + 0.60 
14.20 + 0.20 
20.50 + 5.10 
25.90 + 8.88 
Average Percent 
Recovery + 
93.60 
117. 20 
100.00 
96.20 
94.67 
102. 50 
103.60 
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35 
Leucovorin Recovery from Serum 
Observed vs Expected Leucovorin 
Concentration 
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to analyze seraa saaples were calculated to be less than 5 
percent. 
b. Sample Stability 
The stability of LEU in the sampling dishes was 
evaluated in order to deteraine the aaxiaua length of tiae 
that saaples could be stored in this condition. 
Leucovorin was added to 20 ml. of pooled huaan serum 
to yield a final concentration of 1.07x10-•M~ Nine, 1 ml 
serum samples were then extracted and evaporated as 
previously de~cribed. The samples vere randomly assigned 
to 3 groups of · 3 saaples each, which were then frozen until 
assayed. The first . qroup was assayed the day following 
extraction; the second, 2 days after extraction; and the 
third was assayed on the fifth day after extraction. The 
results of these assays were combined with the results of 3 
assays performed immediately after the extraction process. 
and appear in Table VII. 
The calculated LEU 
extraction procedure was 
concentration 
coapared with 
f olloving 
the LEU 
the 
concentration in the serum samples prior to extraction. No 
statistical differences were noted vhen samples were 
assayed the same day. one day, or two days following the 
extraction procedure (Duncans Multiple Range test. p<0.05). 
Hovgver. vhen the samples were stored for 5 days, there vas 
a significant decrease in the calculated LEU 
concentrations. Fro• these data is was concluded that 
( 
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although analysis of serum samples following the extraction 
procedure need not be done immediately. two days was the 
•aximua acceptable time between the extraction and analysis 
of LEU serum samples. serua samples fro• all cancer 
patients and all normal subjects were assayed the day of 
extraction or within 24 hours. 
3. Separation of Leucovorin in Serum 
Following the characterization of several of the 
important RCSS operating parameters. a aobile phase was 
developed vhich effectively separated LEU from the 
oxidizable. extracted serua coaponents (Table III). 
Figure 22 shovs representative chromatograms for LEU 
and METHF. vhich vere obtained using the parameters 
detailed in Table VIII. The capacities. selectivity. 
resolution, and efficiency of the chromatographic system is 
given in Table YIII. 
The capacities ~alculated for LEU and METHF fall in 
the ranqe vhich is generally considered to be opti•al. 
i.e •• 2 to 10. 
Resolution is a means of measuring the degree of 
separation of any two coaponents in a chromatogram and is 
usually defin~d as the difference between the peak centers 
of two peaks. divided by the average base width of the 
peaks (Equation 18)· 
(F.quation 18) . 
( 
Days 
Frozen 
0 
1 
2 
5 
* n=3 
a = x 
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TABLE VII 
STABILITY OF FROZEN LEUCOVORIN EXTRACT 
Initial Concentration8 
(Moles/Liter) 
1.00 
1.07 
1.07 
1.07 
Calculated Concentration 
After Reconstitution*a 
(Mean+ S.D.) 
0.96 + 0.07 
l. 05 + 0.18 
1.14 + 0.10 
0.82 + 0.07 
Figure 22: Separation of Leucovorin and 
Methyltetrahydrofolate Using 
Radially Compressed Colurrn 
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TABLE VIII 
CHROMATOGRAPHIC PARAMETERS DESCRIBING 
THE SEPARATION OF LEUCOVORIN FROM 
SERUM COMPONENTS 
(NH4 ) 2 RPO 4 92.00 
Methanol 4.50 
Acctonitrile 3.50 
Sodium EDTA 10.00 MM 
pH 3.50 
Column: Radial Pak A 
Flow Rate: 3.0 ml/min 
Column Temperature: 40°c 
Leucovorin Retention 8.05 Min. 
Leucovorin Capacity (K') 
Resolution: (Leucovorin from the 
Closest Eluting Peak): 
Column Efficiency (Leucovorin): 
7.13 
1. 61 
530.00 Plates 
( 
A resolution of 1.5 or great9r indicates 
components are completely separated. The 
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that tvo 
calculated 
resolution between the reduced folates was 2.07 indicating 
complete baseline resolution of these components. 
Efficiency is the measure of band spreading of a peak 
throughout a chromatographic peak. High efficiencies 
generally produce sharper peaks than do low efficiency 
systems. The efficiency calculated for the reduced folates 
under the systea employed in this work, is substantially 
lover than the manufacturers claim for the system (5000 
plates). Chroaatography of folate compounds generally 
results in lov efficiencies which can best be explained by 
the amphoteric nature of the compounds. Because the 
compounds •ay exist in more than one ionic form during the 
separation, the relative retentions vill differ. The net 
result of this effect is band broadening. A second 
explanation is the use of hiqh buffer concentrations vhich 
are necessary for optiaua electrochemical detection, and 
•ay adversely effect resolution and hence efficiency 
(Rausch, 1980). 
Figure 23 is a chroaatograa obtained from the 
injection of 
subject KB 
the reconstituted serua sample obtained from 
imaediately before LEU administration. This 
is representative of the •serum-blank• 
all normal volunteers and patients who 
several peaks were found to elute before 
chromatogram 
obtained from 
received MTX. 
( 
( 
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LEU, and a single peak followed the drug. No additional 
peaks where observed when similar chromatograms were 
allowed to continue for 30 minutes. The serum peaks 
evident in Figure 23 were present in all samples 
chromatographed at approximately the same amounts in all 
extracted serum saaples. These peaks, which were not 
identified, did not interfere with the quantification of 
LEU, although ~ETHF, was masked with the unknown peak 
having a retention time of 4.6 minutes (versus 4.37 ainutes 
for METHF) 
Figure 24 shows the presence of LEU after 
administration of a 10 mg. intravenous dose to subject KB. 
This chromatogram vas taken from the volu.~teers 6 hour 
serum sample. The resolution between LEU and the 
unidentified peak eluting at 6.12 minutes was calculated 
fro• this chromatogram. The resolution of 1.61 indicates 
complete resolution of LEU from the closest unknown peak in 
extracted serua samples. When the resolution between these 
two peaks declined to 1.25 or less, the chromatographic 
column was regenerated or replaced as necessary. 
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D. Protein Binding 
1. Non-Specific Binding 
Non-specific binding of either LEU or METHF to the 
components of the ultrafiltration cell or membrane vas 
negligible. Filtered samples of the drug solutions shoved 
no significant difference (Student's t. p<0.05) when 
coapared to saaple£ taken from the ultrafiltration cell 
before being filtered. 
2. Analysis of Albuain Solution 
Samples obtained from the direct ultrafiltration of 
both dialyzed and non-dialyzed albu•in vere 
chromatographed. The samples obtained from the 
non-dialyzed albumin vere shown to have a component or 
components which interfered vith the quantification of both 
leucovorin and 5-methyl THP. The aajor interfering peat 
had a retention of 5.69 minutes and produced an input 
signal greater than 2.0 volts. Chlorofor•. toluol. and 
decanol. which may be used to induce crystallization of 
albuain, have ~een implicated as possible contaminants of 
coaaercially prepared albumin (Chignell. 1977). Dialysis 
of the albumin solution overnight at 4oc against a large 
voluae of water or buffer has been suggested as a means of 
removing such contaainants (Chignell. 1977t. 
Albumin used for the protein binding determinations 
was obtained from one source (Calbiochem Inc •• Palo Alto, 
( 
paqe 152 
CA.). However, two different lots of albumin were 
received. Lot Mo. 600638, used for the first two 
leucovorin binding experiaents, was not dialyzed and 
nothing in the filtrate interfered with the drug analysis. 
Fraction v Human serum Albumin Lot No. 903635, used for the 
final leucovorin binding study produced several peaks which 
interfered with the chromatography of both leucovorin and 
!ETHF. Dialysis successfully reaoved the contaminant(s) 
and no difference in LEU protein binding was observed using 
either dialyzed or non-dialyzed albuain. 
Calbiochea Inc. confirmed (1980) that tvo different 
manufacturing processes had been used to prepare the two 
lots of albuain. Although the ~ethods of preparation were 
not revealed, it seems likely that contaainant(s) such as 
those described by Chignell (1977) were present. The fact 
that dialysis of the protein solution readily removed the 
contaminants responsible for the interfering peaks ic 
further evidence for this explanation. 
3. Leucovorin Protein Binding 
The protein binding of leucovorin vas deterained over 
a total drug concentration range of Sx107M to 1x10-3M. The 
lover liait of binding deterai~ation vas governed by assay 
sensitivity, the upper limit by leucovorin solubility. 
Leucovorin binding to human serum albumin is 
essentially constant, 69.95~ ± 4.70~, over the clinically 
significant concentration range. Figure 25 shows the 
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percent of leucovorin bound plotted as a function of total 
drug concentration. It is apparent from this figure that 
saturatio& of the protein had not occurred at the highest 
drug concentration examined. !oreover, binding did not 
decline appreciably with increasing drug concentration. 
The limited solubility of leucovorin prevented the 
determination of binding at higher concentrations and also 
prevented the calculation of Scatchard para•eters for LEU. 
Figure 26 represents a scatchard plot for LEU. 1 set of 
data is considered adcissible for scatchard analysis if it 
meets the criterion of having an "everywhere neqativ~ 
slope" (Fletcher, 1973). The degree of scatter evident in 
Figure 26 prevents the conclusion that this condition has 
been met. Therefore, the scatchard model is not applicable 
for analysis of these data. 
Values for affinity constants and numbers of binding 
sites can be estiaated by stepwise computer analysis using 
iterative techniques (Pletcher, 1973). These techniques 
rely on reasonably accurate starting estimates, vhich are 
usually obtained by graphical methods. such esti•ates are 
not available either by Scatchard, Scott, or Klotz plots 
because of the scatter in the leucovorin binding data and 
the limited range over which binding was determined. 
4. Leuco~orin Binding to Bovine Albumin 
Albumin from various animal species can vary greatly 
in their drug binding characteristics (King, 1973). 
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Leucovorin binding to four percent (w/v) bovine serum 
albumin was deterained over a drug concentra~ion range of 
2.5 x 10-• ! to 1.0 x 10-• M. Figure 27. The binding was 
constant over the range studied (69.37~ ! 8.67) as was the 
case vith human serum albumin. A tvo way ANOVA vas 
performed on these data, and it shoved that no significant 
difference (p<0.05) existed between leucovorin binding to 
the two types of albumin. 
So !ETHP Protein Binding 
ftETHF protein binding was determined over the drug 
concentration range of 5x10-7 K to 1x10-3 K. The binding 
of KETHF, un1ike leucovorin, did not remain constant. 
Figure 28 is a plot of percent drug bound as a function of 
total drug concentration. While saturation of the protein 
does not appear to have been reached, it is clear that the 
percent of drug bound to albumin decreased appreciably with 
increasing concentration. At 5x1Q-7 !, 86.241 of the drug 
was bound, at 1x1Q-3 ! binding had decreased to 64p11~. In 
other words, the percent of free drug had increased 2.5 
tiaes over this concentration range. 
Figure 29 is ~ Scatchard plot for KETHP. As with 
leucovorin. the scatter in the data makes it impossible to 
assume that the criterion of an "everywhere negative slope" 
has been met. These data cannot be described in terms of a 
Scatchard •odel. !oreover, graphical techniques cannot 
yield reliable first estimates of Ka's or n•s, and no final 
( 
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values for affinity constants or numbers of binding sites 
can be obtained. 
6. LEUr ftETHF Protein Binding Interactions 
Since LEO and ftETHF coexist in plasma. there is the 
possibility of competition for a common binding site. vhich 
aay alter the bindin~ characteristics of one or both drugs. 
To investigate this potential interaction. the tvo drugs 
were ultrafiltered together and the protein binding 
determined. Four combinations of drug concentrations vere 
evaluated: first. eguinolar concentrations of LEU and ftETHF 
(Sx10-s ft and Sx10-• M); in addition. LEU was prepared in 
excess of METHF (Sx10-s ft and Sx10-• Mr respectively); the 
concentrations were then reversed so that METHP vas in 
excess. 
The effect of ftETBF on the binding of LEU is shovn in 
Table IX. The decrease in LEU binding in combination with 
!ETHP vas significant at all levels tested (tvo vay ANOVlr 
p<0.05). The greatest change ocurred vith ftETHF present in 
ten fold excess of LEU. The percent of LEU bound to 
albumin decreased fro• a mean value of 72.49% ! 2.62~ to a 
mean of 31.361 ~ 4.941. 
The same result vas obtained vhen the effect of LEU on 
the binding of ftETHF was examined. A significant decr9ase 
in ftETHP binding is observed vith all combinations of LEUr 
Table IXe The greatest decline in binding. approximately 
20r is observed vhen both drugs are combined at sx10-s Mr 
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in comparison to KETHF alone at this concentration.. 
The study of the protein. binding interactions between 
LEU and !ETHF yields several conclusions. First. it is 
apparent that. since the degree of binding decreases for 
both drugs when they are present simultaneously, LEU and 
!ETHF appear to share a common binding site (or sites). 
Secondly. since !ETBF binding is influenced to a lesser 
degree by LEU than is LEU by ~ETHF, it is reasonable to 
conclude that METHF has a stronger affinity for the site 
than does LEU. Finally, it is evident that determining the 
protein binding of any of the reduced folates (or folir. 
acid) alone ~n_vit~ does not reflect the physiological 
state in which folates exist. The differences in the 
degree of folate binding reported in the literature. 
particularly with respect to folic acid, may be 
attributable to the presence (or absence) of other folate 
forms at the time of assay, as vell as to the method used 
to determine binding. 
( 
LEU 
CONCENTRATION 
0 
5xl0-6M 
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TABLE IX 
LEUCOVORIN - 5-METHYL THF 
PROTEIN-BINDING INTERACTIONS 
METHF 
_6CONCENTRATI0~5 5xl0 M 5xl0 M 
(%BOUND+ S.D.) 
85.45 + 2.00 81.13 + 2.42 
66.04 + 1.64 71.68 + 3.86 
67 . 72 + 4.90 60 . 58 + 2.75 
( 
( 
5-METHF THF 
CONCENTRATION 
0 
Page 163 
TABLE X 
LEUCOVORIN - 5-METHYL THF 
PROTEIN-BINDING INTERACTIONS 
LEU 
CONCENTRATION 
5xl0-6M 5xl0-5M 
(% BOUND + S.D.) 
72.49 + 2.62 73.83 + 1.43 
42.53 + 4.19 64. 74 + 4.46 
31.36 + 4.94 50. 75 + 1.81 
( 
( 
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7. LEU and ftETHF ftTX Binding Interactions 
Leucovorin is clinically adainistered to patients 
following the infusion of ftTX. Current protocols at Roger 
Williams General Hospital. require that the LEU 
administered result ir. a plasma concentration ten times 
higher than the corresponding MTX concentration. To 
deteraine the effect of MTX on the binding of LEU the tvo 
were ultrafiltered simultaneously using tvo combinations of 
drug. In each case LEU vas present in ten fold excess; 
first at 1x10-• M in the presence of 1x10-7 Mr then at 
1x10-s M with 1x10-• ! MTX added. Table II shows the 
effect of MTI on the binding of LEU. No significant 
difference (t test. p<0.05) was observed in LEU binding 
with MTX. 
Since METBF is the predoainant circulating folate the 
interaction vith Mf X vas also deterained. The same scheae 
of concentrations as described above vas used. The effect 
of 
XII. 
methotrexate on the binding of METHF is shovn in Table 
The degree of ~ETHF binding at 1x10-s M did not 
significantly (t test. p<0.05) in combination vith change 
MTX. 
Methotrexate had a significant effect (t test. p<0.05) 
on the binding of METHF with concentrations of 1x10-7M and 
1x10-•M respectively. However. rather than displacing 
METHF from a binding site. thereby decreasing the extent of 
binding. the binding actually increased. The increase in 
binding was from 84.20~ ~ 2.67% to 97.19~ ! 2.11. which is 
( 
MTX 
CONCENTRATION 
0 
lxl0-7M 
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TABLE XI 
LEUCOVORIN 
PROTEIN-BINDING INTERACTIONS 
WITH METHOTREXATE 
LEU 
CONCENTRATION 
lxl0-6M lxl0-5M 
(%BOUND+ S.D.) 
68.44 + o. 72 71.94 + 3.54 
---------- 66.85 + 1.50 
69.23 + 3.95 -----------
( 
( 
MTX 
CONCENTRATION 
0 
lxl0-6M 
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TABLE XII 
METHF 
PROTEIN-BINDING INTERACTIONS 
WITH METHOTREXATE 
METHF 
CONCENTRATION 
lxl0-6M lxlO-SM 
(% BOUND + S.D.) 
84.20 + 2.68 81.00 + 1. 71 
--------- 78.73 + 3.89 
97.19 + 2.11* 
*Significant at 0.05 Level 
( 
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highly significant. An increase in the percent bound under 
these conditions is unexpected and cannot be readil~ 
explained. The increase aay be the result of assay error 
since the deterainations of free concentrations of METHF 
vith total concentrations of 5x10-7M requires aeasuring 
between 1x10-7M and 5x10-•ft, the lover liait of detection. 
These results indicate that, since no differences in 
binding vere found, MTX does not share a binding site with 
LEU. The saae conclusion can be reached for METHF even 
though the degree of binding vas signficantly increased in 
the presence of MTX at one concentration. If a binding 
site vere shared, the degree of binding might logically be 
expected to decrease, not increase as vas the case. 
Moreover, the binding of METHF did not change with MTX at 
higher concentration. It is therefore unlikely that MTX 
and METHF -share a common binding site. 
E. LEO Pharmacokinetics 
1a Normal Subjects 
The disposition of intravenously administered LEU has 
been characterized in 6 healthy volunteers; 3 males and 3 
females. Figures 30 and 31 shov the serum clearance of the 
drug following the administration of 10 mga to the male and 
female subjects respectively. In both groups the 
disappearance 
distribution 
of LEU was characterized by an initial rapid 
phase followed by a considerably slower 
elimination phase. 
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Figure 30 : Leucovorin Serum Concentration as a Function of 
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Figure 31: Leucovorin Serum Concentration as a Function o~ 
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LEU data for the serum concentration as a function of 
was first analyzed using an ITEL AS/5 Computer systea 
a 
AUTOAN 
decision-making pharmacokinetic computer program: 
(Sedman and Wagner, 1974). This program assumes a 
first order eli•ination rate constant and examines the fit 
of a one, two, or three compartment open model to the data. 
The number of terms in the polyexponential equation is 
deterained, an appropriate model is selected, and the 
microscopic rate constants, and volume of distribution are 
estimated. (Sedman and Wagner, 1974). The serum data for 
the concentration as a function of time for all 6 subjects 
was determined to be best described by a two compartaent 
open model vith elimination occuring solely from the 
central compartment (Figure 32). The biexponential 
equation which describes the plasma concentration as a 
function of time is; 
Cp = Ae --'t + Be -qt 
(Equation 19) 
Where A and B are pre-exponential teras and alpha and beta 
represent the rate constants for distribution and 
elimination respectively (Curry, 1974). 
These values may also 
micro-constants k12, kel, 
well as their derivations 
(Gibaldi and Perrier, 1975). 
be expressed in terms of the 
and k21. These expressions as 
have been described in detail 
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Figure 32: Two Compartment Open-Model 
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The initial estimates provided by lUTOAN were further 
refined using a second computer proqraa. HONLIN (Metzler. 
Elfrinq. and McEvan. 1974). The pharmacokinetic model. in 
this case the two compartment open-model. is specified and 
those values of the pertinent parameters are chosen which 
give the best fit of the experimental data to the model.. 
The fitting process vhich is employed in NORLIN is an 
iterative technique using non-linear least squares 
regression (ftetzler. Elfrin. and !cEvan. 1974). Pour 
weight specifications for the concentration function vere 
evaluated; the veiqhting scheme vhich · provided the best fit 
of the model to the data vas used to obtain the final 
values of the pharmacokinetic paraaeters. In addition, a 
subroutine program, DFUNC. was written to provide the 
necessary equations to fit the data was written and appears 
in Appendix IV. 
The pharmacokinetic parameters describing the 
dispositiion of intravenously administered LEU in all six 
subjects are given in Table IV. Although the 
aicroconstants have relatively small standard deviations 
associated with them. the volumes of distribution show a 
great deal of variability. This can most likely be 
attributed to the large difference in the weights of the 
normal volunteers. e.g. 45 Kg to 100 Kg. Because the 
height of the 6 subjects also varied greatly (over a 31 cm. 
range) the surface areas calculated for the volunteers 
shoved a related variability; 1.37 mz to 2.28 mz. 
( TABLE XIII 
LEUCOVORIN 
PHARMACOKINETIC PARAMETERS CALCULATED 
FROM NORMAL VOLUNTEERS 
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Parameter All Volunteers 
(Mean + S.D.) 
Kela 
Kl2a 
K2la 
Vcl ml 
Vd (Cen.) 
Vd (SS) 
Vd (Beta) 
Vd (Ext rap) 
Vd (Tiss) 
Half-Life 
(Alpha) 
Half-Life 
(Beta) 
Mean + SD, (n=3) 
- 2 
a = x 10 
Min. - 1 1.54 + 0.88 
Min. - 1 0.93 + 0.29 
Min. - 1 1. 96 + 0.50 
*Min. - 1 6.21 + 0.21 
Liters 5.49 + 3.53 
Liters 8.44 + 5. 73 
Liters 21.12 + 8. 95 
Liters 24.10 + 9.39 
Liters 2.95 + 2.23 
Minute 8. 79 + 4.44 
Minute 231. 46 + 31. 76 
( 
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Normalizing the volumes of distribution by expressing these 
teras as either al Kg-a or al m-z rather than as al. 
greatly reduces the effects of subject variability in these 
parameters. 
The description of a biexponential decay in LEU serua 
concentration as a function of time is in agreement vith 
the report of Rothenberq ~1 !l~ (1979) in which a "rapid" 
decline vas followed by a second prolonged elimination 
phase which approaches a "plateau" in appearance.. A 
similar rapid distribution phase (alpha half-life 8.79 * 
4 .. 44 ainutes) and a "slow elimination phase ( beta 
half-life 231.46 t 31.76 minutes) have been characterized 
in the present study. Rothenberg !a1 ~!~ (1979) have 
suggested that the plateau results fro• the selective 
elimination or tissue uptake of only the active fora of 
LEO. leaving the inactive diastereoisomer in the systemic 
circulation for prolonged periods.. The present vork can 
neither confirm or refute such a suggestion since the assay 
method does not distinguish between forms of folinic acid. 
nor vas the active diastereoisomer available for 
administration to the subjects. The total body clearance 
of the drug vas calculated as 62,.1 al min-1 ± 21.3 al 
min-•. Clearance has been calculated according to th~ 
following equation ; 
v = 
cl * Vd~ 
(Equation 20) 
( 
( 
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The large standard deviation eviaent in this parameter is 
•ost likely caused by the preYiousl~ described variability 
in volumes of distribution. 
Literature values reported for the percent of LEU 
excreted unchanged may be used to approximate the renal and 
metabolic clearance of LEU. Spray and Witts (1953) 
reported that an average of 15~ of the administered drug 
vas excreted in the urine in tvo hours. Rothenberq ~ al~ 
(1979) calculated a value of approximately 18~ for the 
amount excreted unchanged. An average value obtained from 
these two reports, 16~5, was used to estimate a renal and a 
aetabolic clearance for LEU. The total body clearance for 
LEU (Vcl) vas calculated to be an average of 62 ml ain-a. 
The renal excretion can be calculated according to Equation 
21; 
c1crenal) = GFR + AS - TR 
(F,quation 21) 
The renal clearance of LEU was calculated to be 10.23 ml 
min-a. Subtracting this value fro• Vcl yields the 
aetabolic clearance: 51.77 ml min-1. 
The 6 noraal subjects vere assumed to have a noraal 
gloaerular filtration rate of 120 ml min-a. Only the free, 
non-protein bound, fraction of circulating drug is subject 
to glomerular filtrationa 
( 
( 
( 
LEU. 
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The contribution of glomerular filtration for LEU. 
assuming the fraction free to be 30~ was calculated as 36 
ml ain-t. Since LEU's calculated renal clearance. 10.23 ml 
min-t. is less tha~ the calculated aaximua glomerular 
filtration rate. there is assuaed to be tubular 
reabsorption of LEU. The extent of reabsorption can be 
obtained fro• the difference between gloaerular filtration 
and renal clearance. The net tubular reabsorption rate for 
LEU was calculated to be approxiaately 26 al min-•. 
A comparison of the pharmacokinetic parameters derived 
f roa the aale and female Yolunteers is presented in Table 
3. No statistical differences {p <0.05) vere obserYed in 
any of the pharaacokinetic parameters calculated. 
2. Cancer Patients 
The disposition of LEU was followed in 4 patients 
undergoing High-Dose !TX therapy at Roger Williams General 
Hospital. One patient. L.B.. received 2 courses of 
treatment approximately 1 aonth apart and LEU disposition 
was characterized following both courses. Three patients 
received the drug intravenously. the fourth vas given LEU 
by intramuscular injection. 
In 3 of the data sets the diappearance of LEU 
following intravenous administration vas characterized by 
an initial rapid distributive phase followed by a slower 
elimination phase. Figures 33 and 34 show the clearance of 
the drug in patient P.F and L.!. The biexponential decay 
( 
page 177 
vas in agreement vith the pattern observed in normal 
~ subjects. The serum concentration-time data for these 
patients vas analyzed first using AUTOAN then NONLIN to 
provide the final values of all parameters. Table XV shows 
the values of the pharmacokinetic parameters derived fro• 
the cancer patients and normal male subjects. No 
statistical differences (p <0.05) were found between 
parameter estimates in the normal subjects versus cancer 
patients. 
Lacking pharmacokinetic parameters for LEU. the rescue 
protocol at Roger Williams General Hospital vas developed 
assuaing that its disposition is similar to that of MTX. 
Leucovorin rescue has been dosed to provide an initial 
plasma concentration ten-fold higher than the projected MTX 
concentration in the patient 30 hours after the termination 
of the !TX infusion. Table XVI is a comparison of the 
expected LEU serum concentration and the calculated initial 
serua concentration determined by electrochemical assay. 
The calculated serum concentration averaged 6.67 times 
(range 3.5 to 11.8) greater than the expected 
concentration. Although the. excess LEU will not result in 
toxicity. the net effect is to reduce the effectiveness of 
MTX therapy. The disparity between observed and expected 
serum conce~trations may be largely attributed to the 
differences in volume of distribution between LEU and MTX. 
Table XVII shows a coaparison of the half-lives and volumes 
( 
( 
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TABLE XIV 
A COMPARISON OF 
LEUCOVORIN 
PHARMACOKINETIC PARAMETERS CALCULATED 
FROM FEMALES VS. MALES* 
Parameter Males 
(Mean + S.D.) 
Kela Min.-1 1.14 + 
-
Kl2a Min.-1 1.12 + 
-
K2la Min.-1 2.25 + 
-
Vd (Cen.) Liter 7.41 + 
-
Vd (SS) Liter 11. 31 + 
-
Vd (Beta) Liter 26.40 + 
-
Vd (Ext.) Liter 29.23 + 
-
Vela Ml/Min. 7.49 + 
-
Vd (Tiss) Liter 3.90 + 
-
tl/2 Min. 8.66 + 
-
tl/2 Min. 240.48 + 
-
*No Statistical Differences (p<0.05) 
a = x 102 
0.43 
0.23 
0.49 
3.48 
5.62 
9.24 
9. 78 
1. 94 
2.16 
2.98 
44.03 
Females 
(Mean + S. D.) 
1. 93 + 0.11 
-
7.33 + 0.20 
-
1. 68 + 0.39 
-
3.58 + 2 . 85 
-
5.51 + 5.08 
-
15.97 + 5. 77 
-
18.97 + 6. 76 
4.94 + 1. 64 
-
2.00 + 2.26 
-
8.93 + 6.36 
-
222.43 + 18 . 41 
-
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Figure 33: Leucovorin Serum Concentration as a 
Function of Time; Patient F.F. 
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Figure 34: Leucovorin Serum Concentration as a Function of 
Time; Patient L.M. 
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TABLE XV 
A COMPARISON OF LEUCOVORIN PHARMACOKINETIC 
PARAMETERS DERIVED FROM NORMAL SUBJECTS 
AND CANCER PATIENTS 
Parameter Normal Volunteers* Cancer Patients* 
(Mean+ S.D.) (Mean + S.D.) 
Kela Min.-1 1.14 + 0.43 1.20 + 0.69 
- -
Kl2a Min.-1 1.12 + 0.23 1. 16 + 0.21 
- -
K21 a Min.-1 2.25 + 0.49 2.90 + 0.60 
- -
Vd (Cen.) Liters 7.41 + 3.48 4.06 + o. 73 
- -
Vd (SS) Liters 11. 31 + 5.62 5.69 + 0.96 
- -
Vd (Beta) Liters 26.40 + 9.24 17. 51 + 2.26 ( - -
Vd (Ext. ) Liters 29.23 + 9. 78 19.07 + 2.68 
- -
Vd (Tiss.) Liters 3.90 + 2.16 1. 63 + 0 .. 24 
-
Clearance Ml/Min 74.9 + 19.4 46.4 + 20.4 
- -
t~ (Alpha) Min 8.66 + 2.98 5.62 + 0.59 
- -
t~ (Beta) Min 240.48 + 44.03 2.68 + 131. 43 
-
* n = 3 
( 
( 
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TABLE XVI 
COMPARISON OF EXPECTED INITIAL LEUCOVORIN SERUM 
Patient 
F.F . 
L.M. -1 
L.M. -2 
CONCENTRATIONS TO CALCULATED LEVELS 
Expected Concentration 
(Moles/Liter) 
1.50 x 
3.50 x 
4.20 x 
Calculated Concentration 
(Moles/Liter) 
1 77 10-6 . x 
1 65 10-6 . x 
1 47 10-6 . x 
( 
TABLE XVII 
COMPARISON OF PHARMACOKINETIC PARAMETERS 
FOR LEUCOVORIN AND METHOTREXATE 
Parameter LEU 
(Mean + S. D. ) 
Half Life (Alpha) (Min.) 8.79 + 4.44 
-
Half Life (Beta) (Min.) 231.46 + 31. 76 
-
Half Life (Gamma) (Min.) 
----------
Vd (Central) (Liters) 5.49 + 3.53 
Vd (SS) (Liters) 8.44 + 5. 73 
-
Binding to HSA 70% 
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MTX 
(Mean + S. D.) 
44 min. + 6.6 
-
120 min . - 240 
624 min. - 1620 
13 .09 + 1.09 
-
73.3 + 15.6 
-
60 - 87%, 45% 
( 
( 
( 
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of distribution reported for ~TX. and the values obtained 
for LEU in the current study. It is evident froa these 
data that MTX pharmacokinetic paraaeters differ greatly 
fro• those of LEU and therefore cannot be used to correctly 
predict its disposition. Two patients fro• whom serum 
saaples vere obtained shoved patterns of LEU disposition 
distinctly different from other subjects. Patient P.F. 
received LEU. 1.1 ag a-2. intravenously 36 hours after the 
end of ~TX infusion. A plot of the serum LEU concentration 
as a function of time is shown in Figure 35. Rather than 
the biphasic disposition evident in the other cancer 
patients 
level of 
the period 
and a!l normal subjects. an essentially constant 
LEU was detected in the patients seruL During 
of sample collection, hour 36 to 42 post 
a change in the elimination of MTX in this 
vas observed. The half-life (beta) had increased 
normal value of 2 to 4 hours to approxiaately 22 
infusion. 
patient 
fro• the 
hours indicating a significant decrease in the rate of ~TX 
clearance. No indication of changes in P.F.•s renal or 
hepatic function vere observed during the change in !TX 
clearance and the event has been unexplainedw It is 
possible however. that the cause of. decreased MTX clearance 
observed in this patient aay also be responsible for the 
change in the disposition of LEU which vas observed in P-F-
(, 
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Patient F.Y. receiYed 12 mg. of LEU intraauscularly 48 
hours following the end pf MTX infusion. This vas the 
fourth dose administered to the patient. Figure 36 is the 
plot of the LEU serum concentration as a function of time 
for F.Y. The serum concentration reaained essentially 
constant oYer the 2 hour sampling period. This may be 
explained by the release and or absorption characteristics 
of the drug from the intramuscular injection site. !ore 
data would be required to be able to characterize the 
intramuscular route of administration as providing a slov 
release rate of LEU and acting as a slow-infusion. 
3. Comparison of Leucovorin Pharmacokinetics 
derived from Microbiologic Versus 
Electrocheaical Assay Methods 
Spray and Witts (1953) described the utilization of 
intravenously administered LEU in normal subjects. LEU vas 
assayed using the microbiologic disc method of Sauberlich 
and Bauaann (1948). Recently Rothenberg ~ s!:. (1979) 
published a radiochemical assay for LEU in serum and urine. 
The disposition of LEU characterized by the two methods are 
very much different. The early work describes a rapid 
der.line in serum concentration whereas Rothenberg ~ al~ 
(1979) found a second slow elimination phase after the 
initial distributive phase. A comparison of 
pharmacokinetic parameters derived from the tvo methods was 
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Figure 35: Leucovorin Serum Concentration as a Function of 
Ti~; Patient P.F. 
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Figure 36: Leucovorin Serum Concentration as a Function 
of Time; Patient F.Y. 
f 
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perforaed using the plasaa concentration•tiae data 
published by Spray and Witts (1953t. 
The data obtained from three normal aale subjects 
given 1 mg. of LEU intravenously (Spray and Witts, 1953), 
vere first analyzed using AOTOAN to yield initial estiaates 
of the aicroconstants. The data appears to be best 
described by a tvo co•partment open aodel as vas the case 
in the current vork. These estiaates vere then used to 
obtain final values for the pharaacokinetic paraaeters 
using NORLIN as previously described. 
Table XVII shows the parameters derived from each 
assay method in 3 normal male subjects. Statistical 
differences (p <0.05) were found in several of the 
parameters; kel. k12, alpha, beta, Vd (extrap.), clearance 
and half-life (beta). Figure 37 is a computer generated 
graph of serum concentration as a function of time using 
the paraaeters derived fro• the LEU serum analyses. The 
y-axis intercepts are different because the studies used 
different doses in the subjects. Evident in Figure 37 is 
the apparently faster rate of elimination described by the 
aicrobiologic method. The half-life (beta) is 32.03 ± 3.82 
min versus 231~46 ± 31.76 min vhen measured by the 
electrochemical method. Rothenberg ~ ~!~ (1979) 
attributes the difference in eliaination rate evident 
between the aicrobiologic and radiochemical methods to the 
inability of the latter to distinquish between the active 
and inactive diastereoiso•ers of LEU. They have further 
( 
( 
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speculated that the sustained elevated serua LEU 
concentration is caused by a preferrential excretion of the 
active isomer. Conclusions regarding the excretion of only 
the active fora of LEU are not possible from the current 
work. However. these data are in agreeaent with Rothenberg 
!! ~l~ (1979) in describing a prolonged eliaination phase. 
( 
( 
TABLE XVIII 
A COMPARISON OF 
PHARMA~OKINETIC PARAMETERS CALCULATED 
FROM MICROBIOLOGIC ASSAY 
VS. ECD METHOD 
Page 190 
Parameter Microbiologic 
(Mean + S.D.) 
Electrochemical 
(Mean + S • D. ) 
Kel *a Min.-1 6.15 + 
Kl2*a Min.-1 1. 79 + 
-
K2l*a Min.-1 3.20 + 
-
Vcl Ml *Min. -1 56.10 + 
-
Vd (Cen.) Liters 9.14 + 
-
Vd (SS) Liters 14.20 + 
-
Vd (Beta) Liters 25.48 + 
Vd (Ext rap) Liters · 62.18 + 
-
Vd (Tiss) Liters 
Half-Life Min. 7.81 + 
(Alpha) -
*Half-Life Min. 32.08 + 
(Beta) -
*Statistically Different (p<0.05) 
a = x 102 
4.60 1.14 + 0.43 
-
0.37 1.12 + 0.23 
-
0.28 2.25 + 0.49 
-
12.70 7.49 + 1.94 
-
2.07 7.41 + 3.48 
-
2.12 11. 31 + 5.62 
-
3.56 26.40 + 9.24 
10.18 29.23 + 9. 78 
-
0.68 8.66 + 2.98 
-
3.82 240.48 + 44.03 
-
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Figure 37: Leucovorin Serum Concentration as a Function of 
Time. A Comparison Using Pharmacokinetic Para-
meters Derived from Two Assay Methods. ECD = 
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( 
l 
page 192 
XI. CONCLUSIONS 
1. High pressure liquid chromatography vas coupled vith 
electrochemical detection and a sensitive, selective, and 
reproducible assay for LEU and !ETHF vas developed. 
2. The electroanalytical detection of reduced folates 
relies on the oxidation of the electroactive species at a 
surface electrode. The rate of oxidation, and therefore 
the generated current, can be affected by the electrode 
material, the buffer strength of the supporting 
electrolyte, and the strength of the applied potential. 
Oil-based, vax-based, and solid electrodes were 
investigated; solid glassy carbon electrodes were found to 
provide the opt~mum balance of durability and sensitivity. 
Ammonium phosphate, dibasic, vas deterained to be a 
suitable supporting electrolyte over a wide pH range, vith 
which low background current and adequate sensitivity vas 
achieved. Raising the applied potential increased, up to a 
limit, the background current and the current produced via 
oxidation of electroactive species. An applied potential 
of 0.8 volts produced adequate sensitivity for the reduced 
folates and ainiaized the oxidation of interfering 
compounds from serum samples. !ETHF vas aore easily 
oxidized than LEU, with a limiting current of 0.3 volts 
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compared to o.e volts for LEU. The lover limit of 
detection for these folates was approximately 12 ng. 
3. Reverse-phase paired-ion chromatography was used to 
effect the separation of LEU and ~ETHF in aqueous systems 
and the separation of LEO fro• the extracted components of 
huaan serua. However, this method was not of adequate 
efficiency to separate METHF from all coaponents of serum. 
The restraints upon the chromatographic conditions imposed 
by electrochemical detection severely limited the 
efficiency of octadecyl silane stationary phases (C-18 
columns). In order to effect separation of LEO fro• other 
plasma constituents it vas necessary to use the recently 
developed RCSS methodology. This technique was evaluated 
in considerable detail and found to off er several 
significant advantages over conventional reverse-phase 
columns. 
4. A method for the extraction and essentially complete 
recovery of LEO from huaan serum has been developed. The 
applicability of this technique to other forms of reduced 
folates vould depend upon their aqueous and -0rganic 
solubilites, ability to form a paired-ion complex, and 
stability during evaporation and storage. 
S. The binding of LEU and METHF to human seru• albumin 
vas determined. Binding was not saturated over the drug -.. 
( 
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concentration range investigated. The presence of both LEU 
and METHF in the albumin solution sign~f icantly reduced the 
degree of binding for both drugs. Since other forms of 
folates are found to varying degrees in huaan bloodr it is 
possible that in vivo binding of the reduced folates is 
substantially less than was determined from in vitro 
experiaents. 
The addition of ftTX to albuain solutions containing 
no significant effect on the degree of LEU or ftETHF had 
binding of the reduced folates. Thusr it is concluded that 
!TI and the two reduced folates studied probably do not 
share a coamon binding site. The apparent absence of a 
protein binding interaction is important clinically. From 
these data it may be concluded that the administration of 
LEU following high-dose MTX therapy would not likely alter 
the equilibrium between free and bound plasma MTX aaounts 
or cause a redistribution of intracellular or extracellular 
MTX. No 
possible 
conclusionsr howevery can be dravn regarding the 
interaction betveen LEUr !ETHFr and MTI for 
proposed active transport mechanisms into cells. 
60 The pharmacokinetics of LEU were characterized in 6 
normal subjects and in 5 patients undergoing high-dose ~TX 
therapy. No significant differences in pharmacokinetic 
parameters betveen the two groups were observed. LEU dosing 
protocols aim for concentrations that are ten times higher 
than are necessary for effective rescue. The current work 
( 
( 
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suggests that such protocols for LEU dosing. based on !TX 
pharaacokineticsr result in plasma or serum LEU 
concentration in excess of even these guidlines.. Although 
high serum LEO concentration pose no threa~ of toxicity. 
and can effectively reduce MTX related toxicity. the 
effectiveness of the high-dose !TX therapy aay be reduced. 
It may be concluded that LEU concAntrations achieved 
in cancer patients are higher than necessary for effective 
rescue and. most importantly. muy decrease the 
effectiveness of ~TX. Based on the pharaacokinetic 
parameters calculated fro• cancer patients. a reduction of 
SOS in LEO doses may be possible and would be expected to: 
1~ improve the efficacy of MTX therapy and; 2. aaintain the 
effectiveness of LEO rescue regimens. 
Future Work 
Several possibilites for further investigation have 
resulted from this work: 
1. The electrocheaical requirement for relatively high 
ionic strength buffers may substantially reduce the 
efficiency of some high pressure liquid chromatographic 
system so Iu 
efficiencies 
the 
were 
current 
reduced 
claimed column efficiencies. 
work calculated column 
by approximately 80~ from the 
The use of post-column addition of supporting 
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electrolyte aay represent a solution to this problea. In 
ibis manner, chromatographic conditions may be optimized 
vith fever concessions to electrochemistry than are 
currently possible. such an approach might be expected to 
produce greater resolution and efficiencies in HPLC and 
aost likely lower the limits of sensitivity. 
2a The renal clearance of LEU has received little 
attention. Furthermore, published reports have not 
adequately performed urine sampling with regard to proper 
pharaacokinetic analysis. Therefore, reliable estimates of 
the total amount of LEU excreted in urine are not 
available. The current assay aethod could be applied to an 
adequately designed pharaacokinetic study, resulting in the 
characterization of the renal and aetabolic clearances of 
LEU. 
3a The extraction procedure described in the current work 
vas not suitable for the analysis of !ETHF. METHF can be 
quantitatively deterained at an oxidation potential of 0.3 
Volts, rather than the 0.8 Volts necessary for the 
oxidation of LEU. By decreasing the applied potential, the 
oxidation of seru• constituents is expected to be reduced 
considerably. Under this condition it may be possible to 
develop an extraction process for METHF that would allov 
for the deteraination of its pharmacokinetics in huaans. 
( . 
( 
4. 
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There is considerable interest in qualitative and 
quantitative analysis of reduced folates (aonoglutaaates) 
and various polyqlutamates within cell. The concentrations 
of these compounds is below the limit of sensitivity 
achieved for the reduced folates. Modifications in the 
electrochemical cell, including increased electrolyte cell 
surface, repositioning of the auxiliary electrode, and 
decreasing the diffusion distance within the cell may be 
expected to provide greater levels of sensitivity. Coupled 
with the improved chroaatographic techniques suggested 
above, this approach may lead to the development of a 
system suitable for the detection of intracellular folates 
and polyglutamates. 
( 
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REPORT OF ACTION 
TITLE OF PROPOS/'.L: 11 Phannacokinetics of Leucovorin in Nonnal Subjects" 
PRif.!CIPAL INVESTIGATOR: D.S. Greene 
This is to certify that the application identified above has 
been r-=v i e1:1ed by the Board approved to review proposals for research 
and other activities involvinq human suhjects. 
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Hydration-
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• : _ •· • • r 
Bloods- Pretreatment: CBC, platelet count, .differential, BUN, · 
serum creatinine, creati.nine clearance, 
bilirubin, alkaline phosphatase, SGOT, 
and urinalysis. 
Follow-up: Daily CBC, platelet count, BUN, serum 
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..... · .. ~ :•. 
creatinine, al~alin~ pho~phatase, SGOT 
x 3days. ·-
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Roger Williams General Hospital 77-317-26 
Providence, PJi.ode Island 
CONSENT FORM page 213 
THE FULL NATURE AND EXTENT .OF YOUR DISEASE HAS BEEN"EXPLAINED TO YOU. 
1. Yo~ are invited to participat~ in the following study: High-Dose 
Methotrexate with Leucovorin Rescue: A Clinical and Pharmacological 
Study. 
You will receive the combination of high dose methotrexate and 
leucovorin rescue. 
2. If you decide to participate, the procedures to be followed are 
explained below: 
These drugs will be administered by vein. It is understood 
that the therapy will be discontinued if severe toxicity 
develops or if the .therapy is found to be ineffective. Also, 
periodic tests will be performed to measure the effectiveness 
of this therapy. 
--------·- ---
3. Those procedures which are investigational have been identified as: 
The investigational portion of this study involves the measure-
ment of the effectiveness of these drugs .and your tolerance to 
· them. 
4. As with any investigative procedure or medication, previously 
unreported or unforeseen complications may occur rarely. The 
foilowing complications or risks have been reported, or are known, 
or may occur: 
5. 
This combination of drugs has side effects· which may include 
~my, all, or none of the following: nausea, vomiting, - ---~- ......•... .... 
diarrnea,, ·a sor.e mouth and throat with or without sores similar 
to canker sores, lowering of the white blood count and/or 
red blood count and/or platelet count, increased risk of 
infection and possible kidney damage. 
The benefits which can be expected have been described· as: 
It is po3sible that your dis~ase may be controlled by a 
decrease in the growth of na!ignant tissue in an ef f_ective 
and safe manner~ It is not possible to predict ·whether or 
not any personal benefit will result from ci1e us~ of this 
trcatmant program. 
( 
( ..... 
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7. 
8. 
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The nlternate procedures, if any, which would be possibly advantageous 
to you have been described as follows: 
Other treatment programs which may include the drugs in this 
program or other combination of drugs similar to those in 
this program are available, but there is no clear evidence that 
other combinations would. provide an increased chance of controlling 
your d~sease and the side effects would be siQilar to the drugs 
proposed in this study. 
Feel free to ask any questions you have about the study and .we will 
be happy ,to answer them. If you have any additional questions later, 
Dr. ~y be contacted through the nurse if 
you are hospitalized or by calling 456-2100 if you are an out-patient. 
Any information that is obtained in connection .with this .study and 
that ·could identify you will remain confidential and will be disclosed 
only with your permission. If you give us your perciission by signing 
this doc~ment, we plan to . disclose data about you, ~hich does not 
identify you by name, for cedical and other scientific purposes, 
including publications. 
9. You are making a decision whether or not to participate in this study. 
Your decision whether or not to participate 'Will not prejudice your 
future relationship with the Roger Williams General ·HospifaL-i:f ______ - --· 
you decide to participate, you are. free to ·withdraw your consent and 
to discontinue your participatio:i at anytioe without prejudice. 
10. Please give. us an indication of your having read this document by 
placing your initials next to each numbered item described above. 
11. Your signature on this document indicates that you have decided 
to. participate having read the information provided above. 
SIGNER OTHER TH.Al~ PATIENT: RELATIO~iSHIP: 
-------------------------- --------------
PERSON EXPLAINING THE STUDY: DATE: . .. .'InLE. ~ .. 
----------------------~ ___ ............ _...._ ... . . . . . . .. . . . . . . 
PRINCIPAL INVESTIGATOR: 
-----------------------------------------------------
WITNESS : DATE: TINE: 
------------------------------------------~ -------- --------
( 
( 
Douglas S. Greene, Ph.D. 
University of Rhode Island 
Department of Pharmacy 
Kingston, Rhode Island 02881 
Dear Dr. Greene: 
,· I i 
~ . . , 
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February 8, 1980 
As Secretary of the Ethics and Clinical Investigations Committee, 
I am pleased to advise you that your Progress Report of your Grant 
Application, Roger Williams General Hospital #80-248-46 titled 
"Pharmacology of Leucovorin in Cancer Chemotherapy" \'las reviewed and 
approved by the Ethics and Clinical Investigations Committee at their 
meeting on February 7, 1980. 
Under Federal and Committee Regulations, 
be submitted for review in February of 1981. 
will be necessary for you .to submit a summary 
this Grant. 
this Grant will automatically 
Prior to the next review, it 
regarding the activities · of 
NPM/am 
cc/Dr. F. Cummings 
Mr. 0. Bisbano 
Cordially, 
·7 ., -. . I) LJ) It«.(,·'- • ..-.,,: 
....... c-., . 
Nancy P. Madeira, Secretary 
Ethics & Clinical Investigations Committee 
~ .... ·~ • ; * ,. 
( 
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INFOR:-fED CONSENT FORM 
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Leucovorin is similar to folic acid, an essential vitamin 
normally contained in the diet. It is a drug normally used with 
I 
methotrexate in cancer chemotherapy. Extemely large amounts have 
been administered to normal subjects with no ill or toxic effects. 
The objective of this research is to study the rate leuco-
vorin is removed from your- body . and to attempt to determine the 
amounts of other compounds produced by your body in your blood 
as a function of time. · 
Subjects volunteering to participate in this project will be 
' required to abstain from all drugs ·and alcohol for a period of 
48 hours prior to each test. In addition, all volunteers will be 
· required to fast for twelve hours before starting the test and 
for at least four hours after the test has begun. The drug, 
Calcium Leucovorin, will be prepared using commercially available 
10 
intravenous preparations. A low dose (~ mg) of leucovorin will 
be administered to you directly into your arm vein by a physician 
using a hypodermic syri~ge. A catheter (i . e . a small tube) will 
be placed in the vein of your arm for the collection of blood. 
Ten milliliters (about two teaspoonfuls) will be collected before 
you receive the dose of leucovorin and thirteen ten milliliter 
blood samples will be collected at fifteen minutes, tJ;Urty minutes, 
forty-five minutes, one hour, one and one half hours, two hours, 
two and one half hours, three hours, four hours, f ive hours, six 
hours, seven hours and eight hours after drug administration. All 
blood samples will be drawn by a physician.or appropriately trained 
personnel. 
,_ 
i . 
'· . I , 
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Leucovorin has been reported to be completely free of toxic 
.reactions except for a single report of an allergic reaction to 
the drug with no lasting ill effects. At the dose of leucovorin 
you will receive, the risk of any side effect is minimal. 
Risks associated with the use of a catheter for the collection 
of blood samples include: infection, hematoma (i.e. soreness. 
and/or "black and blue" mark) or bleeding. 
Medical care for problems resulting from this study will 
be available at Roger Williams General Hospital for emergencies .. 
You will not . be compensated for injuries resulting from this 
study. ..  
You are free to withdraw from participation in this study 
at any time during the investigation. You will not be identified 
in any publication resulting from this work. 
Feel free to ask any questions you have about the study and 
we will be happy to answer them. If you have any additional 
/ 
questions later, Dr. · ·: · · · may be contacted through the 
------
investigators or by calling 456-2060. 
I =···;,, .: ... .... . ,, .. . , .. ~ i · · , having carefully read and under-
,_._._,_ ._, __ ~_· __ ··--------
-
stood the above and having been given the opportunity of asking · 
questions regarding the above project now give my informed consent 
to participation in the study of Leucovorin Pharmacokinetics in 
Normal Subjects, University of Rhode Island. 
Date · · : ~ :;·, · ·· · Volunteer: __ ·~~·-· .. _ .. _/_. _)_· ~._ ._,_·· -;~.f_/~·> _____ __ 
Person explaining the study: -....-.-. _;:· ·. · ~ ·'.:::::·--=.:::. · · "\ 
Principal Investigator :( \ l /. 1 ..--L -.:-~ ·' -- -
- I ,,, 
'''{"t · . c . ~J . l . \· i ·~/ - T.·<" .1 .. ;;:.. / Date.· , ·.\ \ .. v 
, 1 ness. , . ~' .... f' · . / ---' --------
( 
( 
( 
Experimental Protocol .. 
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All those being considered for invol venent in this study will be heal thJ 
ma::be volunteers between the ages of twenty and fifty with no known 
hypersensivity to folic acid or its derivatives. Any medical abnonnality, 
which, in the opinion of the medical consultant or investigators,;.is 
likely to complicate the study or add further risk to the subject will 
result in the subject being excluded fran the study. All subjects will 
be carefully interviewed and pertinent medical information gathered. 
All participants will be provided with the opp:>rtunity of reading and 
having carefully explained the lnfonned Consent Fonn. In addition, 
participants will be provided the opp:>rtunity for further questioning 
of the investigators. Any subject may withdraw frc:xn the study at any 
time during .the investigation. Medical care will be provided at 
Roger Williams General Hospital for medical e~ergencies resulting 
fran this study. Subjects will receive no canpensation for injuries 
received during this study. 
Participants will be ·required to abstain fran all d.Iilgs and alcohol 
for 48 hours prior to the test period. In addition, participants will be 
required to fast twelve hours before d.Iilg achinistration and for at 
least four hours after d.Iilg administration. 
All drug administration and blood sarrple collection will be 
under the direction of a physician at Roger Williams General Hospital 
in Providence, RI. 
Calcium leucovorin will be administered intravenously using 
ccmnercially available preparations at a dose of 1(i' n:g. Blood samples 
will be collected inmediately before d.Iilg administration and at 0.25, 
0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, and 8 hours after d.Iilg 
administration through an indwelling catheter. The test will require 
. , 
( 
( 
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that ten milliliters of blood be taken at each interval . for a total 
of 140 milliters from each volunteer for each test. The risk to the 
_. subjects fran the administration of the drug is judged to be minimal, 
doses of over 500 ng have been adninistered to nonna.l subjects with 
no toxic effects. Risks resulting from the collection of blood 
2 
include the possibility of infection, herotana. ans scarring. The 
anx>unt of blood collected in not excessive, this is less than one-third 
of a pint. 
: , 
. . --- . ----------
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